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ABSTRACT 
 
Chronic wounds represent an under-acknowledged socioeconomic epidemic, affecting 1.8 
million new patients per year and costing the US health care system upwards of $25 billion 
annually. This substantial cost is rapidly growing due to a disproportionate occurrence in the 
ever-aging population. Key features associated with age-related impairment of wound healing 
include limited energy and nutrient exchange, unremitting inflammations, increased reactive 
oxygen species (ROS), and diminished blood flow. Most chronic wound therapies target specific 
molecular mechanisms; however, there are often multiple mitigating factors that prevent normal 
wound closure. This is likely one reason most wound therapies are minimally effective. In the 
standard American diet, carbohydrates are broken down for fuel (glucose). While fasting, 
starvation, and calorie or carbohydrate restriction, beta-oxidation of stored fats in the liver 
produces ketone bodies (primarily acetoacetate (AcAc) and β-hydroxybutyrate (βHB) to serve as 
energy metabolites for extra-hepatic tissues. In addition to enhancing metabolic physiology, 
ketone bodies have recently been discovered to have signaling properties that are independent of 
their function as energy metabolites. Here we present the evidence for a novel method of 
inducing therapeutic ketosis via exogenous ketone supplementation to promote enhanced 
ischemic wound healing in young and aged Fischer 344 rats. Preliminary mechanistic studies 
demonstrated that exogenous ketone supplementation enhanced wound healing via increasing 
proliferation and migration, decreasing lactate production, and decreasing ROS production as 
	 xiv	
well as affecting inflammatory cytokines and growth factors. We conclude that exogenous 
ketone supplementation will be an effective, cost efficient, low toxicity therapy to promote 
enhancement of wound healing in an aged population. 
	 1	
CHAPTER 1: WOUND HEALING PHYSIOLOGY 
 
1.1.  Chapter Synopsis 
The following is a brief review of skin morphology, wound classification and types of 
wound healing, and the classic wound healing cascade. It is important to understand the 
complexity of the orchestration in conjunction with the magnitude of participants and the vast 
number of interactions it takes to heal a wound effectively. Even though most of the time wound 
healing proceeds to completion without complication, the majority of this chapter addresses what 
happens when things do not follow the standard progression. The current topical approach to 
wound healing treatments has failed not only in reversing chronic wound stagnancies but has 
cost the US alone billions of dollars in health care costs. There is a dire need to discover novel 
and effective treatments for chronic wounds. The aged population has a high prevalence of 
chronic wounds due to comorbidities in combination with physiological changes of aging. 
Increasing evidence shows that unresolved inflammation, increased reactive oxygen species 
(ROS), diminished blood flow, and decreased metabolism and ATP production are key 
physiological features associated with age-related impairment of chronic wound healing. In this 
chapter, we concentrate on the importance of these factors as well as how age affects them in a 
wound-healing environment. Additionally, these are the four physiological features that we will 
seek to target in our proposed treatment, which will be discussed in later chapters. A good 
understanding of the information presented in this chapter will be critical to interpreting the 
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rationale behind our proposed therapies and the data represented in the subsequent chapters of 
this dissertation. 
 
1.2.  Skin Morphology  
 The skin is the largest organ in the human body, comprising up to 12-15% of total body 
weight and covering 1.5-2m2 of surface area [1]. There are three distinct layers of the skin: the 
epidermis, the dermis, and the hypodermis. The epidermis is the avascular outermost layer, 
primarily populated by keratinocytes, which regulates body temperature, absorbs nutrients, and 
defends against pathogens. The dermis, the thicker layer deep to the epidermis, contains an 
extracellular matrix (ECM) that provides tensile strength and flexibility.  It also includes 
fibroblasts, nerve endings, hair follicles, sweat glands, sebaceous glands, apocrine glands, 
lymphatic vessels, and blood vessels. Though they are only present in the dermis, the blood 
vessels supply nutrients to both the dermis and the epidermis [2-4]. The deepest layer, the 
hypodermis, is mainly made up of adipose tissue and serves as an anchor, permitting most areas 
of the skin to move freely over the deeper tissues [1]. These distinct layers each play a unique 
role in wound healing and add to the heterogeneity of wound classification. 
 
1.3.  Wound Classification and Closure Types 
 Wound classification takes into account the nature and the severity of the wound to 
determine an appropriate treatment plan. First, the wound is classified as acute or chronic. Acute 
wounds achieve sustained restoration of structure and function in an orderly and timely 
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reparative manner. In contrast, a chronic wound does not proceed through the healing process in 
a timely fashion and does not advance to closure [5].  Discussion of the classification of chronic 
wounds and treatment protocols will occur later in this chapter. The rest of this section will focus 
mostly on acute wound closure.  
     Initially, acute wounds are classified as being open or closed. Open or penetrating 
wounds are those with exposed underlying tissue and/or organs. These include stab, gunshot, and 
surgical wounds. Closed or non-penetrating wounds do not break through the skin. These include 
abrasions, lacerations, contusions, and concussions. There are also some wounds that do not fit 
into either of these categories; these include thermal (burns or frostbite) and chemical wounds 
[6]. Each type of wound has an additional classification for severity. For example, open surgical 
wounds are further classified into four different classes based on surgical location and level of 
contamination [6].  
     Wound healing, or cicatrization, is the process by which tissues restore anatomical 
structure and function after an injury [7, 8]. Factors that affect the wound closure process include 
the type of wound, size, depth, location, the age of wound, presence of infection, condition of the 
patient, and urgency of closure [9]. Wound depth is classified as partial thickness or full 
thickness.  Partial thickness wounds are shallow and involve epidermal loss and partial loss of 
the dermal layer.  Full thickness wounds involve a total loss of the epidermal and dermal layers 
and extend to at least the subcutaneous tissue layer and possibly as deep as the fascia, muscle 
layer, and the bone. Partial thickness wounds heal primarily by re-epithelialization from the 
remaining dermis with minimal scar formation. There are three methods of open wound closure: 
primary, secondary, and tertiary repair [5, 7, 9]. In primary closure or first intention, the wounds 
are sealed immediately with simple suturing, skin graft placement, or flap closure. Wound edges 
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are brought close together, and the wound heals spontaneously with scar formation oriented 
along the Langer’s lines (collagen fiber alignment within the dermis) [5]. Closure by secondary 
or spontaneous intention involves no active intent to seal the wound. This type of healing is 
associated with large, highly contaminated wounds, coupled with extensive tissue loss. They 
close by the natural wound-healing cascade, which results in contraction and increased scar 
formation. Failure to heal within a month can lead to a chronic state [5]. Wound closure by 
tertiary intention or delayed primary closure occurs when wounds are infected or contain foreign 
debris and cannot be closed until the complications are resolved. A contaminated wound is 
initially treated by various methods for several days to control infection. Once the wound is 
ready for closure, surgical intervention allows the wound to heal by first intention. Again, failure 
to heal within a month can lead to a chronic state. Primary or tertiary wound healing is preferred 
to secondary since secondary involves a more severe wound contraction and scar formation.  
 
1.4.  Acute Wound Healing Cascade 
 All wounds undergo the same basic steps of repair regardless of tissue type or nature of 
the injury. Full thickness wounds damage many structures within in the skin. These include 
epidermal keratinocytes and appendages (sweat glands, sebaceous glands, and hair follicles), the 
basement membrane, and dermal fibroblasts and appendages (ECM, nerves, and blood vessels) 
[10]. To heal the gamut of damaged structures, the classic wound-healing model consists of four 
distinct but overlapping phases: hemostasis, inflammation, proliferation, and maturation [11-14]. 
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1.4.1. Hemostasis  
 Hemostasis or the coagulation phase is the initiator of healing and occurs immediately 
following an injury [15, 16]. Ruptured cells and damaged blood vessels activate the blood-
clotting cascade, which promotes platelet activation, adhesion, and aggregation at the site of 
injury to form a fibrin clot. This fibrin clot prevents exsanguination, creates a protective layer to 
minimize infection and further injury, and provides a provisional matrix of support as the wound 
heals [3, 7, 16-18]. Activated platelets are a major source of growth factors that play a significant 
role in the subsequent phases of wound healing [10]. 
 
1.4.2. Inflammation 
 Inflammation, the next phase of wound healing, begins within the first 24 hours of injury 
and can last up to two weeks in the normal wound healing cascade [16]. Physically, 
inflammation is associated with signs of redness, swelling, heat, and pain caused by the release 
of histamine and other active amines by mast cells [16]. The priority of the inflammatory phase 
is to neutralize infection and prepare the wound bed for repair; therefore, it is not the active stage 
of wound closure. Nevertheless, it is the most critical phase of the wound-healing cascade. 
Successful wound repair requires effective and timely resolution of inflammatory responses to 
activate subsequent steps of the wound healing process. Incomplete resolution of the 
inflammatory phase leads to a chronic state [8, 19]. 
 The initial vasoconstriction needed to prevent excess blood loss is closely followed by 
vasodilation and increased capillary permeability. The increased capillary permeability and 
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chemotactic factors facilitate diapedesis of neutrophils into the wound bed.  Likewise, there is an 
influx of pro-inflammatory cytokines (IL-1, IL-6, IL-8, and TNF-α) and growth factors (PDGF, 
TGF-β, IGF-1, and FGF) into the wound bed [16]. Polymorphonuclear neutrophils (PMNs) are 
the most abundant cells in the wound site during the first two days post initial wounding [8]. 
They generate a respiratory burst to destroy phagocytized bacteria by the release of reactive 
oxygen species (ROS) [2, 10, 20, 21]. Electrons donated by the reduced form of nicotinamide 
adenine dinucleotide phosphate (NADPH) are transported across the membrane into lysosomes, 
and superoxide anion (O2-) is produced [22]. O2- is bactericidal but is also toxic to neutrophils 
and surrounding viable tissue if not stringently regulated. In healthy young cells, downstream 
antioxidant enzymes such as superoxide dismutase (SOD), glutathione peroxidase, and catalase 
mitigate ROS production by catalyzing the formation of H2O2 [23-25]. Neutrophils utilize 
myeloperoxidase to combine H2O2 with Cl- to form hypochlorite, which plays a supplementary 
role in eliminating bacteria [3]. Additionally, neutrophils release high levels of proteases 
(elastase, neutrophil collagenase, and neutrophil collagenase MMP-8) and remove necrotic 
debris and foreign material [16]. Once the neutrophils complete their function, usually after 2-3 
days, they are extruded in the eschar (the crust containing dead cells and degraded products of 
the wound) or phagocytized by macrophages.  
 Monocytes from the bloodstream infiltrate into avascular hypoxic areas of the wound site 
and mature into macrophages by stimulation from pro-inflammatory cytokines produced by the 
neutrophils [3, 26]. Macrophages in the wound bed can exhibit two distinct functional 
phenotypes: M1 (classically activated, pro-inflammatory) and M2 (alternatively activated, anti-
inflammatory). Early during the inflammation phase, macrophages that are activated by 
lipopolysaccharide (LPS) or inflammatory cytokines like interferon gamma (IFN-γ) continue the 
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job of neutrophils by phagocytizing bacteria and damaged tissue. Additionally, the M1 
macrophages release pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) 
and interleukin-6 (IL-6) [3]. Later during inflammation, initiated by the phagocytosis of 
apoptotic cells, M1 macrophages phenotypically convert to M2 macrophages [27]. M2 
macrophages, activated by interleukin-4 (IL-4) and interleukin-13 (IL-13), play a critical role in 
the resolution of inflammation. Additionally, they are a predominant component of the transition 
to the proliferative phase by promoting angiogenesis, tissue remodeling, and repair [3, 28-35]. 
Lucas et al. demonstrated that a depletion of macrophages during the inflammatory phase 
significantly delayed wound repair in a mouse model; thus, they demonstrated the critical need 
for macrophages for wound healing completion [36].  
 
1.4.3. Proliferation 
 Until now, the wound bed has been prepping for the active repair phase by preventing 
exsanguination, accomplishing wound debridement, and controlling the bacterial load. 
Proliferation or the reparative phase is subdivided into different stages including granulation 
tissue formation, collagen deposition, re-epithelialization, and angiogenesis [7, 15, 16]. The 
initiation of the proliferative phase is evident by the infiltration of dermal fibroblasts into the 
wound bed. Fibroblasts in the non-wounded dermis are typically dormant and sparsely 
populated; therefore, fibroblasts are recruited from neighboring uninjured cutaneous tissues and 
migrate to the wound bed [16]. A concentration gradient provided by chemotactic growth 
factors, cytokines, and chemokines in conjunction with the alignment of collagen fibrils in the 
provisional ECM govern the direction of fibroblast migration [16, 37]. Once the fibroblasts have 
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reached the wound bed, they anchor in the scaffold of the interim ECM and begin to proliferate 
and synthesize granulation tissue components such as collagen, elastin, and proteoglycans. The 
creation of granulation tissue, named for its irregular grainy appearance, slowly replaces the 
temporary fibrin clot. Initially collagen, predominantly Type III collagen, is laid down in 
irregular bundles providing moderate stability and tensile strength. In the later part of 
proliferation, fibroblasts assume the myofibroblast phenotype, expressing α-smooth muscle actin 
(α-SMA) [2, 38]. The myofibroblast phenotype enables the wound to contract but is dependent 
upon growth factors PDGF and TGF-β [39].  
 Simultaneously, the epidermis must replace the initial wound seal, the fibrin clot, with a 
new epithelial barrier to protect the newly forming ECM. Growth factors released during the 
healing process stimulate the migration and proliferation of keratinocytes. Actively migrating 
cells are incapable of proliferating; therefore, the neo-epithelium is created using new cells from 
the proliferating basal layer of the epithelium near the wound margin. The normal cuboidal basal 
epithelial cells flatten in shape and begin to migrate as a monolayer over the newly deposited 
granulation tissue. The epithelial cells move in a tumbling fashion (also known as the epithelial 
tongue) until the edges establish contact and form a confluent sheet. Once the newly formed 
monolayer of keratinocytes covers the wound’s surface, migration stops, and the sheet enters a 
proliferative state to re-establish the stratified layers of the epidermis and restore barrier function. 
This process has to happen succinctly with ECM foundation or else the wound can easily re-
open.   
 As dermal and epidermal cells migrate and proliferate within the wound bed, there is a 
substantial need for adequate blood supply for nutrient delivery and gas and metabolite 
exchange. Due to vascular disruption, ischemia, and high oxygen consumption by metabolically 
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active cells, the microenvironment of the early wound is hypoxic, oxygen depleted. Compared to 
normal tissue PO2 levels of 45–50 mm Hg, wound oxygen tension is 6 –7 mm Hg after five days 
[40]. An inadequately replenished oxygen supply suppresses wound-healing processes; as an 
example, fibroblasts can survive in a low-oxygen state but cannot replicate or synthesize [16, 
41]. Angiogenesis restores tissue nutrient exchange, reestablishes microcirculation, and increases 
oxygen tension to 30 – 40 mm Hg. Ischemia and hypoxia are critical inducers of angiogenic 
factors to the wound site [40]. Binding of angiogenic factors such as VEGF, FGF, and TGF-β 
cause microvascular endothelial cells of the blood vessels next to the wound site to migrate in the 
same fashion as the fibroblasts. Once in the wound bed, the microvascular endothelial cells 
proliferate to form buds or sprouts. As sprouts grow and encounter other sprouts, they develop a 
cleft that subsequently becomes the lumen of the new vessel and complete a new vascular loop. 
This process continues until the capillary system is sufficiently repaired for nutrient delivery and 
oxygenation [16]. VEGF is noted to be the most potent angiogenic factor for its effects on 
multiple components of the angiogenesis cascade: VEGF is an endothelial cell mitogen, 
chemotactic agent, and inducer of vascular permeability [3, 42]. However, the angiogenic effect 
of VEGF appears to be dependent on nitric oxide (NO). It has been shown that VEGF increases 
NO production by up-regulating endothelial NOS (eNOS). Conversely, it has been shown that 
when blocking eNOS, VEGF angiogenic properties such as endothelial migration and mitogen 
activities are prevented [43, 44]. 
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1.4.4. Maturation 
The maturation or remodeling phase is different from the previous phases in that it does 
not have a time sensitive pressure and can take from months to years to complete. During this 
phase cell proliferation slows, protein synthesis decreases, and most endothelial cells, 
macrophages, and fibroblasts undergo apoptosis or exit the wound. The goal of the remodeling 
phase is to convert the new ECM, with a tensile strength of only 25-30% compared to normal 
skin, to the a final scar with maximum tensile strength. Though tensile strength increases, the 
maximum a wound can achieve is 80% of unwounded skin’s tensile strength.  Collagen is 
remodeled, and Type III collagen that is predominant in the proliferation stage is replaced by 
stronger Type I collagen. The collagen is further strengthened by cross-links between collagen 
fibrils. The final result is a scar that is more brittle and less elastic than normal skin. It should be 
noted that scar tissue lacks the appendages (sweat glands) seen in the undamaged skin. Thus, 
scar represents wound repair rather than regeneration. 
 
1.5. Cellular Energy Metabolism 
Cellular energy metabolism extracts a utilizable form of energy, adenosine triphosphate 
(ATP) from the nutrition we eat via an elaborate set of biochemical reactions. There are two 
categories of metabolic pathways: catabolism and anabolism. Catabolism includes the digestion 
of ingested macromolecules (carbohydrates and fats) into smaller components (sugars and fatty 
acids), which are either fully metabolized for energy or stored for later use. As a result of these 
pathways, the energy released (7.3 kCal/mole) from the hydrolysis of the tertiary (ATP to ADP) 
and secondary (ADP to AMP) phosphate bonds is used to execute all biologically necessary 
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reactions in the body. In contrast, anabolism uses the newly created ATP to synthesize essential 
biomolecules such as proteins, lipids, and nucleic acids (DNA and RNA). The ratio between 
anabolism and catabolism is an important factor in determining wound-healing progression, 
which will be discussed later in this section. 
 
1.5.1. Catabolism 
In a standard American diet (SAD), ingested carbohydrates are metabolized into 
monosaccharides, predominantly glucose, as the main fuel source for ATP. Glucose is 
transferred into the cellular cytosol by low affinity, high capacity membrane transporters 
(GLUTs). While in the cytosol, the process of glycolysis, ten enzymatic steps involving a 
number of intermediates and specific enzymes, converts the 6-carbon glucose into two molecules 
of 3-carbon pyruvate. Glycolysis results in the net gain of 2 ATP (2 ATP are invested in 
reactions 1-5 and 4 ATP are produced in reactions 6-10) and the formation of 2 molecules of 
NADH, an electron carrier that will eventually play an important role in the production of 
additional ATP. Glycolysis is the only pathway to produce ATP without the presence of oxygen.  
The flux through glycolysis is enough to sustain both ATP generation and fueling of the 
biosynthetic pathways.  Additionally, glycolytic intermediates can funnel into multiple 
biosynthetic pathways. As an example glucose-6-phospahte (G6P) can enter the pentose 
phosphate pathway, which generates NADPH to maintain antioxidant capacity and nucleic acid 
synthesis.  
The fate of pyruvate is dependent on the cellular oxygen concentration. In the absence of 
oxygen, lactate dehydrogenase (LDH) converts pyruvate to lactate in a process known as 
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anaerobic respiration or fermentation. Coupled to this reaction are the formation of another ATP 
and the oxidation of NADH to NAD+, which is cycled back to glycolysis. In the presence of 
oxygen, the cells will use aerobic respiration. The two molecules of pyruvate are shuttled into the 
mitochondrial matrix where they are oxidized into acetyl-CoA by the pyruvate dehydrogenase 
complex (PDH). Two additional NADH molecules are created during this step. Acetyl-CoA is 
joined to oxaloacetate, beginning the Krebs cycle. The Krebs cycle or citric acid cycle 
completely oxidizes the remaining carbons from glucose, generates additional electron carriers (6 
NADH and 2 FADH2) to feed the electron transport chain (ETC), and generates 2 ATP. As of 
now, these metabolic pathways have synthesized a net gain of only 4 ATP, 10 NADH, and 2 
FADH2. The electron carriers are shuttled to ETC, in the inner mitochondrial membrane for 
oxidative phosphorylation. NADH and FADH2 are oxidized by the components of the ETC and 
their electrons are passed between the ETC complexes in a series of oxidation/reduction 
reactions. The final electron acceptor of the ETC is molecular oxygen, which reduces to H2O. 
During the transfer of electrons through the ETC, H+ protons are pumped into the inner 
mitochondrial membrane space creating an electrochemical gradient. This electrochemical 
gradient drives the proton motive force used to synthesize ATP. Thus, the ETC generates 32-34 
ATP per glucose molecule (3 ATP per NADH and 2 ATP per FADH2).  
Dietary fats and stored fats are both metabolized via lipolysis to release their glycerol 
backbone and their fatty acid side chains. The free fatty acids undergo β-oxidation to produce 
acetyl-CoA. The metabolic fate of acetyl-CoA is the same as the previously described steps of 
aerobic respiration from glucose. Each round of the β-oxidation cycle reduces the length of the 
free fatty acid’s aliphatic tail by two carbon atoms and produces one NADH and one FADH2. 
This process continues until the entire chain is cleaved into acetyl-CoA units. The ATP yield for 
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every β-oxidation cycle is 17 ATP (3 per NADH, 2 per FADH2, and 12 for the acetyl-CoA/Krebs 
cycle). Thus, the total ATP yield will depend on chain length. Two ATP are required to activate 
the fatty acid; hence a net ATP yield for palmitic acid (C16:0) is 113 ATP.  
 
1.5.2. Anabolism 
Anabolic or biosynthetic pathways utilize the newly created energy to fuel the creation of 
necessary biomolecules. These include glycogenesis (glycogen synthesis), gluconeogenesis 
(glucose synthesis), protein synthesis, and the pentose phosphate pathway.  The main 
biosynthetic pathways to focus on for this dissertation are the pentose phosphate pathway (PPP) 
and gluconeogenesis. As mentioned previously, the first step of glycolysis produces glucose 6-
phosphate (G6P), which can be shuttled to the PPP, an anabolic pathway parallel to glycolysis 
that generates the reducing agent NADPH and synthesizes 5-carbon sugars. The PPP accounts 
for approximately 60% of NADPH production in the cells.  It is important to note that NADPH is 
the reducing agent consumed during biosynthetic reactions, whereas NADH is a reducing agent 
generated in energy-yielding reactions. NADPH is used for fatty acid synthesis and helps fight 
oxidative stress by reducing the antioxidant glutathione via glutathione reductase. The ribose 
sugars generated from the PPP are utilized in the synthesis of nucleotides and nucleic acids.  
Gluconeogenesis (GNG) is a series of eleven enzyme-catalyzed reactions to synthesize 
glucose from non-carbohydrate sources including pyruvate, amino acids (alanine and glutamine), 
lactate, and glycerol. The system is a reciprocal of glycolysis, which together creates a feedback 
mechanism to normalize and maintain blood glucose levels. While most steps in gluconeogenesis 
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are the exact reverse of glycolysis, there are three reactions that require different catalytic 
enzymes to make them more kinetically favorable.  
 In general, normal metabolism is hormone-mediated to alter energy production to meet 
energy need and to restore daily macronutrient balance, especially proteins, through the catabolic 
and anabolic pathways [45-50].  This balanced metabolic profile significantly changes in the 
presence of a wound.  
 
1.6. Wound Healing Metabolism 
 The presence of any substantial wound increases metabolic energy demands from 30-
50% above normal requirements to produce the necessary biomolecules for increased cellular 
proliferation and migration of the various cell types during wound healing [17, 51]. Cuthbertson 
famously described the metabolic response to injury as having an  “ebb” phase, the period of 
traumatic shock or hypometabolism during the first few hours or days after injury and a “flow” 
or hypermetabolic phase (proliferation) that may last weeks to months depending on the 
complexity of the wound [17, 52, 53].  
 It has been well established that non-wounded epidermal cells, as well as wounded skin, 
are mainly dependent upon carbohydrate metabolism via glycolysis and the PPP rather than the 
Krebs cycle for their energy requirement [54-59]. In a hallmark study, Im et al. showed a 4-fold 
increase of glycolytic enzymes of wounded skin compared to normal skin [56]. The contribution 
of the Krebs cycle to glucose metabolism was reduced in wounded skin compared to normal skin 
(8% to 4%) demonstrating a metabolic shift to the PPP and other biosynthetic pathways, needed 
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for repairing the wound. This metabolic shift towards glycolysis was confirmed by the 
observations that the rate of nucleotide formation was higher in wounded skin compared to 
normal skin and a 7-fold increase in the PPP enzymatic activities. Furthermore, glucose-6-
phosphate dehydrogenase (G6PDH) was increased 7-fold, corresponding to the increased 
contribution to the PPP [56]. Additionally, there was evidence that lactate production was tripled 
in day three post-wounding, further confirming the higher flux through glycolysis and 
subsequently anaerobic fermentation. Even though glycolysis is less efficient at creating ATP 
compared to flux through the TCA cycle, the rate of ATP formation was doubled after three days 
of wound healing. The ATP production was seen as a gradient with higher concentrations of 
ATP in the migrating epithelium compared to the marginal proliferating epithelium. The study 
showed a decrease in energy production per unit of glucose in wounded skin compared to normal 
skin, as would be expected in the switch to glycolytic metabolism compared to aerobic 
respirations. The inefficiency of glycolysis forming ATP compared to the ETC is overcome by 
the increased metabolic rate of wounded skin. It has been shown that elevated activities of 
glycolytic enzymes may contribute to increased cellular demand for energy during healing of 
acute wounds [51, 59, 60].  
 
1.7. Nutrition and Wound Healing 
Nutritional status is extremely critical for effective wound healing [61-81]. As mentioned 
earlier in this chapter, maintenance of a balanced anabolism: catabolism ratio is fundamental to 
optimizing the wound healing process. Since healing a wound is crucial to surviving, a wound 
requires high priority of the circulating nutrients in the blood stream. Increased macronutrient 
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intake is required to keep up with the catabolic losses and to allow wound-healing processes. The 
American Society for Parenteral and Enteral Nutrition and Wound Healing recommends 
approximately 30 to 35 kcal/kg/d for optimal wound healing, which is roughly 1.2-1.5 times 
more than a non-wounded patient would ingest [82]. These macronutrients are predominantly 
used as fuel; however, they also have direct effects essential for healing [64]. It should be noted 
that individual energy needs depend on age, gender, nutritional status, basal metabolic rate, body 
mass index (BMI), comorbid conditions, activity level, the stress of illness, severity and number 
of wounds, and wound size of that patient, which supports the heterogeneous classification of 
wounds [17, 83].  
Macronutrients (fats, proteins, and carbohydrates) provide the energy for all body 
functions and are major building blocks for the reparative process. In a healing wound, the influx 
of inflammatory cells, as well as fibroblasts, use carbohydrates as an energy source. Additionally 
carbohydrates have been shown to have a variety of non-energy related roles (structural, 
lubricant, immunologic, hormonal, and enzymatic) [17]. Fats and their derived lipid components 
provide the building blocks for the cell membrane and certain inflammatory mediators, behave as 
signaling molecules, control tissue growth, wound remodeling, and collagen and extracellular 
matrix production [84-91]. Proteins are predominantly metabolized into amino acids and 
peptides for the purpose of protein synthesis; only 5% of protein metabolism is used for energy 
[83]. Protein derived amino acids provide the major structural building blocks of all proteins in 
the body, notably collagen. Amino acids are necessary for the cell membrane, enzymes, and 
cytokine production in the healing wound [64].  
When dietary nutrients are not adequate, or if the catabolic state outweighs the anabolic 
state, the wound can proficiently use substrates available from the rest of the body for energy 
	 17	
production, resulting in what is called protein-energy malnutrition (PEM).  The body catabolizes 
the muscle, skin, and bone to support the synthesis of proteins, inflammatory cells, and collagen 
needed to fight infection and repair the wound, causing a loss of lean body mass (LBM). As an 
individual loses more LBM, wound healing is more likely to be delayed.  A loss of more than 
15% LBM impairs wound healing, a 30% LBM loss stops wound healing, and a loss of 40% 
LBM typically results in death [64, 92-95].  As will be important later, a body in starvation 
(ketosis) has been shown to be muscle sparing, attenuating the catabolic effects [83]. LBM loss 
becomes vital in older adults as many suffer from pre-existing malnutrition and PEM. 
 
1.8. Chronic Wounds 
 Chronic wounds represent an under-acknowledged socioeconomic epidemic, affecting 
1.8 million new patients per year in the US. [96]. The care of these chronic wounds costs the US 
health care system at least $25 billion annually. This substantial cost is rapidly growing due to 
increased healthcare costs, an aging population, an increase in diabetes and obesity, and the 
expanding need for wound care for veterans [96-98]. As more of our population ages (>65 
years), projected to be 20% of the population by 2030, there is a critical need to develop 
effective wound healing treatments to alleviate the considerable medical, social, and economic 
burden facing the country [99]. 
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1.8.1. Classification of Chronic Wounds 
 Chronic wounds are defined as wounds that have failed to proceed through and orderly 
and timely reparative process to produce anatomic and functional integrity.  All wound types 
have the potential to become chronic, and as such, chronic wounds are traditionally divided by 
etiology. A prolonged inflammatory stage, persistent infections, drug-resistant microbial 
biofilms, and the inability of cells to respond to reparative signals are pathophysiological features 
of all chronic wounds [8, 100, 101]. The Wound Healing Society’s Chronic Wound Care 
Guidelines divide chronic wound into four different phenotypes: vascular ulcers (venous and 
arterial), pressure ulcers, and diabetic ulcers.  
 The venous ulcer accounts for more than half of ulcer cases and 70-90% of ulcers found 
on the lower limbs [102]. Venous ulcers affect approximately 1.69% of older adults or 600,000 
patients total in the US annually [96, 103]. They are associated with deep vein thrombosis, 
varicose veins, and venous hypertension. Physically, venous ulcers have skin that is shiny, 
smooth, with minimal to no hair, are superficial, shallow, irregularly shaped, and are 
accompanied by pain and edema. Less common than venous ulcers, arterial ulcers affect 
approximately 100,000 Americans annually [104]. Arterial ulcers occur from hypertension, 
atherosclerosis, and thrombosis, where the reduced blood supply leads to an ischemic state. 
Commonly, they are full thickness wounds with a punched out appearance and smooth edges. As 
compared to the venous ulcers that have prevalence on the lower limbs (between the knee and 
ankle), arterial ulcers usually occur more distal such as the tip of the toe and over distal bony 
prominences.  
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 Pressure ulcers, also known as bedsores, are a result of prolonged pressure, friction and 
shear from body weight and usually occur at a bony prominence such as the sacrum or heel. 
Clinically, they present with redness, itching, blistering, warmth, swelling, and discoloration of 
the overlying skin. They are prevalent in any patient that is wheelchair bound, bedridden, or 
suffering from immobility or sensory neuropathies [105]. 2.5 million pressure ulcers are treated 
in the US per year [106]. The cost of treating one pressure ulcer is estimated to be as much as 
$70,000, totaling to an estimated $11 billion a year for pressure ulcer care [107, 108].  About 
15% of patients in an acute care facility and up to 29% of patients in long-term care will 
experience a pressure ulcer [96]. According to the Centers for Medicare & Medicaid Services 
(CMS), there were a staggering 257, 412 preventable pressure ulcers in 2007 [109]. Additionally, 
pressure ulcers can be a major source of infection, leading to complications and even death. 
Development of a pressure ulcer increases mortality rate by 7.23% [110]. Over the last ten years 
nearly 60,000 deaths occurred annually from hospital-acquired pressure ulcers [96]. Even though 
many resources have been devoted to rectify these overwhelming statistics, it is still extremely 
challenging and costly to prevent pressure ulcers [111-114].  
 As of October 2014, 29.1 million people in the United States have diabetes mellitus of 
which 8.1 million people are undiagnosed [115]. Diabetic ulcers are a common complication in 
uncontrolled diabetes, resulting from impaired immune function, ischemia (due to poor blood 
circulation from high glucose content as well as vascular insufficiencies), and neuropathy. It is 
estimated that up to 25% of all diabetics will develop an ulcer in their lifetime [116]. In 2007, a 
single foot ulcer cost between $7,439 and $20,622, totaling to a $9 billion expense per year 
[117].  
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1.8.2. Current Standard of Care, Alternative Therapies, and Their Disadvantages 
 Identifying and treating the underlying etiology of chronic wounds such as venous 
insufficiency, arterial perfusion, diabetes, or continuous pressure as well as systemic factors such 
as age, nutritional status, immunosuppression, and infection is key to successful wound healing 
therapies. However, the establishment of effective wound healing therapies has been 
unsuccessful due to the magnitude of these underlying pathogenic factors and the heterogeneity 
across and within wound types [118]. Furthermore, it is important to emphasize that no two 
wounds are exactly the same; thus, a treatment that could work for one patient may not be 
effective for another.  
 Most current wound therapies being studied target a specific molecular or cellular 
mechanism where there are often multiple mitigating factors that prevent normal wound closure. 
This is likely one reason most wound therapies are minimally effective.  Many growth factor 
supplements tested in animal models appeared to be promising therapeutic agents promoting 
wound healing [119]; however, human clinical trials have not been very successful [120, 121]. 
Additionally, there is a multitude of topical therapies (antimicrobials, dressings, silver-containing 
products) that are commercially available, with minimal data to support their effectiveness in 
promoting wound healing [122].  
In vitro models have aided in the understanding of basic biology of wound healing; however, 
more complex models to simulate the wound environment (multiple cell types) in conjunction 
with comorbid conditions have not been developed. Many studies in wound repair have relied on 
rodent models; however, skin morphology and the mechanisms of repair are markedly different 
between rodents and humans [118, 123]. Additionally, some pre-clinical studies have used acute 
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wounds in young animals and not appropriately aged animals, demonstrating that there are no 
animal models that comprehensively mimic human chronic wounds [124]. 
 
1.8.2.1. TIME and Amputation  
 Standard clinical therapies for non-healing wounds use the wound bed preparation 
concept, which focuses on optimizing the condition of the wound bed to encourage normal 
healing. In 2002, the acronym TIME was developed as a practical guideline for wound 
management. TIME encompasses four main components of wound bed preparation: Tissue 
management (debridement), control of Infection and inflammation, manage Moisture, and the 
Edge of wound advancement [125, 126].  
Debridement is the surgical removal of necrotic, damaged, or infected tissue, biofilms, 
exudate, and debris to improve the healing of the remaining healthy tissue [127-132]. The goal of 
debridement is to transition an excessively inflamed chronic wound to more of an acute profile, 
promoting resolution of inflammation [122, 133, 134].  Chronic wounds are well characterized as 
being stuck in the inflammatory phase with a marked increase in degrading proteases such as 
matrix metalloproteinases (MMPs) and elastases and persistence of inflammatory cells [126, 
129, 135-137]. Resolution of prolonged inflammation renews tissue healing, lessens exudate, and 
reduces bioburden. It is important to distinguish between normal inflammation associated with 
physiological healing compared to excessive inflammation caused by underlying adverse 
etiologies and infection. Inflammation and infection are controlled using antimicrobials 
(disinfectants, antiseptics, and antibiotics) in a variety of applications including silver dressings, 
iodine dressings, PHMB dressings, honey, and surfactants [126]. Balanced moisture is essential 
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for the action of growth factors, cytokines, and cell migration. Excessive moisture damages 
surrounding skin and insufficient moisture inhibits cellular activities and leads to eschar (scab) 
formation [137]. Wound edge advancement assessment determines if wound contraction or 
epithelialization is progressing and evaluates the effectiveness of the wound treatment. An 
increasing range of treatment modalities has been proposed to improve wound edge advancement 
including electromagnetic therapy (EMT), laser therapy, ultrasound therapy, systemic oxygen 
therapy, and negative pressure wound therapy (NPWT) [126].  
Amputation is the final and last course of action against chronic wounds (when they 
occur on an extremity). This is done to prevent the spread of infection to healthy tissue. 
Amputations are classified as either major (an amputation of the leg above or below the knee) or 
minor (amputation of toes or forefoot) [138]. Many diabetic patients eventually must undergo 
lower extremity amputations as a result of infection brought on by untreated foot ulcers. Diabetic 
foot ulcers are responsible for 20% of diabetes-related hospitalization and underlie up to 80% of 
non-traumatic amputations per year. It is estimated that 12% of individuals with a foot ulcer will 
require amputation. Mortality following amputation is 13-40% at one year, 35-65% at three 
years, and 39-80% at five years, which is worse than most malignancies. Once amputation 
occurs, 50% of patients will develop an ulcer in the contralateral limb within five years [117]. 
 
1.8.2.2. Adjunctive Therapies 
 Even with the standard care practices of wound healing, there is a multitude of treatment 
options and modalities. As previously mentioned, most of these treatments have limited research 
data to prove effectiveness and many have controversial clinical results. Adjunctive treatments 
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for wound healing include negative pressure therapy, hyperbaric oxygen therapy (HBOT), 
dermal substitutes, growth factor supplementation therapy, and stem cell therapy [139, 140].  
Negative Pressure Wound Therapy (NPWT), vacuum-assisted wound therapy or 
commonly known as a wound VAC®, has become a popular adjunctive therapy[141-143]. 
Negative pressure is applied to the wound via foam or gauze dressing moistened with saline, 
which is then covered with a transparent adhesive sheet attached to a vacuum pump. NPWT has 
been shown to manage wound drainage, reduce edema, reduce the bio-burden of 
microorganisms, increase wound perfusion, and loosen the exudate [126]. This therapy in 
combination with debridement has been shown to promote granulation tissue formation, 
contraction and epithelialization [135]. However, a systematic review and meta-analysis of 21 
studies found no clear evidence that wounds heal either better or worse with NPWT compared to 
standard of care [144]. Additionally, the mechanism of action for NPWT is poorly understood, 
and few studies have focused on the efficacy of this therapy in older adults [118].  
Hyperbaric oxygen therapy (HBOT), originally utilized for decompression illness, has 
been an adjunctive therapy for wound healing for more than two decades. It involves placing a 
patient in a sealed chamber where 100% oxygen is pressurized to 1.5-3 atmospheres absolute 
(ATA) for 60-120 minutes over a course of multiple treatments [139]. There isn’t an optimized 
protocol for treatment and the mechanism of action for HBOT to improve wound healing is 
poorly understood. However, it is speculated that HBOT helps reduce edema via 
vasoconstriction and fluid absorption, increases oxygen perfusion aiding collagen elongation and 
deposition, and stimulates epithelial progenitor cells and stem cell release for vasculogenesis 
[139]. Published systematic reviews have reported mix results regarding the efficacy of HBOT, 
as observational studies have shown a significant advantage of HBOT for wound healing; 
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however, six randomized trials did not show a benefit [145].  There are some promising animal 
data suggesting that HBOT is effective for all ages; however, there are no studies specifically 
focused on the efficacy of HBOT in older adults [146, 147]. 
Both biosynthetic skin substitutes (synthetic) and cultured autologous-engineered skin 
(natural) are available to provide the protective barrier of skin when placed over a wound [148-
154].  The synthetic substitutes are made of an acellular material, and the natural substitutes 
consist of cultures allogeneic or autologous cell suspensions or sheets used alone or with a 
dermal matrix. The purpose of engineered skin products is to expedite wound healing by serving 
as a scaffold for cellular ingrowth, stimulating the release of growth factors from the wound bed, 
and restoring the functional properties of the skin [154, 155]. The skin substitutes (SS) can be 
either permanent or temporary, depending on design and composition. It’s important to note that 
although each of skin substitutes has their advantages and have applications, none of them can 
fully simulate native skin. Both types of SS have been shown to be quite effective in increasing 
the speed of wound healing, decreasing recurrence, reducing the number of required surgical 
procedures, and reducing patient hospitalization time [148, 153, 155, 156].  Nevertheless, the 
commercially available skin substitutes have several limitations such as reduced vascularization, 
scarring, failure to integrate, poor mechanical integrity, and immune rejection. Furthermore, the 
cost associated with the use of the current skin substitutes is very high. For example, it is 
estimated that the cost for each 1% body surface areas covered by the commercially available 
Epicel ™ is more than $13,000 [157]. As it relates to this project, the effect of the patient age on 
skin substitutes is poorly characterized [118].  
It is well characterized that growth factors play a substantial role in both healing and non-
healing wounds. Wound healing products have been designed to accelerate repair by augmenting 
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or modulating these growth factors in hopes of mediating inflammation and promoting 
angiogenesis. Among all the possible growth factors, platelet-derived growth factor (PDGF) has 
been approved by the Food and Drug Administration (FDA) for the treatment of diabetic foot 
ulcers [4]. PDGF has been shown to stimulate granulation, increased odds of wound healing and 
decrease rates of amputations in diabetic patients [158-165].  Growth factors EGF and FGF have 
also been studied as topical wound healing therapies; however, the heterogeneity of wounds, 
applications, patient management protocols, and clinical trial outcomes has limited their use to 
outside of the USA [122].  
  Stem cells have the unique capability to differentiate into the variety of tissues in the 
body. Stem cells derived from various sources including bone marrow, adipose, peripheral and 
umbilical blood, in addition to vascular progenitor cells have been shown to migrate towards the 
wound site and contribute to the wound healing process [166-168]. These cells have been to 
shown to increase angiogenesis, increase granular tissue formation, enhance wound healing, and 
reduce scarring [166, 168-172]. Even though stem cell research seems promising, the use of stem 
cells is hampered by immunogenicity, potential for malignancy, pluripotency maintenance, 
ethical consideration, and limited supply [118].  Additionally, harvesting bone marrow derived 
stem cells is painful and leads to donor site morbidity [173].  
 The field of wound care is ever expanding with advances in technology. However, there 
is still no superior substitute to allowing the body to heal systemically on its own accord in 
conjunction with reconstruction using patients’ own tissues and carefully thought-out surgical 
procedures. The therapy proposed in the next chapter of this dissertation focuses on exploiting 
the body’s systemic physiology to enhance wound healing.   
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1.9. Age Influence on Chronic Wounds 
 Chronic wounds disproportionally affect older adults. 72% of hospitalized patients with 
pressure ulcers were 65 and older. Most chronic wounds are associated with co-morbid 
conditions prevalent in older adults, including cardiovascular disease, unrelieved pressure, 
obesity, or diabetes mellitus [96]. However, Wicke and associates in 2009 demonstrated that age 
was an independent risk factor for delayed wound closure. By the age of 70, the frequency of 
wound closure was significantly lower than the younger counterparts [174]. It should be noted 
that the effect of aging on wound repair is primarily a temporal delay; a change in the quality of 
wound closure has not been reported [175]. The exact mechanisms responsible for this increased 
risk remain unknown. In this dissertation we focus on four physiological attributes that we feel 
lead to the prevalence of chronic wounds in older adults: unresolved inflammation, unmitigated 
ROS production, decreased angiogenesis/blood flow, and decreased metabolism. 
 
1.9.1. Age-Related Changes in Skin Morphology  
 Though the skin is incredibly durable, like all other systems, it eventually succumbs to 
the inevitable effects of aging. The skin is also the most visible indicator of age. Clinically, 
drying, roughness, sagging, wrinkling, and alterations in pigmentation characterize aged skin. 
Physiological changes in the skin include both structural and biochemical changes. 
Morphologically, the skin is characterized by atrophy due to the flattening of the 
epidermis/dermis junction and a decrease of epidermal and dermal cellular content, collagen 
	 27	
disorganization, a decrease in microcirculation, and an increase in time for keratinocyte 
maturation [4, 176-179]. The thickness of the skin decreases about 6.4% per decade on average. 
Keratinocytes change shape as the skin ages, becoming shorter and fatter while corneocytes 
become bigger as a result of decreased epidermal turnover. The cellular content of the dermis 
(fibroblasts, mast cells, and macrophages) and protein content (collagen) are reduced with age. 
The collagen and elastin that remain in the dermis are less organized, resulting in a decreased 
elasticity of the skin [180].  Enzymatically active melanocytes decrease at a rate of 8-20% per 
decade, resulting in the irregular pigmentation of elderly skin. Alterations in the aging skin not 
only have an impact on wound healing but also make the skin more susceptible to injury. The 
flattening of the epidermis/dermis junction results in less resistance to shearing forces and 
increased vulnerability to insult as well as increased separation.   
 
1.9.2.  Age-Related Changes in the Wound Healing Cascade 
 Aging affects every phase of wound healing [176]. It has been demonstrated that aged 
wounds have decreased levels and response to growth factors, reduced microcirculation, 
diminished cell proliferation and migration, and diminished ECM secretion [181-183]. Aging is 
also associated with delays in macrophage and T cell infiltration, angiogenesis, and re-
epithelialization [118].  It has been hypothesized that age-associated disadvantages in healing 
may arise from overexpression of matrix metalloproteinases, which normally aid in 
phagocytosis, angiogenesis, cell migration during epidermal restoration, and tissue remodeling. 
Protease expression and activity are elevated in older human adults, which leads to the 
perpetuation of the pro-inflammatory state and inhibits progression to the reparative phase [184].   
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 Inflammation is a major contributing factor in wound chronicity and the aging 
phenotype. As previously mentioned, chronic wounds are characterized as being stuck in the 
inflammatory phase. Without resolution, the wound cannot advance to the reparative phase. This 
inability to resolve inflammation is believed to be the most significant delaying factor in the 
healing of chronic wounds [185]. It has been established that aged individuals have a consistent 
low-grade inflammation marked by elevated cytokines like TNF-α, IL-6, and CRP, even when 
the individual is healthy, or infection is absent [186]. This is in direct contrast to young 
individuals, who only produce elevated levels of cytokines in response to injury or infection. 
This low-grade inflammation has been implicated in the higher prevalence of co-morbidities 
such as cardiovascular disease and diabetes in older adults. It has been suggested that 
inflammation may be a common underlying cause of several age-related diseases or could be a 
common pathway by which multiple diseases lead to disability and adverse outcomes in older 
adults [186]. This already heightened inflammatory response is worsened in the presence of a 
wound. It has been shown that there are increased numbers of neutrophils with prolongation of 
the pro-inflammatory state as well as a delay in macrophage recruitment [185]. Additionally, a 
study by Mahbub and colleagues demonstrated that M1 macrophages fail to transition to the M2 
phenotype, perpetuating the inflamed state in an aged population [187]. 
 ROS are produced in the healing wound as a bactericidal tool; however, when the levels 
are not quenched by downstream antioxidants elevated ROS levels transcend the beneficial effect 
and cause mitochondrial dysfunction, DNA damage, lipid peroxidation, and even cell death [188, 
189].  Additionally, ROS are produced as a normal by-product of oxidative phosphorylation; 
thus in a wound environment cells are hit with ROS from neutrophilic respiratory bursts as well 
as from enhanced energy metabolism necessary to heal the wound [23, 190, 191]. The energy 
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metabolism shift to anaerobic respiration during wound healing likely protects the mitochondria 
from over usage and damage related to ROS production [55]. Skin mitochondria in the human 
aged population demonstrated an increased incidence of mitochondrial DNA (mtDNA) 
mutations leading to mitochondrial dysfunction [192, 193].  Electron microscope images of aged 
mitochondria show disorganization and degeneration via absent cristae, vacuolation, and 
swelling [194]. Additionally, it has been determined that both superoxide anion and H2O2 are 
increased in aged dermal fibroblasts [195]. Several studies have shown that the aged phenotype 
has decreased levels of antioxidants to quench the increased ROS [196-199].  Treiber et al. 
demonstrated that the skin of manganese superoxide dismutase (MnSOD, SOD2) deficient mice 
was phenotypically similar to aged animals with characteristics such as atrophy of dermal 
connective tissue, muscle fibers, and subcutaneous fat, loosely packaged collagen fibrils, 
damaged mitochondria, and decreased cellular proliferation [200].  
 It has been demonstrated that angiogenesis is decreased with age because of reduced 
levels of the angiogenic factors: FGF, VEGF, and TGF-β, impaired vasodilation, proliferation 
and migration of angiogenic, microvascular endothelial cells. It is important to note that the 
coexistence of hypertension, diabetes, smoking, and hypercholesterolemia exacerbates the 
inherent effects of aging that are detrimental to angiogenesis [176, 201].  
 The metabolic challenge of a wound is exacerbated in elderly patients, who have a higher 
prevalence of malnutrition combined with reduced total energy expenditure, basal metabolic rate, 
and protein synthesis [17]. Without appropriate energy (ATP) levels, wound healing is 
significantly impaired. The ATP deficiency creates an imbalance of energy production versus 
utilization. To compensate, anaerobic respiration increases in the wound bed, which only 
produces 2 ATP per glucose molecule as compared to the potential 38 ATP made from normal 
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aerobic respiration [41]. Gupta et al. showed that key metabolic enzymes were decreased in aged 
rats [51].  It has been illustrated that mitochondria become larger and less numerous with age, 
mitochondrial respiratory chain (MRC) enzyme activities decrease as well as mitochondrial 
membrane potential [202]. Furthermore, there is a significant reduction in mitochondrial 
bioenergetic capacity with advancing age, which has been shown in numerous animal models 
and recently in a study with human volunteers [202, 203].  
 
1.10. Closing Remarks 
 In summary, there is come controversy regarding whether chronological age alone affects 
wound healing. However, it is well documented that there is increased ROS production with age, 
leading to cellular damage, reduced blood flow leading to the lessening of nutrient exchange, 
decreased metabolic activity and ATP production at the wound bed, and unresolved chronic 
inflammation. It is easily deduced how these factors may lead to increased prevalence of chronic 
wounds in older adults. Most approaches to accelerate wound healing focus on delivery of 
growth factors by topical application. The discouraging results of focusing on single molecular 
targets are not surprising since wound healing is the product of a complex set of interactions 
between numerous factors.   It is here that we aim to switch the approach to optimizing the 
body’s physiology to reach the wound bed systemically as well as targeting multiple facets of 
impaired wound healing with one therapy- exogenous ketone supplementation, which will be 
discussed further in the next chapter. 
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CHAPTER 2: ORAL KETONE SUPPLEMENTATION AS A NOVEL THERAPEUTIC 
FOR DELAYED WOUND HEALING 
 
2.1. Chapter Synopsis 
 In the previous chapter, I provided a thorough overview of chronic wounds and the non-
efficacious therapies that are currently available, especially for the aged population. Here I 
provide a rationalization for the use of an oral exogenous ketone supplement as a novel therapy 
for wound healing. The ketogenic diet has been used since the 1920s for refractory epilepsy in 
children. Though it has been proven to be effective, it is hard to maintain and is limited in a 
clinical setting. Recently, it has been shown that ketone bodies themselves may confer 
therapeutic benefits, paving the way for an exogenous ketone supplement that does not require 
dietary restriction. Ketones have been shown to decrease inflammation, decrease ROS levels, 
increase blood flow, and increase ATP hydrolysis and increase metabolism. As previously 
described, these are the four underlying age-dependent features we will utilize to determine the 
efficacy of our treatment. For these reasons, we hypothesize that exogenous ketone 
supplementation will augment wound healing and we propose to test their effects in vivo using 
an ischemic wound model in young and aged Fischer 344 rats and in vitro using patient-derived 
primary human dermal fibroblasts isolated from discarded skin.  
 Portions of this chapter have previously been published in “Kesl SL, Poff AM, Ward NP, 
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Fiorelli TN, Ari C, Van Putten AJ, Sherwood JW, Arnold P, D’Agostino DP. Effects of 
Exogenous Ketone Supplementation on Blood Ketone, Glucose, Triglyceride, and Lipoprotein 
Levels in Sprague-Dawley Rats. Nutrition and Metabolism (2016)”, Poff AM, Kesl SL, 
D’Agostino DP “Ketone Supplementation for Health and Disease” Book Chapter, Oxford Press 
(Submitted), and “ Trujilio AN*, Kesl SL*, Sherwood J, Wu M, Gould LJ. (2014) 
Demonstration of the Rat Ischemic Wound Model. Journal of Visualized Experiments: JoVE ”. * 
Indicates that both authors contributed equally to the work. Copies of these articles may be found 
in Appendix C. See Appendix B for copyright permissions. Materials and methods presented in 
this chapter can be found in Appendix A.  
 
2.2. Ketone	Body	Synthesis	and	Metabolism 
 Ketone bodies are naturally elevated to serve as alternative metabolic substrates for extra-
hepatic tissues during the prolonged reduction of glucose availability, suppression of insulin,  
and depletion of liver glycogen, such as occurs during starvation, fasting, vigorous exercise, 
calorie restriction, or the ketogenic diet (KD). As blood glucose levels drop, the body goes 
through a metabolic shift from glucose-based metabolism towards fatty acid oxidation and 
hepatic ketogenesis to generate ATP. As a result, hepatic cells synthesize necessary glucose 
through gluconeogenesis (GNG) and β-oxidation metabolizes fats (dietary and stored) to form 
Acetyl CoA. During GNG, the oxaloacetate stores are depleted, causing the Acetyl CoA from 
fatty acid oxidation to accumulate and not enter the Krebs cycle. The excess Acetyl CoA 
produces the ketone bodies beta-hydroxybutyrate (βHB) and acetoacetate (AcAc) via a 3-step 
enzymatic process known as ketogenesis. From the liver, these substrates are transported 
	 48	
systemically to extra-hepatic tissues (i.e. muscle, brain, and skin) where Acetyl CoA is 
reconstructed and used to generate ATP via the Krebs cycle and the ETC [1, 2]. Additionally, 
AcAc can be decarboxylated to produce the third ketone body, acetone. Although acetone has 
been considered mainly to be a metabolic by-product that is eliminated via the lungs and urine, it 
has recently been shown to play an important role in the anticonvulsant properties of the 
ketogenic diet [3-7]. 
 
2.3. Review of Ketogenic Diet and Therapeutic Uses 
 The classical ketogenic diet (KD) consists of a 4:1 ratio of fat to protein and carbohydrate 
combined, with 80-90% of total calories derived from fat [8]. For most patients this equates to 
eating less than 50 grams of carbohydrates and around 100 grams of protein a day [9]. Actual 
carbohydrate and protein intake must be individually optimized to maintain therapeutic ketone 
production. The macronutrient ratio of the KD induces the metabolic shift towards hepatic 
ketogenesis, elevating AcAc and βHB in the blood. Compared to other low carb diets like the 
Atkins diet, the ketogenic diet requires only adequate protein. Excess protein intake can fuel 
GNG, resulting in glucose synthesis that disables ketogenesis. It is important to emphasize that 
not all low carbohydrate diets are ketogenic. The ketogenic diet is really a high-fat diet, and not a 
high-protein diet.  
 Emerging evidence supports the therapeutic potential of the ketogenic diet (KD) for a 
variety of disease states, leading investigators to research methods of harnessing the benefits of 
nutritional ketosis without the dietary restrictions. The KD has been used as an effective non-
pharmacological therapy for pediatric intractable seizures since the 1920s [10-12]. In a study of 
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150 epileptic children who averaged 400 seizures per month and were on multiple anti-epileptic 
medications, 60% reported a significant decrease in seizure frequency [12]. In addition to 
epilepsy, the ketogenic diet has elicited significant therapeutic effects for weight loss and type-2 
diabetes (T2D) [13]. Several studies have shown significant weight loss on a high fat, low 
carbohydrate diet without significant elevations of serum cholesterol [14-21]. Another study 
demonstrated the safety and benefits of long-term application of the KD in T2D patients. Patients 
exhibited significant weight loss, reduction of blood glucose, and improvement of lipid markers 
after eating a well-formulated KD for 56 weeks [22]. Recently, researchers have begun to 
investigate the use of the KD as a treatment for acne, polycystic ovary syndrome (PCOS), 
cancer, amyotrophic lateral sclerosis (ALS), traumatic brain injury (TBI) and Alzheimer’s 
disease (AD) with promising preliminary results [23-35]. 
 
2.3.1. Potential Concerns and Side Effects 
 Although the KD has clear therapeutic potential, several factors limit the efficacy and 
clinical utility of the KD for metabolic therapy. Patient compliance to the KD can be low due to 
the severe dietary restriction, the diet being perceived as unpalatable, and intolerance to high-fat 
ingestion. Maintaining ketosis can be difficult as consumption of even a small quantity of 
carbohydrates or excess protein can rapidly inhibit ketogenesis [36, 37]. Furthermore, enhanced 
ketone production and tissue utilization can take several weeks (keto-adaptation), and patients 
may experience mild hypoglycemic symptoms during this transitional period [38]. One common 
concern regarding the KD is its purported potential to increase the risk of atherosclerosis by 
elevating blood cholesterol and triglyceride levels [39, 40]. This topic remains controversial as 
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some, but not all studies have demonstrated that the KD elevates blood levels of cholesterol and 
triglycerides [41-46]. Kwitervich and colleagues demonstrated an increase in low-density 
lipoprotein (LDL) and a decrease in high-density lipoprotein (HDL) in epileptic children fed the 
classical KD for two years [8]. In this study, total cholesterol increased by ~130%, but then 
stabilized at the elevated level over the 2-year period. A similar study demonstrated that the lipid 
profile returned to baseline in children who remained on the KD for six years [47]. Children 
usually stay on the diet for approximately two years then return to a diet of normal fat and 
carbohydrate ingestion [48]. In contrast, the majority of recent studies have suggested that the 
KD can lead to significant benefits in biomarkers of metabolic health, including blood lipid 
profiles [49-56]. In these studies, the KD positively altered blood lipids, decreasing total 
triglycerides and cholesterol while increasing the ratio of HDL to LDL [52-61]. Although, the 
KD is well established in children, the diet has only recently been accepted as a strategy to 
control seizures in adults. In 2014, Schoeler et al reported on the feasibility of the KD for adults, 
concluding that 39% of individuals achieved > 50% reduction in seizure frequency, similar to 
results seen in pediatric studies. Patients experienced similar gastrointestinal adverse events that 
have been previously described in pediatric patients, but they did not lead to discontinuation of 
the diet in any patient [62].   
 
2.4. Exogenous Ketone Supplementation 
Considering both the broad therapeutic potential and limitations of the KD, an oral ketone 
supplement that could rapidly induce and sustain therapeutic ketosis without the need for dietary 
restriction would be an attractive and practical alternative. Recent studies suggest that many of 
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the benefits of the KD are due to the effects of ketone body metabolism. Veech et al. have 
summarized the potential therapeutic uses for ketone bodies, which will be discussed later in this 
chapter [3, 63]. Furthermore, there is potential for an additive therapeutic effect between a 
standard KD and an oral ketone supplement for patients consuming a low carbohydrate or 
ketogenic diet. Additionally, in some scenarios, a ketone supplemented ketogenic diet may be 
more effective than KD or ketone supplementation alone. Several natural and synthetic ketone 
supplements capable of inducing nutritional ketosis have been identified. There are numerous 
sources of ketones and ketogenic precursors being developed and tested, including medium chain 
triglycerides, diols, salts, and esters that have been shown to elevate blood ketone levels without 
dietary restriction. The investigation of natural and synthetic ketogenic precursors to establish 
nutritional ketosis without the need for dietary restriction has revealed that each formulation has 
distinct properties in terms of extent and duration of ketosis as well as metabolic effects. Most of 
the developed ketone supplements are currently under investigation for safety and efficacy in a 
number of disease states. For this dissertation, we focus on five ketogenic agents including 1, 3-
butanediol (BD), medium chain triglyceride oil (MCT), sodium/potassium-βHB mineral salt 
(BMS), combination of BMS+MCT, and 1,3-butanediol acetoacetate diester/ ketone ester (KE).  
 
2.4.1. 1,3-Butanediol 
1,3-Butanediol (BD) is a FDA approved organic alcohol used as a food flavoring solvent, an 
intermediate in the manufacture of certain polyester plasticizers, and a humectant for cosmetics 
[64, 65]. When ingested orally, BD is metabolized by the liver via alcohol dehydrogenase (ADH) 
to β-hydroxybutyraldehyde, which is rapidly oxidized to βHB by aldehyde dehydrogenase [66]. 
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BD contributes approximately 6 kcal/g of energy and can produce dose-dependent millimolar 
concentrations of ketones in the blood [67-69]. Extensive toxicology studies have concluded that 
BD is safe with very little adverse health effects in humans or animals [70-73]. BD has been 
investigated as a therapy to reduce brain damage following cerebral ischemia. BD attenuated 
hypoxic damage via a cerebral protective effect mediated by brain ketone metabolism [74]. 
Additionally, ketosis induced via exogenous BD supplementation has been shown to increase 
survival time of mice exposed to hypoxia in a stroke model [75]. BD supplementation has been 
shown to significantly prolong the survival time in mice with metastatic cancer by 51% [26]. 
Recently, BD has been investigated therapeutically as a backbone of ketone mono- and di-esters, 
which are discussed later in this chapter.  
 
2.4.2. MCT Oil 
 Medium chain triglycerides (MCTs) contain a glycerol backbone esterified to medium-
chain fatty acids (MCFAs), which are fatty acids with hydrocarbon side chains 6 to 12 carbons in 
length. MCFAs include caproic acid (C6:0, hexanoic acid), caprylic acid (C8:0, octanoic acid), 
capric acid (C10:0, decanoic acid), and lauric acid (C12:0, dodecanoic acid). MCTs are naturally 
found in coconut oil (15%), palm kernel oil (7.9%), cheese (7.3%), milk (6.9%), butter (6.8%), 
and yogurt (6.6%) [76, 77]. Compared to long-chain fatty acids (LCFAs), MCFAs have a lower 
melting point, smaller molecule size, and are less calorically dense (8.3 calories per gram versus 
9.2). These distinct physiochemical properties allow MCTs to be absorbed directly into the 
bloodstream through the portal vein without the need for bile or pancreatic enzymes for 
degradation. Additionally, MCTs do not require carnitine to enter the mitochondria, but rather 
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quickly cross the double mitochondrial matrix where they are metabolized to acetyl co-A, and 
subsequently, to ketone bodies. Thus, they are easily and rapidly digested, transferred to the 
liver, and used for energy rather than stored as fat. In comparison, LCFA metabolism is much 
slower requiring re-esterification in the small intestine, transport by chylomicrons via the 
lymphatic and vascular systems, and oxidation in the liver for energy or storage. MCTs are 
metabolized as rapidly as glucose but have roughly twice the energy density [78]. In the early 
1980s, Dr. Vigen K. Babayan of the Nutrition Laboratory at Harvard University developed a 
process to produce MCTs in large quantities [79]. These commercialized MCTs are acquired 
through lipid fractionation from natural fats such as coconut oil and milk and are predominantly 
comprised of C:8 and C:10 MCTs [80, 81].  
 Since the 1970s, MCTs have been used in a modification of the classical KD as an 
alternative fat source [82]. The ketogenic properties of MCTs allow patients to eat less total fat 
in their diet and include more carbohydrate and protein without sacrificing their nutritional 
ketosis. Although MCTs have the potential to be an efficient and beneficial ketogenic fat, they 
are currently limited in clinical use due to gastrointestinal (GI) side effects stimulated by the 
large dose needed to induce ketonemia (greater than 40 g/day) [78]. The original modified KD 
with MCT allowed 60% of its energy to be derived from MCTs; however, this amount caused GI 
distress in some children [83-86]. For this reason, an additional modified KD with MCT was 
developed using only 30% of its energy from MCTs; however, it induced much lower levels of 
ketosis [87, 88].  
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2.4.3. βHB Salt 
 Originally, researchers attempted to administer βHB or AcAc in their free acid forms; 
however, this was shown to be too expensive and ineffective at producing sustained ketosis. 
Subsequently, it was suggested to buffer the free acid from of βHB with sodium salts, but this 
causes potentially harmful sodium overload and mineral imbalance at therapeutic levels of 
ketosis, and is largely ineffective at preventing seizures in animal models [89]. A study showed 
that oral administration of Na+/βHB in doses from 80-900mg/kg/day elevated blood ketone 
levels to 0.19-0.36 mM in children with acyl CoA dehydrogenase deficiency [90]. However, to 
achieve the same level of ketosis a 70 kg man would need to ingest between 5.6 to 63 g/day, 
costing up to $200 a day. Considering the potential effects of such a large sodium load, the costs 
of the administration of Na+ /βHB salts to achieve ketosis made this approach unrealistic [63].  
 Recently, a βHB mineral salt was developed in collaboration with Savind Inc. These 
ketone salts are balanced with minerals to prevent sodium overload and can include arginine, 
potassium, calcium, magnesium, lithium, lysine, histidine, ornithine, creatine, agmatine 
(guanidine), or citrulline. Maintaining an optimal sodium-mineral ratio should help offset any 
potential adverse effects of sodium on blood pressure. It is speculated that this formulation will 
be especially beneficial for elderly patients most susceptible to sodium-induced hypertension 
[91]. The mineral salt has to be delivered as a concentrated liquid because potassium βHB is too 
hygroscopic to isolate as a powder (it picks up water from the atmosphere and turns into a paste 
at an astonishing rate, whether by itself or mixed with sodium βHB). Many people experience 
the “low carb flu” during keto-adaptation (2-3 week phase characterized by enhancement of 
ketone production and tissue utilization from being on a ketogenic diet) caused by glucose 
withdrawal in the brain and a depletion of minerals, especially sodium and potassium, in the 
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plasma [38]. These symptoms can be attenuated or reversed with sufficient supplementation of 
sodium, potassium, calcium, and magnesium.  
 Several mineral combinations are currently being tested for safety and efficacy. In a recent 
case study, a 100 kg male subject was administered a 4% Na+/K+ βHB salt solution (containing 
11 grams of sodium and 7.1 grams βHB) and his plasma levels of βHB were significantly 
elevated 30-60 minutes after administration. After receiving the same dose for three days, the 
patient had sustained elevated blood ketone levels from 15-120 minutes after administration. 
Similar results were seen in a 70kg male who fasted three days prior to administration of the 
ketone salt supplement [92]. In a 15-week study, Sprague-Dawley rats were administered 
Na+/Ca+2-β-hydroxybutyrate mineral salt (S-BHB),  20% by weight (~25 g/kg/day) in their food 
fed ad libitum. The S-BHB supplemented rats exhibited sustained elevated blood ketone levels 
(1mM βHB) at 1, 4, 8, 10, and 13 weeks of chronic feeding which did not affect blood glucose 
levels compared to controls (unpublished data).  
 
2.4.4. Combination BMS+MCT 
 Considering the variety of ketogenic precursors available, researchers are investigating 
unique combinations of the individual supplements in hopes of optimizing their benefits. A 
combination of βHB salts and MCT oil has been administered in 1:1 to 1:2 mixtures. This 
mixture allows for a lower dosing of the components compared to administering the individual 
compounds, thus reducing potential for side effects (sodium-induced hypertension, GI side 
effects, etc) and resulting in distinct synergistic blood ketone profile [92].  
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 In a case study, a 100 kg male was administered a combination of a 4% Na+/K+ βHB salt 
solution (containing 11 grams of sodium and 7.1 grams βHB) + 20 mL MCT oil. This 
combination demonstrated higher elevation of blood ketone levels than either βHB salts or MCT 
oil alone, starting at 15 minutes post consumption and lasting for 4 hours. Similar results were 
observed in a 70-kg male who fasted 3 days prior to administration; however elevated blood 
ketone levels were observed sooner after supplementation and were sustained for a considerable 
longer time after administration (8 hours). This effect was accompanied by a reduction in blood 
glucose, and a lower starting blood glucose concentration on each subsequent day of 
supplementation [92]. In a 15-week study, Sprague-Dawley rats were administered a 1:1 mixture 
of Na+/Ca+2-β-hydroxybutyrate mineral salt + Medium Chain Triglyceride Oil (S/MCT) (20% 
by weight (~25 g/kg/day) in their food fed ad libitum. The combination-supplemented rats had 
significantly sustained and elevated blood ketone levels as weeks 3, 4, 8, 10, and 13 without 
significantly affecting blood glucose levels during the study (unpublished data).  
 
2.4.5. Ketone Esters 
Researchers have developed and investigated several synthetic ketone mono- and di-
esters to produce nutritional ketosis without dietary restriction. In these compounds, gastric 
esterases rapidly liberate ketones as a free acid from a backbone molecule, which varies 
depending upon the specific formulation, but is often R,S-1,3-butanediol. As previously 
discussed, 1,3-BD is subsequently metabolized by the liver to produce βHB [4]. Thus, the ketone 
esters currently available are unique amongst the aforementioned ketone supplements in that 
many contain, and thus directly elevate, AcAc rather than only βHB.  
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 In the late 1970s, Birkhahn et al. were the first to synthesize a monoester of glycerol and 
AcAc (monoacetoacetin) for parenteral nutrition. These studies demonstrated that 
monoacetoacetin induced hyperketonemia comparable to fasted rats at a dose of 50 g/kg per day 
[93-95]. In attempts to increase the caloric density of monoacetoacetin, they synthesized both a 
monoester and triester of glycerol and βHB. These esters are hydrolyzed to release free βHB, 
thus elevating blood ketones. Later, Desrochers and colleagues synthesized mono- and di-esters 
of 1,3-BD with either AcAc or βHB [96]. These and other esters developed by or in collaboration 
with Henri Brunengraber and Richard Veech have been shown to induce various degrees of 
hyperketonemia (2-7mM) in rats, mice, dogs, pigs, and humans [97-102]. Clarke and colleagues 
demonstrated the safety of these ketone esters in rats and humans [103, 104]. Recently, a R,S-
1,3-butanediol acetoacetate diester (KE) was developed in collaboration with Savind Inc. A 
single dose of the KE administered via intragastric gavage elevated both AcAc and βHB blood 
levels to >3mM in rats [4]. In a 15-week study, the KE was administered to Sprague-Dawley rats 
in a low dose (5%, 10 g/kg/day) (LKE) and a high dose (20%, 25 g/kg/day) (HKE) in food fed 
ad libitum. Both doses significantly elevated blood ketone levels without affecting blood glucose 
levels. Serum clinical chemistry of both LKE and HKE did not reveal any changes in any major 
markers for kidney and liver function compared to standard diet fed rats (unpublished data). 
 
2.4.6. Potential Concerns and Side Effects: Ketoacidosis 
 Ketoacidosis is one major concern for the use of oral ketone supplements without dietary 
restriction. Ketoacidosis is normally only seen in patients with diabetes mellitus. In this 
circumstance, the lack of insulin prevents glucose delivery to the tissues to be used as energy. 
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High glucose levels spill over into the urine, taking water and solutes (sodium and potassium) 
with it in a process known as osmotic diuresis. The body senses that it is in starvation mode and 
enhances b-oxidation of fatty acids for ketogenesis. The resulting ketone bodies are used as fuel. 
Additionally, insulin acts as a negative feedback loop to ketogenesis. Any rise in insulin and/or 
glucose normally inhibits ketogenesis immediately or excess ketones are expelled through 
ketonuria. Without insulin, the body is overwhelmed by ketone bodies. Since the ketone bodies 
are acidic, the uncontrolled elevation of ketone bodies (20-25 mM) drops the blood pH and can 
lead to organ failure, cerebral edema, and even death. If not properly administered, oral ketone 
supplementation does have the potential to induce ketoacidosis; however, optimal dosing 
circumvents this danger. Oral ketone supplementation will be optimized to elevate blood ketone 
levels to the 2-7 mM range, which is far below the elevation seen in ketoacidosis.  
 
2.5. Potential Physiology Factors Affected to Enhance Wound Healing 
 It has been well established that optimized nutritional support aids wound healing. [105, 
106]. Demling et al. stated that in order to optimize healing, a substrate that is more dependent 
on intake rather than on the bodily breakdown of protein needs to be available [107]. In the 
traditional classification, ketone bodies are known as a carrier of energy from the liver to extra-
hepatic tissue. However they can also be considered as a nutritional supplement and an anabolic 
agent [108]. Indeed, Nair et al. concluded that βHB promotes protein synthesis in human beings 
[109]. Recently, it has been shown that βHB possess a variety of signaling functions that may 
regulate a broad range of cellular functions. [110-113]. It has been shown that βHB can regulate 
cellular processes via histone deacetylase (HDAC) inhibition, binding to cell surface receptors, 
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and altering the levels of other regulatory metabolites including acetyl-CoA, succinyl-CoA, and 
NAD+ [110]. These unique cellular and physiological properties support the assertion that 
ketone bodies themselves confer many of the benefits associated with the KD. We hypothesize 
that ketone bodies may augment wound healing via the suppression of inflammation, inhibition 
of oxidative stress, enhancement of blood flow, and enhancement of metabolic efficiency. 
Additionally, ketones may aid diabetic foot ulcer healing via modulation of blood glucose levels 
and enhancement of insulin sensitivity.  
 
2.5.1. Ketones and Inflammation 
 As mentioned in the previous chapter, chronic wounds are stuck in the inflammatory 
phase. A therapy that promotes resolution of inflammation may push the chronic wound to a 
more acute wound phenotype, therefore progressing to closure. Several studies have determined 
that the KD reduces circulating inflammatory markers in animals and in humans [114-117]. 
Additionally, Ketone bodies themselves have been shown to decrease inflammatory biomarkers 
including TNF-a, IL-6, IL-8, MCP-1, E-selectin, I-CAM, and PAI-1 [17, 118]. In an unpublished 
study from the D’Agostino laboratory, rats were fed one of three exogenous ketone supplements 
LKE, HKE, S-BHB, or S/MCT mixed into standard rodent chow at 5- 20% by weight for 15 
weeks. Inflammatory profiling was performed on serum collected from the animals at the end of 
the chronic feeding study and revealed decreases in several pro-inflammatory cytokines 
including IL-1β, IL-6, IFN-γ, MCP-1, and RANTES.  
 Recently, Dixit and colleagues demonstrated in both in vitro and in vivo that βHB inhibits 
the NLRP3 inflammasome, which controls activation of caspase-1 and release of the pro-
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inflammatory cytokines IL-1β and IL-18 from M1 macrophages. The authors concluded that 
elevating blood ketones could be a therapeutic option for patients with NLRP3-mediated chronic 
inflammatory diseases [119]. It has been established that elevated levels of IL-1β are present in 
wounds of diabetic humans and mice, consistent with increased inflammasome activity. Since 
M1 macrophages are activated by IL-1β, the NLRP3 is thought to perpetuate this pro-
inflammatory phenotype, leading to impaired wound healing [120]. Two studies have shown that 
blocking the activation of the inflammasome decreased pro-inflammatory cytokine levels and 
accelerated wound healing in diabetic mice [120, 121].  This evidence supports the hypothesis 
that oral ketone supplementation could produce similar effects on the inflammasome.  
 
2.5.2. Ketones and ROS  
  Veech and others have determined some of the molecular mechanisms by which ketone 
bodies suppress oxidative stress [122-124]. In non-wounded skin, the major source of free 
radicals is the half-reduced semiquinone of co-enzyme Q in the electron transport chain of the 
mitochondria. At physiological levels, ketone bodies increase the oxidation of co-enzyme Q, 
decreasing mitochondrial oxygen radical generation, thereby reducing the amount of ROS 
produced [3, 63, 124]. Additionally, ketone metabolism induces reduction of the mitochondrial 
NAD+ and cytoplasmic NADP electron carriers. As previously mentioned in Chapter 1, NADH 
is important for energy producing pathways and NADPH is necessary for the regeneration of the 
endogenous antioxidant reduced glutathione (GSH) [125].  
Eric Verdin and colleagues have recently demonstrated βHB is an endogenous and 
specific inhibitor of class 1 histone deacetylases (HDACs) [126]. Elevated βHB levels by fasting, 
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calorie restriction, and exogenous administration increased global histone acetylation in mouse 
tissues and induced the transcription of genes encoding oxidative resistance factors FOXO3A 
and MT2 via selective depletion of HDAC 1 and HDAC2. Furthermore, the authors 
demonstrated in vivo that exogenous ketone supplementation could prevent oxidative stress. 
Mice were pretreated with βHB via a subcutaneous pump for 24 hours prior to receiving an 
injection of paraquat, which induces the production and accumulation of ROS. Protein 
carbonylation was suppressed by 54%, lipid peroxidation was completely suppressed, and 
endogenous antioxidants mitochondrial superoxide dismutase (MnSOD, SOD2) and catalase 
(CAT) were elevated in the renal tissue of βHB pre-treated mice. 
Regulated ROS levels are critical for optimal wound healing. Normal oxidative 
phosphorylation, transient hypoxia, and increased neutrophil and macrophage respiratory bursts 
release ROS during wound healing. The increased level of ROS transcends the beneficial effect 
and causes additional tissue damage and healing delay. This unquenched ROS production is 
prevalent in the aged population.  Recently, Moor et al demonstrated age-dependent deficiencies 
in the glutathione and SOD2 antioxidant pathways. In an ischemic wound model, wounds from 
aged rats had lower SOD2 protein and activity, decreased ratio of reduced/oxidized glutathione, 
and decreased glutathione peroxidase activity [127]. These age-exaggerated insufficiencies lead 
to excessive inflammation and impaired wound healing.  
 One of the hallmarks of aging is mitochondrial dysfunction [128].  Electron microscope 
images of aged mitochondria show disorganization and degeneration via absent cristae, 
vacuolation, and swelling. Treatment with lipoic acid and carnitine stimulates repair of 
mitochondrial membranes, returns functionality to the mitochondria, and demonstrates a young 
phenotype [129]. Bough et al showed increased mitochondrial biogenesis in rats maintained on a 
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KD for 4-6 weeks [130, 131]. Interestingly, exogenous ketone supplementation with a ketone 
ester has been shown to induce mitochondrial biogenesis [132]. Mice in this study were fed a 
diet from which approximately 30% of calories were derived from the D-β-hydroxybutyrate-R-
1,3-butanediol monoester for one month. The mitochondrial content and expression of electron 
transport chain proteins were significantly increased in the intrascapular brown adipose tissue as 
compared to control mice, although calorie intake was matched between the two groups. These 
experiments support the hypothesis that ketone supplementation could have therapeutic benefits 
for an aged population.  
 
2.5.3. Ketones and Blood Flow and Angiogenesis 
  Restoration of blood flow via angiogenesis is critical for healing a wound, as well as the 
integration of skin substitutes. Venous, arterial and diabetic blood flow insufficiencies are major 
underlying contributors to chronic wound development.  Additionally, most older patients have 
hypertension or other comorbidities that affect blood flow. In a study by Hasselbalch and 
colleagues, 8 volunteers (4 male, 4 female, 24±4 years of age, normal weight) were given an 
infusion of Na+-βHB via antecubital vein at a rate of 4-5 mg/kg/min corresponding to an infusion 
of ~350mL/hr for 3-3.5 hours. Global cerebral blood flow was measured via the Kety-Schmidt 
technique; ketone supplementation showed a 39% increase in cerebral blood flow [133].  
 As noted in Chapter 1 of this dissertation, VEGF is the most potent angiogenic factor for 
its effects on multiple components of the angiogenesis cascade: endothelial cell mitogenesis, 
chemotaxis, and induction of vascular permeability [134, 135]. In addition to VEGF, endothelin-
1 (ET-1)  is another cytokine produced in the response to hypoxia and is a crucial promoter of 
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cell proliferation, migration and chemotaxis, and angiogenesis in wound healing [136-138]. A 
study by Isales and colleagues demonstrated that supplementation of mouse brain microvascular 
endothelial cells with βHB and AcAc both independently increased ET-1 and had an added affect 
when applied together. βHB but not AcAc increased VEGF levels [139]. Though this area needs 
further exploration, this may be one mechanism that oral ketone supplementation may augment 
wound healing.  
 
2.5.4. Ketones and Metabolism 
 In the 1940s Henry Lardy demonstrated that βHB and AcAc had distinct energetic 
efficiencies compared to 16 major carbohydrate, lipid, and intermediary metabolites in their 
ability to increase bull sperm mobility while simultaneously decreasing oxygen consumption. 
[140, 141]. Nearly 50 years later, Richard Veech and colleagues confirmed that ketone bodies 
increased metabolic efficiency and elucidated the molecular mechanisms in the working perfused 
rat heart [124, 142]. They demonstrated that supplementation of glucose-containing perfusate (10 
mM glucose) with 5 mM ketones (4 mM βHB, 1 mM AcAc) increased cardiac hydraulic work 
by approximately 25% while simultaneously reducing oxygen consumption [124]. Their study 
demonstrated the ketone-mediated increase in metabolic efficiency was facilitated by a reduction 
of the mitochondrial NAD couple and an oxidation of the coenzyme Q couple increasing the 
energy span between the sites (mentioned previously to decrease ROS production). This results 
in an increase in energy released by electrons in the ETC, causing more protons to be pumped 
into the inner mitochondrial space. The electrochemical gradient is enhanced, hyperpolarizing 
the cell, and increasing the ΔG0 (free enthalpy) of ATP hydrolysis; thus, increasing metabolic 
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efficiency. Additionally, ketone bodies were shown to cause a 16-fold elevation in acetyl-CoA 
content and increased Krebs cycle intermediates. Furthermore, thermodynamic tables for heat of 
combustion, calculated with bomb calorimeter experiments, show that βHB produces more 
energy than glucose per carbon molecule [143].  
 Decreased availability of ATP negatively impacts nearly every aspect of the healing 
process [144]. Decreased nutrient and oxygen exchange during wound healing limits ATP 
production to fuel wound healing processes. Additionally, the skin predominantly uses anaerobic 
respiration, which decreases the potential ATP production by 90% compared to aerobic 
respiration [145-147]. Chiang and colleagues developed a new intracellular ATP delivery 
technique in which highly fusogenic lipid vesicles (ATP-vesicles) are used to encapsulate 
magnesium-ATP (Mg-ATP). When the vesicles come into contact with the cell membrane, they 
fuse together and deliver the contents into the cytosol. Using eleven controlled-pairs of adult 
nude mice, they demonstrated accelerated wound healing via enhanced development of 
granulation tissue, more rapid re-epithelialization, and elevated VEGF levels [31, 63].  
 
2.5.5. Ketones Suppress Blood Glucose via Increasing Insulin Sensitivity 
Failure to heal in diabetic lower limbs is associated with hyperglycemia, insulin 
resistance, tissue hypoxia, chronic inflammation, oxidative stress, impairment of the immune 
system, and metabolic dysfunction [148, 149]. A study by Rubinstein et al. showed that once 
diabetes was a controlled, diabetic foot ulcers in 11 of 15 patients healed in 4 to 13 weeks [150]. 
In addition, diabetic patients with glucose under 200 mg/dl showed a decrease in surgical site 
infections after foot and ankle surgery [151]. Recent studies suggest that many of the benefits of 
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the KD are due to the effects of ketone body metabolism. Interestingly, in studies on T2D 
patients, improved glycemic control, improved lipid markers, and retraction of insulin and other 
medications occurred before weight loss became significant, suggesting physiological effects of 
ketone metabolism [3, 63]. Exogenous ketone supplements may provide therapeutic benefits for 
the underlying hyperglycemia and insulin resistance as reports have demonstrated that oral 
ketone administration lowers blood glucose by increasing insulin sensitivity. This could be 
critical for older adults as all have demonstrable insulin resistance, even if not diabetic.  Richard 
Veech has suggested this hypoglycemic effect is the result of ketones activating pyruvate 
dehydrogenase (PDH), which enhances insulin-mediated glucose uptake and the production of 
acetyl-CoA. In addition, the body regulates ketone production via ketonuria and ketone-induced 
insulin release, which shuts off hepatic ketogenesis. The insulin from this process may increase 
glucose disposal which, when coupled with PDH activation, could drive down blood glucose 
levels. The administration of 5 mM ketone has been shown to increase acetyl-CoA production 
16-fold in the glucose-perfused isolated rat heart. Additionally, in this model, ketones and insulin 
increased cardiac hydraulic efficiency to a similar degree, approximately 25-35% [124]. 
 Male rats were fed a standard diet with 30% of calories replaced with the R-3-
hydroxybutyrate-R-1,3-butanediol monoester for 14 days. The ketone ester-supplemented diet 
induced nutritional ketosis (3.5mM βHB), and both plasma glucose and insulin were decreased 
by approximately 50% [132]. Glucose was decreased from 5 mM to 2.8 mM, and insulin was 
decreased from 0.54 ng/mL to 0.26 ng/mL. In a similar study by the same group, mice receiving 
a KE diet exhibited a 73% increase in the Quantitative Insulin-Sensitivity Check Index 
(QUICKI), a surrogate marker of insulin sensitivity, compared to control, calorie-matched mice 
[132]. Fasting plasma glucose levels were not altered in these mice, but fasting plasma insulin 
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levels were reduced by approximately 85% in the KE-fed mice compared to controls, 
demonstrating that exogenous ketones enhance insulin sensitivity [152].  
The histone deacetylase inhibitor (HDACI) activity of βHB could also be beneficial in 
T2D by altering the direct regulation of HDAC-dependent glucose metabolism and by inducing 
resistance to oxidative stress. HDACs regulate the expression of genes encoding many metabolic 
enzymes, and HDAC3 knockout animals exhibit reduced glucose and insulin. SAHA, a class I 
HDAC inhibitor, has been shown to improve insulin sensitivity and increase oxidative 
metabolism and metabolic rate in a mouse model of diabetes [153]. Butyrate, a short-chain fatty 
acid that is structurally similar to β-hydroxybutyrate and also acts as a HDACI lowers blood 
glucose and insulin levels and improves glucose tolerance and respiratory efficiency [154]. The 
vascular dysfunction in T2D is thought to be caused by oxidative stress [155]. HDAC inhibition 
prevents renal damage in mouse models of diabetic nephropathy through modulation of redox 
mechanisms [156]. Therefore, βHB suppression of oxidative stress through HDAC inhibition 
may help restore insulin sensitivity and manage complications of diabetes. 
 
2.6. Ischemic Wound Healing Model 
  As mentioned previously, a chronic wound is by definition one that entirely fails to heal. 
In this respect, there is no standardized animal model that reflects the human chronic wound 
environment. However, animal models have been developed that attempt to mimic these 
conditions for the purpose of furthering our understanding of the complexity of chronic wounds. 
The rat species, often employed due to its wide availability, size and docile nature is used for 
wound healing studies as it is large enough to provide a suitable skin area for incisional and 
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excisional wounding, imaging and tissue collection [157]. Yet, it should be noted that the skin of 
a rat and a human are different morphologically, as rats are loose-skinned animals. This distinct 
anatomical characteristic enhances wound contraction over re-epithelialization in rat integument 
[157]. Additionally, the presence of a subcutaneous panniculus carnosus muscle in rats, 
contributes to healing by both contraction and collagen formation [158, 159]. These very 
important morphological distinctions were considered in the optimization of the following rat 
ischemic skin wound model used for this dissertation. Additionally, specific modifications were 
implemented to decrease wound contraction and reduce the influence of the panniculus carnosus 
muscle [160]. 
 In the rat ischemic wound model, a dorsal bi-pedicle 10.5 x 3 cm flap is surgically 
created on day 0. A silicone sheet is placed under the panniculus carnosus fascia and above the 
paraspinous muscles, limiting revascularization from the underlying tissue, which increases the 
duration of flap ischemia. Two 6mm punches are created within the flap, extending just above 
the fascia, creating ischemic wounds.  Additionally, two 6 mm punches are created lateral to the 
flap, where there isn’t silicone sheet, providing control non-ischemic wounds within the same 
animal. 
 One of the main factors in the development of a chronic wound is localized tissue 
ischemia (reduced blood flow) contributing to the inability to clear inflammation [160]. In 2005, 
Dr. Lisa Gould developed and validated this model as a modification of the ischemic wound 
model originally described by Schwartz et al. and subsequently used in modified form by Chen 
et al. [161, 162]. The wound model was modified to test the induction of angiogenesis in the 
wound bed.  
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 Wound healing in rats has often been the subject of debate due to their ability to heal 
infected wounds and high rate of inter-animal variability [160]. One of the original goals of the 
model during its development was to decrease this variation. Modifications to the width of the 
flap, reducing the number of wounds with specific placement (centered on the flap with 
consistent cranio-caudal location) and introduction of a silicone sheet has accomplished this 
goal. Wound healing by contraction has also been reduced and healing by epithelialization, as in 
humans, is the measured outcome. Adaptation of the model to a different strain of rat, ie the 
F344, has also proven successful and reproduces the degree of ischemia observed using Sprague 
Dawley rats.  
 To achieve consistency with this model while performing multiple surgeries, it was found 
that it is important to create the ischemic wounds prior to elevation of the flap for silicone sheet 
placement [160]. Additionally, not punching through the panniculus carnosus fascia is critical to 
provide a viable wound bed to remain over the silicone. The silicone acts not only to prevent 
vascular regrowth but also as a “splint” that reduces wound contraction. The application of the 
adhesive and dressings to prevent infection and maintain a moist environment for wound healing 
is also important. Product choice can be what is preferred or used in the researcher’s animal 
facility. However, it is not uncommon for some of the animals to be able to remove their 
dressings, no matter what type of adhesive/dressing combination is used. 
 The bi-pedicled flap should remain viable throughout a time course of healing which is 
approximately 28 days, depending on rat strain and other co-morbidities present. Rarely, 
abscesses can form in the flap (particularly near sutures) and seromas may form under the flap. 
Fluid can be drained and antibiotics administered if necessary. However, if the flap loses 
viability and becomes necrotic it is recommended that that animal no longer be used. Wound 
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excision for biochemical analysis does introduce variability due to (1) some normal tissue must 
be retained for support (2) the choice of tissue homogenization and preparation for isolation of 
RNA, DNA or protein and (3) inherent inter-animal variability [127, 160, 163]. One could 
consider this last point a limitation to the model. It was found that reducing the size of the flap 
(<2.0 cm) or flap trauma can cause necrosis, indicating that minor variations in technical or 
environmental factors such as temperature or stress levels, may also lead to biochemically 
detectable variation between wound samples from one rat to another [160]. 
 In summary, this model, with a longitudinal, bi-pedicle flap ranging from 2.0-3.0 cm in 
width and a strategically placed silicone sheet, is a reliable model of prolonged tissue ischemia. 
Once the user is adept at using the techniques to create a consistent ischemic wound, they should 
be able to adapt it to additional ages and species of rodents (mice included). The excisional 
wounds can be treated topically, or systemic treatments utilized to further explore the 
mechanism(s) involved in chronic wound formation, exacerbated inflammatory responses, 
aberrant angiogenesis and delayed wound closure.	
 
2.7. Use of Primary Human Dermal Fibroblasts in vitro 
 Though immortal cells lines are more abundant and more cost efficient to maintain, in this 
dissertation, we utilized primary human dermal fibroblasts isolated from discarded skin. 
Compared to immortal cell lines, primary cell lines maintain a physiology that is more closely 
identified to in vivo physiology. The caveat is that they must be used at early passage, generally 
passage 2-8. Additionally, due to the heterogeneity of patients, the in vitro work was repeated in 
at least two different patient-derived cell lines thereby reducing individual confounding. Also, 
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fibroblasts behave differently depending on the location from which they are isolated; therefore, 
skin for these studies was collected from similar anatomic locations. The complex extracellular 
environment, paracrine, and autocrine interactions and range of cell types involved in wound 
repair limits in vitro models to confirm what we see in in vivo models. Additionally, since there 
is such a gamut of players and interactions, by focusing on just one cell type we may miss some 
of the potential mechanism for our therapy.  
 
2.8. Central Hypothesis and Project Goals 
  There is a dire need to discover novel and effective treatments for chronic wounds.  There 
are often multiple mitigating factors that prevent normal wound closure leading to minimally 
effective wound therapies as few multifactorial treatments are available. 
 Exogenous ketone supplements are being developed as an alternative or adjuvant method 
of inducing therapeutic ketosis aside from the classic ketogenic diet. It seems clear that these 
novel compounds have the potential to offer benefits for both healthy and diseased individuals 
alike. It is likely that most, if not all, of the conditions which are known to benefit from the KD 
would receive some benefit from exogenous ketone supplementation. Importantly, ketone 
supplementation provides a tool for achieving therapeutic ketosis in patients who are unable, 
unwilling, or uninterested in consuming a low carbohydrate or ketogenic diet. It may also help 
circumvent some of the difficulties associated with KD therapy, as it allows for rapid induction 
of ketosis in a dose-dependent fashion, which can be sustained with prolonged consumption. 
Simultaneously, it could provide patients with the opportunity to reap the benefits of ketosis 
without the practical and social difficulties of a highly restrictive diet. 
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 Therefore, we hypothesize that exogenous ketone supplementation will improve metabolic 
and physiological attributes to promote accelerated healing in the impaired wound environment 
associated with aging.. To date, the majority of ketone-based metabolic enhancement strategies 
have focused on enhancing brain and heart metabolism; thus, this dissertation proposes a novel 
therapy, which will be evaluated in a cutaneous wound-healing model [164, 165]. Although this 
dissertation focuses on the underlying features of the aging phenotype, similar molecular deficits 
have been described in diabetes and other disorders [166], suggesting that administration of 
ketones as an alternative fuel may have broader applications. The studies completed in this 
dissertation provide an important step in the potential discovery of effective and novel treatments 
for chronic wounds. 
 
2.9. Closing Remarks 
 In this chapter I have provided scientific rationale for the potential utility of oral ketone 
supplementation against age impaired wound healing. Approaching the healing wound from a 
metabolic perspective provides an innovative opportunity to stimulate beneficial physiological 
and cellular mechanisms that may be lacking or attenuated in the aged population. Chapters 3-5 
will consist of the results and a detailed discussion of this dissertation work. A summary of the 
findings, closing remarks, and major implications of this data will be discussed in Chapter 6.  
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CHAPTER 3: ESTABLISHING THERAPEUTIC KETOSIS (METABOLIC THERAPY) 
WITH EXOGENOUS KETONE SUPPLEMENTATION 
 
3.1. Chapter Synopsis 
 In this chapter, we present data demonstrating the effects of five oral ketone supplements 
on blood ketones, glucose, triglyceride, and lipoprotein levels in Sprague-Dawley rats. Though 
each ketogenic precursor had a distinctive effect on each of the parameters, overall oral ketone 
supplementation rapidly elevated blood ketone levels and suppressed blood glucose levels 
without significantly affecting heart health biomarkers. Additionally we sent serum and 
hippocampal samples from KE (5 g/kg) and BMS+MCT (10 g/kg) supplemented rats to 
Metabolon Inc. to determine the effects that oral ketone supplementation would have on the 
metabolome. Ketone supplements increased Kreb’s cycle intermediates, antioxidants, and 
adenosine, which supports our hypothesis that oral ketone supplementation, will enhance wound 
healing.  
 Portions of this chapter have previously been published in “Kesl SL, Poff AM, Ward NP, 
Fiorelli TN, Ari C, Van Putten AJ, Sherwood JW, Arnold P, D’Agostino DP. Effects of 
Exogenous Ketone Supplementation on Blood Ketone, Glucose, Triglyceride, and Lipoprotein 
Levels in Sprague-Dawley Rats. Nutrition and Metabolism (2016)”. A copy of this article may 
be found in Appendix C. See Appendix B for copyright permissions. Materials and methods 
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presented in this chapter can be found in Appendix A.  
3.2. Effects of Exogenous Ketone Supplementation on Blood Ketones, Glucose, 
Triglyceride, and Lipoprotein Levels in Sprague-Dawley Rats 
 Nutritional ketosis induced with the KD has proven effective for the metabolic 
management of seizures and potentially other disorders [1-26]. We hypothesized that oral 
administration of ketone supplements could safely produce sustained nutritional ketosis (>0.5 
mM) without carbohydrate restriction. Thus, we tested the effects of 28-day administration of 
five ketone supplements on blood glucose, ketones, and lipids in male Sprague-Dawley rats. The 
supplements included: 1,3-butanediol (BD), a sodium/potassium β-hydroxybutyrate (βHB) 
mineral salt (BMS), medium chain triglyceride oil (MCT), BMS+MCT 1:1 mixture, and 1,3 
butanediol acetoacetate diester (KE). Rats received a daily 5-10g/kg dose of their respective 
ketone supplement via intragastric gavage. Weekly whole blood samples were taken for analysis 
of glucose and βHB at baseline and 0.5, 1, 4, 8, and 12 hrs post-gavage, or until βHB returned to 
baseline. In this section, we present evidence that chronic administration of ketone supplements 
can induce a state of nutritional ketosis without the need for dietary carbohydrate restriction with 
little or no effect on lipid biomarkers. The notion that we can produce the therapeutic effects of 
the KD with exogenous ketone supplementation is supported by our previous study which 
demonstrated that acutely administered KE supplementation delays central nervous system 
(CNS) oxygen toxicity seizures without the need for dietary restriction [27]. We propose that 
exogenous ketone supplementation could provide an alternative method of attaining the 
therapeutic benefits of nutritional ketosis, and as a means to further augment the therapeutic 
potential of the KD. 
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3.2.1 Ketone supplementation causes little to no change in triglycerides and lipoproteins 
  One common concern regarding the KD is its purported potential to increase the risk of 
atherosclerosis by elevating blood cholesterol and triglyceride levels [28, 29].  This topic 
remains controversial as some, but not all studies have demonstrated that the KD elevates blood 
levels of cholesterol and triglycerides [30-35].  Kwitervich and colleagues demonstrated an 
increase in low-density lipoprotein (LDL) and a decrease in high-density lipoprotein (HDL) in 
epileptic children fed the classical KD for two years [36]. In that study, total cholesterol 
increased by  ~130%, and stabilized at the elevated level over the 2-year period. A similar study 
demonstrated that the lipid profile returned to baseline in children who remained on the KD for 
six years [37]. Children typically remain on the diet for approximately two years then return to a 
diet of common fat and carbohydrate ingestion [38]. The implications of these findings are 
unclear, since the influence of cholesterol on cardiovascular health is controversial and 
macronutrient sources of the diet vary per study. In contrast, more recent studies suggest that the 
KD can actually lead to significant benefits in biomarkers of metabolic health, including blood 
lipid profiles [39-46]. In these studies, the KD positively altered blood lipids, decreasing total 
triglycerides and cholesterol while increasing the ratio of HDL to LDL [42-51].  Although, the 
KD is well established in children, it has only recently been utilized as a strategy to control 
seizures in adults. In 2014, Schoeler and colleagues reported on the feasibility of the KD for 
adults, concluding that 39% of individuals achieved > 50% reduction in seizure frequency, 
similar to the results reported in pediatric studies. Patients experienced similar gastrointestinal 
adverse events to those previously described in pediatric patients, but they did not lead to 
discontinuation of the diet in any patient [52].  
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With oral ketone supplementation, we observed a significant elevation in blood βHB 
without dietary restriction and with little change in lipid biomarkers (Figure 3.1).  Over the 4 
week study, MCT-supplemented rats demonstrated decreased HDL compared to controls. No 
significant changes were observed in any of the triglycerides or lipoproteins (HDL, LDL) with 
any of the remaining exogenously applied ketone supplements. 	It should be noted that the rats 
used for this study had not yet reached full adult body size [53]. Their normal growth rate and 
maturation was likely responsible for the changes in triglyceride and lipoprotein levels observed 
in the control animals over the 4 week study (baseline data not shown, no significant differences) 
[54, 55]. Future studies are needed to investigate the effect of ketone supplementation on fully 
mature and aged animals.  Overall, our study suggests that oral ketone supplementation has little 
effect on the triglyceride or lipoprotein profile after 4 weeks. However, it is currently unknown if 
ketone supplementation would affect lipid biomarkers after a longer duration of consumption. 
Further studies are needed to determine the effects of ketone supplements on blood triglyceride 
and lipoproteins after chronic administration and as a means to further enhance the 
hyperketonemia and improve the lipid profile of the clinically implemented (4:1) KD.  
 LDL is the lipoprotein particle that is most often associated with atherosclerosis. LDL 
particles exist in different sizes: large molecules (Pattern A) or small molecules (Pattern 
B).  Recent studies have investigated the importance of LDL-particle type and size rather than 
total concentration as being the source for cardiovascular risk [29]. Patients whose LDL particles 
are predominantly small and dense (Pattern B) have a greater risk of cardiovascular disease 
(CVD). It is thought that small, dense LDL particles are more able to penetrate the endothelium 
and cause in damage and inflammation [56-59]. Volek et al. reported that the KD increased the 
pattern and volume of LDL particles, which is considered to reduce cardiovascular risk [47]. 
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Though we did not show a significant effect on LDL levels for ketone supplements, future 
chronic feeding studies will investigate the effects of ketone supplementation on lipidomic 
profile and LDL particle type and size.  
 
3.2.2. Therapeutic levels of hyperketonemia suppress blood glucose levels 
 We demonstrated that therapeutic ketosis could be induced without dietary (calorie or 
carbohydrate) restriction and that this acute elevation in blood ketones was significantly 
correlated with a reduction in blood glucose (Figure 3.2-3.4). The BMS ketone supplement did 
not significantly induce blood hyperketonemia or reduce glucose in the rats.  The KE 
supplemented rats trended towards reduced glucose levels; however, the lower dose of this agent 
did not lower glucose significantly, as reported previously in acute response of mice (60). MCTs 
have previously been shown to elicit a slight hypoglycemic effect by enhancing glucose 
utilization in both diabetic and non-diabetic patients [60-62]. Kashiwaya et al. demonstrated that 
both blood glucose and blood insulin decreased by approximately 50% in rats fed a diet where 
30% of calories from starch were replaced with ketone esters for 14 days, suggesting that ketone 
supplementation increases insulin sensitivity or reduces hepatic glucose output [63].  This 
ketone-induced hypoglycemic effect has been previously reported in humans with IV infusions 
of ketone bodies [64, 65]. Recently, Mikkelsen et al. showed that a small increase in βHB 
concentration decreases glucose production by 14% in post-absorptive healthy males [66]. 
However, this has not been previously reported with any of the oral exogenous ketone 
supplements we studied. Ketones are an efficient and sufficient energy substrate for the brain, 
and will therefore prevent side effects of hypoglycemia when blood levels are elevated and the 
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patient is keto-adapted.  Owen et al. most famously demonstrated this in 1967 wherein keto-
adapted patients (starvation induced therapeutic ketosis) were given 20 IU of insulin.  The blood 
glucose of fasted patients dropped to 1-2mM, but they exhibited no hypoglycemic symptoms due 
to brain utilization of ketones for energy [67]. Therefore, ketones maintain brain metabolism and 
are neuroprotective during severe hypoglycemia. The rats in the MCT group had a correlation of 
blood ketone and glucose levels at week 4, whereas the combination of BMS+MCT produced a 
significant hypoglycemic correlation both at baseline and at week 4. No hypoglycemic 
symptoms were observed in the rats during this study. Insulin levels were not measured in this 
study; however, future ketone supplementation studies should measure the effects of exogenous 
ketones on insulin sensitivity with a glucose tolerance test. An increase in insulin sensitivity in 
combination with our observed hypoglycemic effect has potential therapy implications for 
glycemic control in T2D [68]. Furthermore, it should be noted that the KE metabolizes to both 
AcAc and βHB in 1:1 ratio [27]. The ketone monitor used in this study only measures βHB as 
levels of AcAc are more difficult to measure due to spontaneous decarboxylation to acetone; 
therefore, the total ketone levels (βHB +AcAc) measured were likely higher, specifically for the 
KE (14). Interestingly, the 10 g/kg dose produced a delayed blood βHB peak for ketone 
supplements MCT and BMS+MCT.  The higher dose of the ketogenic supplements elevated 
blood levels more substantially, and thus reached their maximum blood concentration later due 
to prolonged metabolic clearance. It must be noted that the dosage used in this study does not 
translate to human patients, since the metabolic rate of rats is considerably higher.  Future studies 
will be needed to determine optimal dosing for   human patients.  
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3.2.3. Effects of ketone supplementation on organ weight and body weight percentage 
 Ketone supplementation did not affect the size of the brain, lungs, kidneys or heart of 
rats. As previously mentioned, the rats were still growing during the experimental time frame; 
therefore, organ weights were normalized to body weight to determine if organ weight changed 
independently to growth. There could be several reasons why ketones influenced liver and spleen 
weight. The ratio of liver to body weight was significantly higher in the MCT supplemented 
animals (Figure 3.5). MCTs are readily absorbed in the intestinal lumen and transported directly 
to the liver via hepatic portal circulation. When given a large bolus, such as in this study, the 
amount of MCTs in the liver will likely exceed the β-oxidation rate, causing the MCTs to be 
deposited in the liver as fat droplets [69]. The accumulated MCT droplets in the liver could 
explain the higher liver weight to body weight percentage observed with MCT supplemented 
rats. Future toxicology and histological studies will be needed to determine the cause of the 
observed hepatomegaly. It should be emphasized that the dose in this study is not optimized in 
humans. We speculate that an optimized human dose would be lower due to the higher metabolic 
rate of the rats and may not cause hepatomegaly or potential fat accumulation. Nutritional ketosis 
achieved with the KD has been shown to decrease inflammatory markers such as TNF-α, IL-6, 
IL-8, MCP-1, E-selectin, I-CAM, and PAI-1 [8, 70], which may account for the observed 
decrease in spleen weight. As previously mentioned, Veech and colleagues demonstrated that 
exogenous supplementation of 5mM βHB resulted in a 28% increase in hydraulic work in the 
working perfused rat heart and a significant decrease in oxygen consumption [71-73]. Ketone 
bodies have been shown to increase cerebral blood flow and perfusion [74]. Also, ketone bodies 
have been shown to increase ATP synthesis and enhance the efficiency of ATP production [14, 
68, 73]. It is possible that sustained ketosis results in enhanced cardiac efficiency and O2 
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consumption. Even though the size of the heart did not change for any of the ketone 
supplements, further analysis of tissues harvested from the ketone-supplemented rats will be 
needed to determine any morphological changes and to understand changes in organ size.  It 
should be noted that the Harlan standard rodent chow 2018 is nutritionally complete and 
formulated with high-quality ingredients to optimize gestation, lactation, growth, and overall 
health of the animals. The same cannot be said for the standard American diet (SAD). Therefore, 
we plan to investigate the effects of ketone supplements administered with the SAD to determine 
if similar effects will be seen when the micronutrient deficiencies and macronutrient profile 
mimics what most Americans consume. 
 MCT oil has recently been used to induce nutritional ketosis although it produces dose-
dependent gastrointestinal (GI) side effects in humans that limit the potential for its use to 
significantly elevate ketones (>0.5 mM).  Despite these limitations, Azzam and colleagues 
published a case report in which a 43-year-old-man had a significant decrease in seizure 
frequency after supplementing his diet with 4 tablespoons of MCT oil twice daily [75]. An 
attempt to increase his dosage to 5 tablespoons twice daily was halted by severe GI intolerance. 
Henderson et al. observed that 20% of patients reported GI side effects with a 20g dose of 
ketogenic agent AC-1202 in a double blind trial in mild to moderate Alzheimer’s patients [76].   
We visually observed similar gastrointestinal side effects (loose stools) in the rats treated with 
MCT oil in our study. Rats were closely monitored to avoid dehydration, and gastric motility 
returned to normal between 12-24 hrs.  Interestingly, the BMS+MCT supplement elevated βHB 
similarly to MCT oil alone, without causing the adverse gastrointestinal effects seen in MCT-
supplemented rats. However, this could be due to the fact in a 10 g/kg dose of BMS+MCT, only 
5 g/kg is MCT alone, which is less than the 10 g/kg dose that elicits the GI side effects. This 
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suggests that this novel combination may provide a more useful therapeutic option than MCT oil 
alone, which is limited in its ability to elevate ketones in humans. 
 Exogenously delivered ketone supplements significantly altered rat weight gain for the 
duration of the study (Figure 3.6). However, rats did not lose weight and maintained a healthy 
range for their age. Rats have been shown to effectively balance their caloric intake to prevent weight 
loss/gain [77-79]. Due to the caloric density of the exogenous ketone supplements (Table 3.1) it is 
possible for the rats to eat less of the standard rodent chow and therefore fewer carbohydrates while 
maintaining their caloric intake. Food intake was not measured for this study. However, if there 
was a significant carbohydrate restriction there would be a significant change in basal blood 
ketone and blood glucose levels.  As the hallmark to the KD, carbohydrate restriction increases 
blood ketone levels and reduces blood glucose levels. Neither an increase in basal blood ketone 
levels nor a decrease in basal blood glucose levels was observed in this study (Figure 3.7). 
Additionally, if there were an overall blood glucose decrease due to a change in food intake, this 
would not explain the rapid reduction (within 30 minutes) in blood glucose correlated with an 
elevation of blood ketone levels after an intragastric bolus of ketone supplement (Figures 3.2-
3.4).  
Several studies have investigated the safety and efficacy of ketone supplements for disease 
states such as AD and Parkinson’s disease, and well as for parenteral nutrition [68, 80-86]. Our 
research demonstrates that several forms of dietary ketone supplementation can effectively 
elevate blood ketone levels and achieve therapeutic nutritional ketosis without the need for 
dietary carbohydrate restriction. We also demonstrated that ketosis achieved with exogenous 
ketone supplementation can reduce blood glucose, and this is inversely associated with the blood 
ketone levels. Although preliminary results are encouraging, further studies are needed to 
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determine if oral ketone supplementation can produce the same therapeutic benefits as the classic 
KD in the broad-spectrum of disease states that are currently under investigation. Ketone 
supplementation could be used as an alternative method for inducing ketosis in patients who 
have previously had difficulty implementing the KD because of palatability issues, gall bladder 
removal, liver abnormalities, or intolerance to fat. Additional experiments should be conducted 
to see if ketone supplementation could be used in conjunction with the KD to assist and ease the 
transition to nutritional ketosis and enhance the speed of keto-adaptation. In this study we have 
demonstrated the ability of several ketone supplements to elevate blood ketone levels, providing 
multiple options to induce therapeutic ketosis based on patient need. Though additional studies 
are needed to determine the therapeutic potential of ketone supplementation, many patients that 
previously were unable to benefit from the KD may now have an alternate method of achieving 
therapeutic ketosis. Ketone supplementation may also represent a means to further augment 
ketonemia in those responsive to therapeutic ketosis, especially in those individuals where 
maintaining low glucose is important. 
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Figure 3.1 Effects of ketone supplementation on triglycerides and lipoproteins: Ketone 
supplementation causes little change in triglycerides and lipoproteins over a 4-week study. Graphs 
show concentrations at 4-weeks of total cholesterol (A), Triglycerides (B), HDL (C), and LDL (D).  
MCT supplemented rats had significantly reduced concentration of HDL blood levels compared 
to control (p<0.001)(B). One-Way ANOVA with Tukey’s post hoc test, results considered 
significant if p<0.05. Error bars represent mean (SD). 	
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Figure 3.2 Effects of ketone supplementation on blood βHB. (A, B) Blood βHB levels at times 0, 
0.5, 1, 4, 8, and 12 hours post intragastric gavage for ketone supplements tested. (A) BMS+MCT and 
MCT supplementation rapidly elevated and sustained significant βHB elevation compared to controls 
for the duration of the 4-week dose escalation study. BMS did not significantly elevate βHB at any 
time point tested compared to controls. (B) BD and KE supplements, maintained at 5 g/kg, 
significantly elevated βHB levels for the duration of the 4-week study. Two-Way ANOVA with 
Tukey's post hoc test, results considered significant if p<0.05. Error bars represent mean (SD). 
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Figure 3.3 Effects of ketone supplementation on blood glucose. (A, B) Blood glucose levels at 
times 0, 0.5, 1, 4, 8, and 12 hours (for 10   dose) post intragastric gavage for ketone supplements 
tested. (A) Ketone supplements BMS+MCT and MCT significantly reduced blood glucose levels 
compared to controls for the duration of the 4-week study. BMS significantly lowered blood glucose 
only at 8 hrs/week 1 and 12hrs/week (B) KE, maintained at 5 g/kg, significantly reduced blood 
glucose compared to controls from week 1-4. BD did not significantly affect blood glucose levels at 
any time point during the 4-week study. Two-Way ANOVA with Tukey's post hoc test, results 
considered significant if p<0.05. Error bars represent mean (SD)  
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Figure 3.4 Relationship between blood ketone and glucose levels: (A) BMS+MCT (5 g/kg) 
supplemented rats demonstrated a significant inverse relationship between elevated blood ketone 
levels and decreased blood ketone levels (r2=0.4314, p=0.0203). (B) At week 4, BMS+MCT  (10 
g/kg) and MCT (10 g/kg) showed a significant correlation between blood ketone levels and 
blood glucose levels (r2=0.8619, p<0.0001; r2=0.6365, p=0.0057). Linear regression analysis, 
results considered significant if p<0.05.  
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Figure 3.5 Effects of ketone supplementation on organ weight Data is represented as a 
percentage of organ weight to body weight. (A, B, D, F) Ketone supplements did not significantly 
affect the weight of the brain, lungs, kidneys or heart.  (C) Liver weight was significantly increased 
as compared to body weight in response to administered MCT ketone supplement compared to 
control at the end of the study (day 29) (p<0.001). (E) Rats supplemented with BMS+MCT, MC and 
BD had significantly smaller spleen percentage as compared to controls (p<0.05, p<0.001, p<0.05). 
Two-Way ANOVA with Tukey's post-hoc test; results considered significant if p<0.05. Error bars 
represent mean (SD). 
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Figure 3.6 Effects of ketone supplementation on body weight: Rats administered ketone 
supplements gained less weight over the 4-week period; however, did not lose weight and maintained 
healthy range for age. KE supplemented rats gained significantly less weight during the entire 4-
week study compared to controls. BMS+MCT, BMS, and BD supplemented rats gained significantly 
less weight than controls over weeks 2-4.MCT supplemented rats gained significantly less weight 
than controls over weeks 3-4. Two-Way ANOVA with Tukey's post hoc test, results considered 
significant if p<0.05. Error bars represent mean (SD). 
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Figure 3.7 Effects of ketone supplementation on basal blood ketone and basal blood glucose 
levels: Rats administered ketone supplements did not have a significant change in basal blood 
ketone levels (A) or basal blood glucose levels (B) for the four week study. Two-Way ANOVA 
with Tukey’s post-hoc test, results considered significant if p<0.05. Error bars represent mean 
(SD) 
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3.3. Effect of Sustaining Dietary Ketosis Through Exogenous Ketone Supplementation on 
the Serum and Hippocampal Metabolome of Sprague-Dawley rats 
 In the previous section, we reported that oral administration of ketone supplements 
produced nutritional ketosis (>0.5 mM) without carbohydrate restriction and the effects of a 28-
day administration of five ketone supplements on blood glucose, ketones, and lipids in male 
Sprague-Dawley rats. We hypothesized that the 28-day administration would affect metabolomic 
markers. Serum (~300 µL) and hippocampal tissues for ketone supplements KE and BMS+MCT 
were collected on day 28 at 4 hours post-intragastric gavage (peak ketone elevation). Metabolon 
analyzed samples by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and gas 
chromatography-mass spectrometry (GC-MS). Both ketone supplements significantly increased 
serum Krebs cycle intermediates: citrate, fumarate and malate. KE supplement significantly 
increased alpha-ketoglutarate and BMS+MCT supplement significantly increased succinate in 
the rat serum. Additionally, both supplements affected medium chain fatty acids, antioxidants, 
and adenosine in both serum and hippocampal tissue. Although both forms of ketone 
supplementation increased brain and blood ketone levels, the global metabolic profiles were 
different. 
 
3.3.1 Oral administration of ketone supplements elevates blood ketone levels, increases 
Krebs cycle intermediates, MCFAs, antioxidants, and adenosine in serum and hippocampal 
tissue and implications for wound healing 
 Global metabolomic profiling of serum from KE and BMS+MCT supplemented rats 
exhibited a total of 142 out of 388 metabolites that were significantly changed from control for 
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KE-treated rats and 119 out of 388 metabolites were significantly altered compared to control for 
BMS+MCT treated rats. Additionally, 12 of 290 metabolites were significantly changed in the 
hippocampal tissue for KE-treated rats and 36 of 290 metabolites were significantly altered for 
BMS+MCT treated rats (Table 3.1). These metabolic changes provide preliminary insight to 
possible mechanisms by which ketones could enhance wound healing as well as potential 
mechanisms to target other disease states.  
 Metabolomics analysis confirmed elevated ketone bodies βHB as well as AcAc in the 
serum and elevated βHB in the hippocampus (Figure 3.8). βHB is a more stable molecule since 
it cannot be decarboxylated to acetone; therefore, it is the predominant ketone body within the 
blood stream and likely a reason only βHB was elevated in the hippocampus. It should be noted 
that KE metabolizes to both βHB and AcAc as compared to BMS+MCT that only metabolizes to 
βHB. However, both supplements elevated AcAc, KE showed a 9-fold increase and 
interestingly, BMS+MCT demonstrated a 15-fold increase. It should be noted that KE was at a 5 
g/kg dose and BMS+MCT was given at a 10 g/kg dose. Both ketone supplements demonstrated a 
2:1 ratio of βHB: AcAc (KE 15.78:8.84, BMS+MCT 35.33:15.39) in the serum. Thus, total 
blood ketones seen in our previous study were likely higher in the KE-treated and BMS+MCT-
treated animals. The commercially available blood ketone meters used in previous study offer the 
most cost feasible method of measuring blood ketones, but are only able to measure βHB, not 
AcAc.  Additionally, BMS+MCT treated animals had significantly lower serum glucose (0.87, 
p<0.05).  This observation supports the hypoglycemic effect demonstrated in the previous study 
as well as previous studies by Veech and colleagues [87, 88]. As discussed, this hypoglycemic 
effect has been attributed to the enhancement insulin sensitivity, which may help diabetic foot 
ulcers specifically. As discussed, MCFAs are one of the main components of MCT oil namely 
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caprylic acid (C8:0) and Capric acid (10:0); these medium chain fatty acids were significantly 
elevated in the serum and hippocampal tissue of BMS+MCT supplemented rats (Figure 3.9). 
This demonstrates that the MCT oil is being metabolized into its MCFAs, which are available in 
the blood stream and tissues to be used for energy. Interestingly, KE supplemented rats also had 
significantly elevated capric acid in the serum and hippocampal tissue.   
 Krebs cycle intermediates citrate, fumarate and malate were significantly elevated in the 
serum of both KE-treated and BMS+MCT-treated animals (Figure 3.10). Additionally, KE 
significantly elevated the intermediate α-ketoglutarate and BMS+MCT significantly elevated 
succinate. These elevations were not seen in the hippocampal tissue. As discussed, non-wounded 
skin predominantly uses anaerobic respiration with only about 30% going to the Krebs cycle; this 
is exaggerated during wound healing when hypoxia due to tissue damage shifts the metabolic 
profile to only using 4% Krebs cycle [89-92]. However, ketones have been shown to increase 
blood flow; thus, increased blood flow would lead to potential increased oxygenation and the 
restoration of the non-wounded skin metabolic profile. Even with a 30% Krebs cycle flux, an 
increase in Acetyl CoA via ketolysis would produce a net increase in ATP production. Indeed, 
Veech and colleagues demonstrated a 16-fold increase in acetyl CoA with a ketone ester 
supplementation [88]. Acetyl co-A was significantly elevated via BMS+MCT supplementations 
but not KE in the hippocampal tissue, supporting this finding. Levels of pyruvate and lactate 
were unchanged in both ketone supplements in both the serum and hippocampal tissue 
demonstrating that there wasn’t an increased flux of glycolysis and anaerobic respiration. Even 
though there initially wouldn’t be sufficient oxygen for the wound bed to use the intermediates in 
the ETC, Krebs cycle intermediates have other anabolic fates that would be important to wound 
healing. Citrate is a precursor to fatty acid synthesis; α-ketoglutarate has been shown to scavenge 
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H2O2 in cell cultures and is an amino acid synthesis precursor [93]. Krebs cycle intermediates 
were shown to be decreased in aged rats; this supplementation may restore these levels to those 
of a young person or at least elevate them [94]. Significant amino acid synthesis is supported by 
significant serum elevations in the amino acids glycine and serine. Additionally, KE-treated rats 
had a significant increase in PPP intermediates ribose-5-phosphate and ribulose/xylulose-5-
phosphate demonstrating an increase flux through the pathway and potentially nucleic acid 
synthesis needed for wound healing. From this data, we can speculate that if the ketones were 
being used as energy a higher portion of the glucose can be shunted to the PPP instead of being 
metabolized for energy.  
 Surprisingly, oxidative stress (oxidized glutathione, GSSG (serum)) and antioxidant 
capacity (reduced glutathione (hippo), carnosine (serum), and anserine (serum)) were elevated, 
suggesting a heightened state of oxidative stress and antioxidant defense with ketone 
supplementation. As discussed by Moor and colleagues, age alone affects the levels of SOD2 and 
glutathione antioxidant profile [95]. Without appropriate oxidative stress, neutrophil respiratory 
bursts cannot effectively clear bacteria from the wound bed; however, without appropriate 
antioxidant capacity, the reactive oxygen species become damaging to neighboring tissue. This 
ketogenic elevation of both oxidative stress and antioxidant defense may help clear bacteria as 
well as quench ROS to promote wound healing in an aged phenotype. Additionally, carnosine (β-
alanyl-L-histidine) and anserine (β-alanyl-N-methylhistidine) were elevated by KE and 
BMS+MCT supplementation (Figure 3.11). Carnosine is a natural dipeptide widely and 
abundantly distributed in excitable tissue. Although its physiologic role is not completely 
understood, many beneficial actions have been attributed to carnosine, such as being an 
antioxidant, antiglycating and ion-chelating agent, and a free-radical scavenger. Several studies 
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have shown that supplementation with carnosine accelerates wound healing [96-100].  Anserine 
is a dipeptide containing beta alanine and histidine and has been shown to exhibit equal 
antioxidant activity to carnosine by reducing the primary molecular products of lipid 
peroxidation [101-103]. A study by Altavilla et al. demonstrated that reduction of lipid 
peroxidation restores impaired VEGF expression leading to accelerated wound healing and 
angiogenesis in a diabetic wound model [104]. This supports a possible mechanism of action for 
ketone supplementation to augment wound healing. However, further experiments need to be 
performed to optimize dose as too high of an oxidative state, which can be seen in the KE 
supplementation can potentially be damaging, especially in an aged patient.  
 Commonly known for its role in energy transfer via phosphorylation, adenosine also 
plays a role in the regulation of blood flow as a potent vasodilator. Adenosine was significantly 
elevated in the serum via KE supplementation and trended towards significance for BMS+MCT; 
however, BMS+MCT supplemented rats showed a significant elevation of adenosine in their 
hippocampal tissue (KE not significant). Even though BMS+MCT did not show a significant 
elevation in the blood stream, this suggests that the BMS+MCT supplemented rat tissues were 
more efficient at using it; therefore a larger portion had already been sequestered in the 
hippocampal tissue. High levels of AMP could reflect a metabolic insufficiency for the KE 
supplement, which may be due to the high dose; further studies optimizing the dose of ketone 
supplements are needed. Masino and colleagues have demonstrated that increased adenosine of 
the A1 subtype plays a key role in the anticonvulsant success of ketogenic strategies [105-108]. 
Additionally, several studies have shown that topical adenosine application accelerates wound 
healing via adenosine A2A receptors and promoting angiogenesis [109-117].  
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A recent study by Sood et al, was the first to document a global metabolomic profile of 
diabetic and non-diabetic wounds, 7 days post injury. In non-diabetic mice, 88 of the 129 
detected metabolites had a significant response to injury, 85 up regulated and 3 down-regulated. 
In diabetic wounds, 81 metabolites had a significant response to injury with 76 up regulated and 
5 down regulated. Interestingly, they found 62 unique metabolites that differed between the non-
diabetic and diabetic wound phenotype [118]. From their study, glycine was dysregulated in 
diabetic wounds and both ketone supplements significantly increased glycine in the serum (1.3, 
1.27 fold change). A recent metabolic profiling of cancer cells has correlated glycine with 
increased cell proliferation; however, it remains to be determined whether glycine is essential for 
cell proliferation during wound healing [119].  Two recent studies suggest that Kynurenine, a 
kynurenate precursor, may play a role in both anti-inflammatory activity and fibroblast 
proliferation during wound repair; additionally, it has been shown to be dysregulated in diabetic 
wounds [120, 121]. KE supplemented rats showed an increase in kynurenate but didn’t reach 
significance (2.61 fold) (0.05<p<0.10). Additionally, metabolite OH-phenylpyruvate was shown 
to be dysregulated and KE supplementation significantly enhanced the levels 3.59 fold in the 
serum. Little is known about the role during wound healing. Further experiments need to be 
conducted to determine the meaning of this observation.  
 The metabolomics profiling data presented here help us to understand the metabolic 
consequences of KE and BMS+MCT administration and offers insights into potential 
mechanisms of action by which ketone supplementation may augment wound healing as well as 
affect other disease states for future studies. 
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Table 3.1 Global metabolism profile of serum and hippocampal tissue following chronic 
administration of KE and BMS+MCT: Rats received a daily 5-g/kg dose of water (control) 
(n=11), KE (n=11), or BMS+MCT (n=12) via intragastric gavage for 29 days. On day 29, blood 
serum (~300 µL) and hippocampal tissues were collected 4-hours post-intragastric gavage (peak 
ketone elevation) and global metabolomics profiling was performed at Metabolon Inc. using gas 
and liquid chromatography and tandem mass spectrometry. Tx1=KE and Tx2=BMS+MCT. 
Results were considered significant when p<0.05 and direction is indicated by red or green 
arrows. 388 known metabolites were identified in the serum and 290 were identified in the 
hippocampus. KE significantly increased 106 metabolites and significantly decreased 36 in the 
serum compared to control; increased 10 and decreased 2 compared to control in the 
hippocampus (p<0.05, Welch’s two sample t-test). BMS+MCT significantly increased 57 
metabolites and significantly decreased 62 metabolites compared to control in the serum; 
increased 28 and decreased 8 compared to control in the hippocampus (p<0.05). An additional 24 
metabolites trended towards significance compared to control for KE and 58 for BMS+MCT 
(0.05<p<0.10).  
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Figure 3.8 Ketone supplementation elevates blood ketone levels in serum and hippocampal 
tissues: KE and BMS supplemented rats had elevated blood ketone levels in their serum. KE 
elevated βHB 15.76 fold and AcAc 8.84 fold. BMS+MCT elevated βHB 35.33 fold and AcAc 
15.39 fold.  KE elevated βHB 2.7 fold in hippocampus and BMS+MCT elevated βHB 3.39 fold. 
Figure 3.9 Ketone supplementation increases medium chain fatty acids in serum and 
hippocampal tissue: KE significantly increased medium chain fatty acid (MFCA) Caprate in the 
serum (3.15 fold) and in the hippocampus (1.92 fold) (p<0.05). BMS+MCT significantly 
increased Caprate in the serum (3.98 fold) and in the hippocampus (3.16 fold) (p<0.05). 
BMS+MCT significantly increased Caprylate in the serum (13.19 fold) and in the hippocampus 
(3.24) fold (p<0.05).  
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Figure 3.10 Ketone supplementation increases Krebs cycle intermediates: KE and 
BMS+MCT supplemented rats had significantly elevated Krebs cycle intermediates in their 
serum. Both, KE and BMS+MCT increased citrate (1.99 fold, 2.34 fold) (A), fumarate (1.92, 
2.45 fold) (B), and malate (2.03, 2.68 fold) (C) Additionally KE increased alpha-ketoglutarate 
(1.98 fold) (D) and BMS+MCT increased succinate (1.66 fold) (E). Krebs cycle precursor Acetyl 
CoA was significantly elevated by BMS+MCT in the hippocampus (1.37 fold) (F).  Krebs cycle 
intermediates were unchanged in hippocampal tissues.  
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Figure 3.11 Ketone supplementation increases antioxidants: KE and BMS+MCT 
significantly increased antioxidants carnosine (3.23, 1.79 fold) and anserine (5.66, 3.70 fold) in 
the serum (p<0.05). Carnosine and anserine were unchanged in the hippocampus.  
 
 
Figure 3.12 Ketone supplementation increases Adenosine: KE significantly increased 
adenosine levels in the serum (9.18 fold) (p<0.05).  BMS+MCT significantly increased 
adenosine levels in the hippocampus (10.95 fold).  
 
 
	 113	
3.4. References for Chapter 3 
1. Sirven J, Whedon B, Caplan D, Liporace J, Glosser D, O'Dwyer J, Sperling M: The 
ketogenic diet for intractable epilepsy in adults: preliminary results. Epilepsia 1999, 
40(12):1721-1726. 
2. Wilder R: The effect of ketonemia on the course of epilepsy. Mayo Clin Bulletin 1921, 
2:307-308. 
3. Thiele E: Assessing the efficacy of antiepileptic treatments: the ketogenic diet. 
Epilepsia 2003, 44 Suppl 7:26-29. 
4. Paoli A, Rubini A, Volek JS, Grimaldi KA: Beyond weight loss: a review of the 
therapeutic uses of very-low-carbohydrate (ketogenic) diets. European journal of 
clinical nutrition 2013, 67(8):789-796. 
5. Foster GD, Wyatt HR, Hill JO, McGuckin BG, C B, Mohemmed BS, Szapary PO, Rader 
DJ, Edman JS, Klein S: A randomized trial of a low-carbohydrate diet for obesity. 
The New England journal of medicine 2003, 348:2082-2090. 
6. Westman EC, Feinman RD, Mavropoulos JC, Vernon MC, Volek JS, Wortman JA, 
Yancy WS, Phinney SD: Low-carbohydrate nutrition and metabolism. The American 
journal of clinical nutrition 2007(86):276-284. 
7. Westman EC, Yancy WS, Edman JS, Tomlin KF, Perkins CE: Effect of 6-month 
adherence to a very low carbohydrate diet program. The American journal of 
medicine 2002, 113(1):30-36. 
8. Forsythe C, Phinney S, Fernandez M, Quann E, Wood R, Bibus D, Kraemer W, Feinman 
R, Volek J: Comparison of low fat and low carbohydrate diets on circulating fatty 
acid composition and markers of inflammation. Lipids 2008, 43(1):65-77. 
9. Boden G, Sargrad K, Homko C, Mozzoli M, Stein T: Effect of a low-carbohydrate diet 
on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 
diabetes. Annals of internal medicine 2005, 142(6):403-411. 
10. Gumbiner B, Wendel J, McDermott M: Effects of diet composition and ketosis on 
glycemia during very-low-energy-diet therapy in obese patients with non-insulin-
dependent diabetes mellitus. The American journal of clinical nutrition 1996, 
63(1):110-115. 
11. Nielsen J, Joensson E: Low-carbohydrate diet in type 2 diabetes: stable improvement 
of bodyweight and glycemic control during 44 months follow-up. Nutrition & 
metabolism 2008, 5:14. 
12. Yancy W, Foy M, Chalecki A, Vernon M, Westman E: A low-carbohydrate, ketogenic 
diet to treat type 2 diabetes. Nutrition & metabolism 2005, 2:34. 
	 114	
13. Dashti HM, Al-Zaid NS, Mathew TC, Al-Mousawi M, Talib H, Asfar SK, Behbahani AI: 
Long term effects of ketogenic diet in obese subjects with high cholesterol level. 
Molecular and cellular biochemistry 2006, 286(1-2):1-9. 
14. Maalouf M, Rho JM, Mattson MP: The neuroprotective properties of calorie 
restriction, the ketogenic diet, and ketone bodies. Brain Res Rev 2009, 59(2):293-315. 
15. Mavropoulos JC, Yancy WS, Hepburn J, Westman EC: The effects of a low-
carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study. 
Nutrition & metabolism 2004, 2:35. 
16. Seyfried T, Flores R, Poff A, D'Agostino D: Cancer as a metabolic disease: 
implications for novel therapeutics. Carcinogenesis 2014, 35:515-527. 
17. Poff AM, Ari C, Arnold P, Seyfried TN, D'Agostino DP: Ketone supplementation 
decreases tumor cell viability and prolongs survival of mice with metastatic cancer. 
International journal of cancer Journal international du cancer 2014, 135:1711-1720. 
18. Poff A, Ari C, Seyfried T, D'Agostino D: The ketogenic diet and hyperbaric oxygen 
therapy prolong survival in mice with systemic metastatic cancer. PloS one 2013, 
8(6):e65522. 
19. Seyfried T, Shelton L: Cancer as a metabolic disease. Nutrition & metabolism, 7:7. 
20. Fine E, Segal-Isaacson C, Feinman R, Herszkopf S, Romano M, Tomuta N, Bontempo A, 
Negassa A, Sparano J: Targeting insulin inhibition as a metabolic therapy in 
advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition 
(Burbank, Los Angeles County, Calif) 2012, 28(10):1028-1035. 
21. Zhao Z, Lange D, Voustianiouk A, MacGrogan D, Ho L, Suh J, Humala N, Thiyagarajan 
M, Wang J, Pasinetti G: A ketogenic diet as a potential novel therapeutic intervention 
in amyotrophic lateral sclerosis. BMC neuroscience 2006, 7:29. 
22. White H, Venkatesh B: Clinical review: ketones and brain injury. Critical care 
(London, England) 2011, 15(2):219. 
23. Prins M: Cerebral metabolic adaptation and ketone metabolism after brain injury. 
Journal of cerebral blood flow and metabolism : official journal of the International 
Society of Cerebral Blood Flow and Metabolism 2008, 28(1):1-16. 
24. Henderson S, Vogel J, Barr L, Garvin F, Jones J, Costantini L: Study of the ketogenic 
agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-
blind, placebo-controlled, multicenter trial. Nutrition & metabolism 2009, 6:31. 
25. Brownlow M, Benner L, D'Agostino D, Gordon M, Morgan D: Ketogenic diet improves 
motor performance but not cognition in two mouse models of Alzheimer's 
pathology. PloS one 2013, 8(9):e75713. 
	 115	
26. Kossoff EH, Hartman AL: Ketogenic diets: new advances for metabolism-based 
therapies. Current Opinion in Neurology 2012, 25:173-178. 
27. D'Agostino D, Pilla R, Held H, Landon C, Puchowicz M, Brunengraber H, Ari C, Arnold 
P, Dean J: Therapeutic ketosis with ketone ester delays central nervous system 
oxygen toxicity seizures in rats. American journal of physiology Regulatory, integrative 
and comparative physiology 2013, 304(10):R829-836. 
28. McPherson P, McEneny J: The biochemistry of ketogenesis and its role in weight 
management, neurological disease and oxidative stress. Journal of physiology and 
biochemistry 2012, 68(1):141-151. 
29. Jimmy Moore and Eric C. Westman M: Cholesterol Clarity: What the HDL is wrong 
with my numbers. Las Vegas,NV: Victory Belt Publishing Inc.; 2013. 
30. Dekaban A: Plasma lipids in epileptic children treated with the high fat diet. Archives 
of neurology 1966, 15(2):177-184. 
31. Chesney D, Brouhard B, Wyllie E, Powaski K: Biochemical abnormalities of the 
ketogenic diet in children. Clinical pediatrics 1999, 38(2):107-109. 
32. Schwartz R, Boyes S, Aynsley-Green A: Metabolic effects of three ketogenic diets in 
the treatment of severe epilepsy. Developmental medicine and child neurology 1989, 
31(2):152-160. 
33. Katyal N, Koehler A, McGhee B, Foley C, Crumrine P: The ketogenic diet in 
refractory epilepsy: the experience of Children's Hospital of Pittsburgh. Clinical 
pediatrics 2000, 39(3):153-159. 
34. Ellenbroek J, van Dijck L, Töns H, Rabelink T, Carlotti F, Ballieux B, de Koning E: 
Long-term ketogenic diet causes glucose intolerance and reduced beta and alpha cell 
mass but no weight loss in mice. American journal of physiology Endocrinology and 
metabolism 2014, 306(5):E552-E558. 
35. Bergqvist A: Long-term monitoring of the ketogenic diet: Do's and Don'ts. Epilepsy 
Research 2012, 100(3):261-266. 
36. Kwiterovich P, Vining E, Pyzik P, Skolasky R, Freeman J: Effect of a high-fat 
ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in 
children. JAMA : the journal of the American Medical Association 2003, 290(7):912-
920. 
37. Groesbeck D, Bluml R, Kossoff E: Long-term use of the ketogenic diet in the 
treatment of epilepsy. Developmental medicine and child neurology 2006, 48(12):978-
981. 
38. Patel A, Pyzik P, Turner Z, Rubenstein J, Kossoff E: Long-term outcomes of children 
treated with the ketogenic diet in the past. Epilepsia 2010, 51(7):1277-1282. 
	 116	
39. Brehm BJ, Seeley RJ, Daniels SR, D'Alessio DA: A randomized trial comparing a 
very low carbohydrate diet and a calorie-restricted low fat diet on body weight and 
cardiovascular risk factors in healthy women. The Journal of clinical endocrinology 
and metabolism 2003, 88(4):1617-1623. 
40. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser 
D, Bolotin A, Vardi H et al: Weight loss with a low-carbohydrate, Mediterranean, or 
low-fat diet. The New England journal of medicine 2008, 359(3):229-241. 
41. Volek JS, Phinney SD, Forsythe CE, Quann EE, Wood RJ, Puglisi MJ, Kraemer WJ, 
Bibus DM, Fernandez ML, Feinman RD: Carbohydrate restriction has a more 
favorable impact on the metabolic syndrome than a low fat diet. Lipids 2009, 
44(4):297-309. 
42. Feinman RD, Volek JS: Low carbohydrate diets improve atherogenic dyslipidemia 
even in the absence of weight loss. Nutrition & metabolism 2006, 3:24. 
43. Sharman MJ, Gomez AL, Kraemer WJ, Volek JS: Very low-carbohydrate and low-fat 
diets affect fasting lipids and postprandial lipemia differently in overweight men. J 
Nutr 2004, 134(4):880-885. 
44. Sharman MJ, Kraemer WJ, Love DM, Avery NG, Gomez AL, Scheett TP, Volek JS: A 
ketogenic diet favorably affects serum biomarkers for cardiovascular disease in 
normal-weight men. J Nutr 2002, 132(7):1879-1885. 
45. Westman EC, Mavropoulos J, Yancy WS, Volek JS: A review of low-carbohydrate 
ketogenic diets. Current atherosclerosis reports 2003, 5(6):476-483. 
46. Wood RJ, Volek JS, Davis SR, Dell'Ova C, Fernandez ML: Effects of a carbohydrate-
restricted diet on emerging plasma markers for cardiovascular disease. Nutrition & 
metabolism 2006, 3:19. 
47. Volek JS, Sharman MJ, Forsythe CE: Modification of lipoproteins by very low-
carbohydrate diets. J Nutr 2005, 135(6):1339-1342. 
48. Volek JS, Westman EC: Very-low-carbohydrate weight-loss diets revisited. Cleveland 
Clinic journal of medicine 2002, 69(11):849, 853, 856-848 passim. 
49. Volek JS, Sharman MJ, Gomez AL, DiPasquale C, Roti M, Pumerantz A, Kraemer WJ: 
Comparison of a very low-carbohydrate and low-fat diet on fasting lipids, LDL 
subclasses, insulin resistance, and postprandial lipemic responses in overweight 
women. J Am Coll Nutr 2004, 23(2):177-184. 
50. Volek JS, Sharman MJ: Cardiovascular and hormonal aspects of very-low-
carbohydrate ketogenic diets. Obesity research 2004, 12 Suppl 2:115s-123s. 
 
	 117	
51. Volek JS, Sharman MJ, Gomez AL, Scheett TP, Kraemer WJ: An isoenergetic very low 
carbohydrate diet improves serum HDL cholesterol and triacylglycerol 
concentrations, the total cholesterol to HDL cholesterol ratio and postprandial 
pipemic responses compared with a low fat diet in normal weight, normolipidemic 
women. J Nutr 2003, 133(9):2756-2761. 
52. Schoeler NE, Wood S, Aldridge V, Sander JW, Cross JH, Sisodiya SM: Ketogenic 
dietary therapies for adults with epilepsy: feasibility and classification of response. 
Epilepsy & behavior : E&B 2014, 37:77-81. 
53. Sengupta P: The Laboratory Rat: Relating Its Age With Human's. International 
journal of preventive medicine 2013, 4(6):624-630. 
54. Tsuchiya N, Harada Y, Taki M, Minematsu S, Maemura S, Amagaya S: [Age-related 
changes and sex differences on the serum chemistry values in Sprague-Dawley rats--
I. 6-30 weeks of age]. Experimental animals / Japanese Association for Laboratory 
Animal Science 1995, 43(5):671-678. 
55. Saito K, Ishikawa M, Murayama M, Urata M, Senoo Y, Toyoshima K, Kumagai Y, 
Maekawa K, Saito Y: Effects of sex, age, and fasting conditions on plasma lipidomic 
profiles of fasted Sprague-Dawley rats. PloS one 2013, 9(11). 
56. Ellington A, Kullo I: Atherogenic lipoprotein subprofiling. Advances in clinical 
chemistry 2008, 46:295-317. 
57. Mudd J, Borlaug B, Johnston P, Kral B, Rouf R, Blumenthal R, Kwiterovich P: Beyond 
low-density lipoprotein cholesterol: defining the role of low-density lipoprotein 
heterogeneity in coronary artery disease. Journal of the American College of 
Cardiology 2007, 50(18):1735-1741. 
58. Sacks F, Campos H: Clinical review 163: Cardiovascular endocrinology: Low-density 
lipoprotein size and cardiovascular disease: a reappraisal. The Journal of clinical 
endocrinology and metabolism 2003, 88(10):4525-4532. 
59. Wierzbicki A: Quality as well as quantity? Beyond low-density lipoprotein-
cholesterol - the role of particle size. International journal of clinical practice 2007, 
61(11):1780-1782. 
60. Tantibhedhyangkul P, Hashim S, Van Itallie T: Effects of ingestion of long-chain 
triglycerides on glucose tolerance in man. Diabetes 1967, 16(11):796-799. 
61. Eckel R, Hanson A, Chen A, Berman J, Yost T, Brass E: Dietary substitution of 
medium-chain triglycerides improves insulin-mediated glucose metabolism in 
NIDDM subjects. Diabetes 1992, 41(5):641-647. 
 
	 118	
62. Yost T, Erskine J, Gregg T, Podlecki D, Brass E, Eckel R: Dietary substitution of 
medium chain triglycerides in subjects with non-insulin-dependent diabetes mellitus 
in an ambulatory setting: impact on glycemic control and insulin-mediated glucose 
metabolism. Journal of the American College of Nutrition 1994, 13(6):615-622. 
63. Kashiwaya Y, Pawlosky R, Markis W, King MT, Bergman C, Srivastava S, Murray A, 
Clarke K, Veech RL: A ketone ester diet increases brain malonyl-CoA and 
Uncoupling proteins 4 and 5 while decreasing food intake in the normal Wistar Rat. 
The Journal of biological chemistry 2010, 285(34):25950-25956. 
64. Senior B, Loridan L: Direct regulatory effect of ketones on lipolysis and on glucose 
concentrations in man. Nature 1968, 219(5149):83-84. 
65. Miles JM, Haymond MW, Gerich JE: Suppression of glucose production and 
stimulation of insulin secretion by physiological concentrations of ketone bodies in 
man. The Journal of clinical endocrinology and metabolism 1980, 52(1):34-37. 
66. Kristian HM, Thomas S, Niels HS, Thomas G, Gerrit van H: Systemic, cerebral and 
skeletal muscle ketone body and energy metabolism during acute hyper-D-β-
hydroxybutyrataemia in post-absorptive healthy males. The Journal of Clinical 
Endocrinology & Metabolism 2014. 
67. Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF: Brain 
metabolism during fasting. The Journal of clinical investigation 1967, 46(10):1589-
1595. 
68. Veech R: The therapeutic implications of ketone bodies: the effects of ketone bodies 
in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, 
and mitochondrial metabolism. Prostaglandins, leukotrienes, and essential fatty acids 
2004, 70(3):309-319. 
69. Papamandjaris AA, MacDougall DE, Jones PJ: Medium chain fatty acid metabolism 
and energy expenditure: obesity treatment implications. Life sciences 1997, 
62(14):1203-1215. 
70. Ruskin D, Kawamura M, Masino S: Reduced pain and inflammation in juvenile and 
adult rats fed a ketogenic diet. PloS one 2009, 4(12):e8349. 
71. Kashiwaya Y, Sato K, Tsuchiya N, Thomas S, Fell D, Veech R, Passonneau J: Control 
of glucose utilization in working perfused rat heart. The Journal of biological 
chemistry 1994, 269(41):25502-25514. 
72. Sato K, Kashiwaya Y, Keon C, Tsuchiya N, King M, Radda G, Chance B, Clarke K, 
Veech R: Insulin, ketone bodies, and mitochondrial energy transduction. FASEB 
journal : official publication of the Federation of American Societies for Experimental 
Biology 1995, 9(8):651-658. 
	 119	
73. Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF, Jr.: Ketone bodies, potential 
therapeutic uses. IUBMB Life 2001, 51(4):241-247. 
74. Linde R, Hasselbalch S, Topp S, Paulson O, Madsen P: Global cerebral blood flow and 
metabolism during acute hyperketonemia in the awake and anesthetized rat. Journal 
of cerebral blood flow and metabolism : official journal of the International Society of 
Cerebral Blood Flow and Metabolism 2006, 26(2):170-180. 
75. Azzam R, Azar N: Marked Seizure Reduction after MCT Supplementation. Case 
reports in neurological medicine 2013, 2013:809151. 
76. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC: Study of the 
ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, 
double-blind, placebo-controlled, multicenter trial. Nutrition & metabolism 2008, 
6:31. 
77. Corwin RL: Binge-type eating induced by limited access in rats does not require 
energy restriction on the previous day. Appetite 2004, 42(2):139-142. 
78. Keenan KP, Ballam GC, Dixit R, Soper KA, Laroque P, Mattson BA, Adams SP, 
Coleman JB: The effects of diet, overfeeding and moderate dietary restriction on 
Sprague-Dawley rat survival, disease and toxicology. The Journal of nutrition 1997, 
127(5 Suppl). 
79. Keenan KP, Smith PF, Hertzog P, Soper K, Ballam GC, Clark RL: The Effects of 
Overfeeding and Dietary Restriction on Sprague-Dawley Rat Survival and Early 
Pathology Biomarkers of Aging. Toxicologic Pathology 1994. 
80. Clarke K, Tchabanenko K, Pawlosky R, Carter E, Knight N, Murray A, Cochlin L, King 
M, Wong A, Roberts A et al: Oral 28-day and developmental toxicity studies of (R)-3-
hydroxybutyl (R)-3-hydroxybutyrate. Regulatory toxicology and pharmacology : RTP 
2012, 63(2):196-208. 
81. Clarke K, Tchabanenko K, Pawlosky R, Carter E, Todd King M, Musa-Veloso K, Ho M, 
Roberts A, Robertson J, Vanitallie T et al: Kinetics, safety and tolerability of (R)-3-
hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regulatory toxicology 
and pharmacology : RTP 2012, 63(3):401-408. 
82. Kashiwaya Y, Bergman C, Lee J-H, Wan R, King M, Mughal M, Okun E, Clarke K, 
Mattson M, Veech R: A ketone ester diet exhibits anxiolytic and cognition-sparing 
properties, and lessens amyloid and tau pathologies in a mouse model of 
Alzheimer's disease. Neurobiology of Aging 2013, 34(6):1530-1539. 
83. Birkhahn R, McCombs C, Clemens R, Hubbs J: Potential of the monoglyceride and 
triglyceride of DL-3-hydroxybutyrate for parenteral nutrition: synthesis and 
preliminary biological testing in the rat. Nutrition (Burbank, Los Angeles County, 
Calif) 1997, 13(3):213-219. 
	 120	
84. Puchowicz M, Smith C, Bomont C, Koshy J, David F, Brunengraber H: Dog model of 
therapeutic ketosis induced by oral administration of R,S-1,3-butanediol 
diacetoacetate. The Journal of nutritional biochemistry 2000, 11(5):281-287. 
85. Brunengraber H: Potential of ketone body esters for parenteral and oral nutrition. 
Nutrition (Burbank, Los Angeles County, Calif) 1997, 13(3):233-235. 
86. Desrochers S, Dubreuil P, Brunet J, Jetté M, David F, Landau BR, Brunengraber H: 
Metabolism of (R,S)-1,3-butanediol acetoacetate esters, potential parenteral and 
enteral nutrients in conscious pigs. The American journal of physiology 1995, 268(4 Pt 
1):E660-E667. 
87. Kashiwaya Y, King MT, Veech RL: Substrate signaling by insulin: a ketone bodies 
ratio mimics insulin action in heart. The American journal of cardiology 1997, 80(3A). 
88. Kashiwaya Y, Sato K, Tsuchiya N, Thomas S, Fell DA, Veech RL, Passonneau JV: 
Control of glucose utilization in working perfused rat heart. The Journal of biological 
chemistry 1994, 269(41):25502-25514. 
89. Im MJ, Freshwater MF, Hoopes JE: Enzyme activities in granulation tissue: Energy 
for collagen synthesis. The Journal of surgical research 1976, 20(2):121-125. 
90. Im MJ, Hoopes JE: Enzyme activities in the repairing epithelium during wound 
healing. The Journal of surgical research 1970, 10(4):173-179. 
91. Im MJ, Hoopes JE: Energy metabolism in healing skin wounds. The Journal of 
surgical research 1970, 10(10):459-464. 
92. Im MJC, Hoopes JE: Energy metabolism in healing skin wounds. Journal of Surgical 
Research 1970. 
93. Long L, Halliwell B: Artefacts in cell culture: α-Ketoglutarate can scavenge 
hydrogen peroxide generated by ascorbate and epigallocatechin gallate in cell 
culture media. Biochemical and Biophysical Research Communications 2011, 406(1). 
94. Gupta A, Manhas N, Raghubir R: Energy metabolism during cutaneous wound 
healing in immunocompromised and aged rats. Molecular and cellular biochemistry 
2004, 259(1-2):9-14. 
95. Moor AN, Tummel E, Prather JL, Jung M, Lopez JJ, Connors S, Gould LJ: 
Consequences of age on ischemic wound healing in rats: altered antioxidant activity 
and delayed wound closure. Age (Dordrecht, Netherlands) 2014, 36(2):733-748. 
96. Fitzpatrick DW, Fisher H: Carnosine, histidine, and wound healing. Surgery 1982, 
91(1):56-60. 
97. Nagai K, Suda T, Kawasaki K, Mathuura S: Action of carnosine and beta-alanine on 
wound healing. Surgery 1986, 100(5):815-821. 
	 121	
98. Roberts PR, Black K, Santamauro JT, Zaloga GP: Dietary Peptides Improve Wound 
Healing Following Surgery. Nutrition 1998, 14(3). 
99. Sakae K, Yanagisawa H: Oral treatment of pressure ulcers with polaprezinc (zinc L-
carnosine complex): 8-week open-label trial. Biological trace element research 2014, 
158(3):280-288. 
100. Ansurudeen I, Sunkari VG, Grünler J, Peters V, Schmitt CP, Catrina S-BB, Brismar K, 
Forsberg EA: Carnosine enhances diabetic wound healing in the db/db mouse model 
of type 2 diabetes. Amino acids 2012, 43(1):127-134. 
101. Boldyrev AA, Dupin AM, Pindel EV, Severin SE: Antioxidative properties of 
histidine-containing dipeptides from skeletal muscles of vertebrates. Comparative 
biochemistry and physiology B, Comparative biochemistry 1988, 89(2):245-250. 
102. Boldyrev AA, Severin SE: The histidine-containing dipeptides, carnosine and 
anserine: Distribution, properties and biological significance. Advances in Enzyme 
Regulation 1990, 30. 
103. Kohen R, Yamamoto Y, Cundy KC, Ames BN: Antioxidant activity of carnosine, 
homocarnosine, and anserine present in muscle and brain. Proceedings of the 
National Academy of Sciences of the United States of America 1988, 85(9):3175-3179. 
104. Altavilla D, Saitta A, Cucinotta D, Galeano M, Deodato B, Colonna M, Torre V, Russo 
G, Sardella A, Urna G et al: Inhibition of lipid peroxidation restores impaired 
vascular endothelial growth factor expression and stimulates wound healing and 
angiogenesis in the genetically diabetic mouse. Diabetes 2001, 50(3):667-674. 
105. Masino SA, Geiger JD: The ketogenic diet and epilepsy: is adenosine the missing 
link? Epilepsia 2009, 50(2):332-333. 
106. Masino SA, Kawamura M, Ruskin DN: Adenosine receptors and epilepsy: current 
evidence and future potential. International review of neurobiology 2014, 119:233-255. 
107. Masino SA, Kawamura M, Wasser CD, Wasser CA, Pomeroy LT, Ruskin DN: 
Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship 
between metabolism and brain activity. Current neuropharmacology 2009, 7(3):257-
268. 
108. Masino SA, Li T, Theofilas P, Sandau US, Ruskin DN, Fredholm BB, Geiger JD, 
Aronica E, Boison D: A ketogenic diet suppresses seizures in mice through adenosine 
A₁  receptors. The Journal of clinical investigation 2011, 121(7):2679-2683. 
109. Chen W, Wu Y, Li L, Yang M, Shen L, Liu G, Tan J, Zeng W, Zhu C: Adenosine 
accelerates the healing of diabetic ischemic ulcers by improving autophagy of 
endothelial progenitor cells grown on a biomaterial. Scientific reports 2015, 5:11594. 
	 122	
110. Chiang B, Essick E, Ehringer W, Murphree S, Hauck MA, Li M, Chien S: Enhancing 
skin wound healing by direct delivery of intracellular adenosine triphosphate. 
American journal of surgery 2007, 193(2):213-218. 
111. Cronstein BN: Adenosine receptors and wound healing. TheScientificWorldJournal 
2004, 4:1-8. 
112. Feoktistov I, Biaggioni I, Cronstein BN: Adenosine receptors in wound healing, 
fibrosis and angiogenesis: Springer; 2009. 
113. Montesinos MC, Desai A, Chen J-FF, Yee H, Schwarzschild MA, Fink JS, Cronstein 
BN: Adenosine promotes wound healing and mediates angiogenesis in response to 
tissue injury via occupancy of A(2A) receptors. The American journal of pathology 
2002, 160(6):2009-2018. 
114. Montesinos MC, Desai-Merchant A, Cronstein BN: Promotion of Wound Healing by 
an Agonist of Adenosine A2A Receptor Is Dependent on Tissue Plasminogen 
Activator. Inflammation 2015. 
115. Valls MD, Cronstein BN, Montesinos MC: Adenosine receptor agonists for promotion 
of dermal wound healing. Biochemical pharmacology 2009. 
116. Valls MDD, Cronstein BN, Montesinos MC: Adenosine receptor agonists for 
promotion of dermal wound healing. Biochemical pharmacology 2009, 77(7):1117-
1124. 
117. Victor-Vega C, Desai A, Montesinos MC, Cronstein BN: Adenosine A2A receptor 
agonists promote more rapid wound healing than recombinant human platelet-
derived growth factor (Becaplermin gel). Inflammation 2002, 26(1):19-24. 
118. Sood RF, Gu H, Djukovic D, Deng L, Ga M, Muffley LA, Raftery D, Hocking AM: 
Targeted metabolic profiling of wounds in diabetic and non-diabetic mice. Wound 
repair and regeneration : official publication of the Wound Healing Society [and] the 
European Tissue Repair Society 2015. 
119. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner 
MW, Clish CB, Mootha VK: Metabolite profiling identifies a key role for glycine in 
rapid cancer cell proliferation. Science (New York, NY) 2012, 336(6084):1040-1044. 
120. Li Y, Kilani RT, Rahmani-Neishaboor E, Jalili RB, Ghahary A: Kynurenine increases 
matrix metalloproteinase-1 and -3 expression in cultured dermal fibroblasts and 
improves scarring in vivo. The Journal of investigative dermatology 2014, 134(3):643-
650. 
121. Salimi Elizei S, Poormasjedi-Meibod M-SS, Li Y, Baradar Jalili R, Ghahary A: Effects 
of kynurenine on CD3+ and macrophages in wound healing. Wound repair and 
regeneration : official publication of the Wound Healing Society [and] the European 
Tissue Repair Society 2015, 23(1):90-97. 
	 123	
CHAPTER 4: ENHANCING WOUND HEALING WITH EXOGENOUS KETONE 
SUPPLEMENTATION 
 
4.1. Chapter Synopsis 
 In the previous chapter, we determined that exogenous ketone supplementation 
significantly elevated blood ketone levels and reduced blood glucose levels in juvenile Sprague-
Dawley rats. In this chapter, we present data demonstrating that both BD and BMS+MCT 
ketone supplements elicit age-dependent rapid elevation of blood ketone levels and reduction of 
blood glucose levels in young (8 month) and aged (20 month) Fischer 344 rats similar to those 
determined in Chapter 3. Additionally, we present data demonstrating the effects of food-
integrated oral ketone supplementation on an ischemic wound-healing model in young and aged 
Fischer 344 rats. In the ischemic wound model, the flap placement on the dorsum prevents the 
use of oral gavage; therefore, the ketone supplements were mixed into the food and fed ad 
libitum. Nonetheless, this allowed continuous delivery of the ketone supplements in smaller 
doses as the rats fed throughout the day. Compared to a bolus administration, multiple daily 
doses or inclusion in the food may provide more sustained benefits. Additionally, we chose one 
synthetic (BD) and one natural (BMS+MCT) ketone supplement for the following studies. 
Though KE would seem to be a logical choice to continue with, the Fischer 344 rats refused to 
eat the food mixed with this supplement; therefore, BD was used. 
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 Portions of this chapter have been taken from a manuscript Poff AM, Kesl SL, 
D’Agostino DP “Ketone Supplementation for Health and Disease” Book Chapter, Oxford Press 
(Submitted). A copy of this article may be found in Appendix C. Materials and Methods 
presented in this chapter may be found in Appendix A.  
 
4.2. Dietary Ketone Supplementation Increases Blood Flow and Wound Closure in an 
Ischemic Wound Model in Young and Aged Fischer Rats 
It has been well established that the ketogenic diet (KD) induces “keto-adaptation”, a 
physiologic state characterized by a shift away from glucose metabolism and towards fat and 
ketone body metabolism. [1-3].  As discussed in previous chapters, there are many 
physiological changes associated with sustained ketosis that may contribute to its multifaceted 
therapeutic potential for many disease states including chronic wounds. Thus, we previously 
measured blood glucose, ketones, lipids, and other biochemical metabolites in response to 
chronic oral ketone administration to show physiological equivalence to KD [4]. Increasing 
evidence shows that limited energy and nutrient exchange is associated with age-related 
impairment of wound healing. We hypothesized that oral ketone supplementation without 
dietary restriction would enhance wound closure in young and aged Fischer rats by improving 
blood flow and supplying an alternative energy substrate. In our preliminary studies, we 
measured the magnitude and duration of ketosis following administration of a single 6.5g/kg 
dose of ketone precursors: 1,3-Butanediol (BD), Na+/K+ βHB salt and medium chain 
triglyceride (MCT) oil 1:1 mixture (BMS+MCT), or water in young and aged Fischer 344 rats 
(n=6). Substances were administered through an intragastric gavage, and whole blood samples 
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(10 µl) were acquired for analysis of glucose and βHB at 0, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours 
following administration. Following the creation of ischemic wounds, the ketogenic 
supplements were added to a standard diet fed ad libitum for 28 days. Laser Doppler imaging of 
the ischemic peri-wound tissue every seven days demonstrated significantly increased blood 
flow in young rats (n=10) fed BD at day 14 and 28 (p<0.001) and BMS+MCT at day 7, 14, and 
28 (p<0.01). In aged rats, blood flow was significantly increased in BD-fed at day 14 and 
BMS+MCT-fed at days 7 and 14 (p<0.05). Wound size was significantly smaller in young rats 
fed BD and BMS+MCT compared to control at 11 and 14 days following wound creation 
(p<0.05). In aged rats, BD-fed wounds were significantly smaller at days 11 and 14 (p<0.05) 
and in BMS+MCT-fed at days 11, 14, and 28 (p<0.05). Wound healing improved by three days 
in aged BD-fed, seven days in young BMS+MCT-fed, and ten days in aged BMS+MCT-fed 
compared to the healing time line of the control animals. 
4.2.1 Aged rats metabolize exogenous ketone supplements differently than young rats 
In Chapter 3, we studied if oral ketone administration could elicit similar physiological 
effects as the KD by determining how blood glucose, ketones, and lipids and other biochemical 
metabolites are affected by chronic ketone administration [4]. Here we present evidence that 
chronic administration of ketone supplements can induce a state of nutritional ketosis without 
the need for dietary carbohydrate restriction, enhance blood flow, and augment wound closure 
in young and aged Fischer 344 rats.  
Both young and aged rats exhibited elevated ketones within 30 minutes of the bolus 
administration for both BD and BMS+MCT supplements and were sustained for 12 hours 
(p<0.05). However, BD supplemented aged rats demonstrated a peak elevation of blood βHB 
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levels at 8 hours, which was delayed compared to their younger counterparts who had peaked 
blood βHB levels at 4 hours post intragastric gavage. Additionally, aged animals supplemented 
with either of the ketone supplements demonstrated a ~1.5x higher elevation of blood ΒHB 
levels for the same dose compared to the young animals (Figures 4.1A, B). An additional set of 
young and aged animals were tested with a 10 g/kg dose of their respective ketone supplements 
and a similar pattern emerged, young and aged animals’ blood βHB levels both peaked at 12 
hours post gavage (data not shown).  Aged animals administered BD appeared sedated, had 
increased blood BHB up to 8 mM, and hypoglycemia (<50 mg/dL). We speculated that these 
sedative effects might be because BD is metabolized as an alcohol; thus, we decided that an 
intragastric gavage at 10 g/kg was not optimal for aged animals. Young animals were able to 
tolerate the dose.  
The metabolic challenge of a wound is exacerbated in elderly patients [5]. Without 
sufficient energy (ATP) levels, wound healing is significantly impaired. As discussed, the ATP 
deficiency creates an imbalance of energy production versus utilization (the catabolism to 
anabolism ratio) leading to loss of lean body mass (LBM) [6, 7]. Additionally, Gupta and 
colleagues demonstrated that metabolic enzymes hexokinase, citrate synthase, 
phosphofructokinase, and lactate dehydrogenase were decreased in aged rats. Additionally, the 
metabolic enzyme glucose-6-phosphate dehydrogenase exhibited elevated activity and the 
beginnings stages followed by a significant decreased activity in a later phase compared to 
controls [8]. These age-dependent metabolic changes could explain the difference between the 
young and aged rats’ response to acute ketone supplementation. However, ketones have been 
shown to increase Kreb’s cycle intermediates, mitochondrial biogenesis, and enhance overall 
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metabolic efficiency; thus, this is one potential mechanism of how the prolonged ketone 
administration could have enhanced wound healing.  
 
4.2.2. Hypoglycemic effect of hyperketonemia attenuated with age 
In Chapter 3, we demonstrated that at baseline and 4 weeks, 4 hours after intragastric 
gavage with BMS+MCT (5 g/kg), the elevation of blood ketones was inversely correlated with 
the reduction in blood glucose (r2=0.4314, p=0.0203, r2=0.8619, p<0.0001). This correlation 
was not observed at any time point for BD supplemented rats [4]. Veech and colleagues have 
demonstrated that administration of similar ketone supplement simultaneously decreased blood 
glucose and blood insulin by approximately 50%. Our data show the same correlation between 
elevated blood ketone levels and reduced blood glucose levels with exogenous BMS+MCT 
supplementation in 8-month-old Fischer rats, supporting the work of Veech and confirming our 
previous work (Figure 4.2). However, this hypoglycemic effect is not apparent in the 20-month 
animals (Figure 4.2).  As discussed, metabolic changes that occur during aging may play a role 
in diminishing this relationship. Furthermore, insulin resistance has been shown to increase with 
age [9]. Veech and colleagues have determined that ketone-induced hypoglycemia occurs via 
increasing insulin sensitivity [10-12]. In the older adult, with pre-existing has insulin resistance, 
the same ketone-induced effect on insulin sensitivity may not occur or it may not be enough to 
cause hypoglycemia. It should be noted that even though there wasn’t a significant correlation 
between blood ketone levels and blood glucose levels in aged ketone supplemented rats, there 
was suppression of glucose based on the linear regression analysis (data not shown). This 
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observation supports the speculation that an age-dependent metabolic change diminishes the 
significant correlation but doesn’t completely neutralize the relationship.  
Additionally, hyperketonemia was observed throughout the 28-day wound healing study 
in the BD supplemented young and aged rats, but was not noted in the BMS+MCT 
supplemented rats (Figure 4.5A). In Chapter 3, we demonstrated that ketone supplementation 
caused a sustained reduction in glucose over the time course of the intragastric gavage study; 
however, this sustained reduction of glucose was not observed over the course of the wound 
healing study (Figure 4.5B). In a follow-up chronic feeding study (15 weeks), food-integrated 
ketone supplementation resulted in elevated blood ketone levels without affecting the blood 
glucose levels throughout the study, which supports our findings in this study (data not shown, 
unpublished data).  
 
4.2.3. Ketone supplementation increases blood flow in both young and aged rats 
Restoration of blood flow via angiogenesis is critical for healing a wound and to support 
revascularization of grafts including tissue engineered skin substitutes. Venous, arterial, and 
diabetic blood flow insufficiencies are major underlying contributors to chronic wound 
development. Additionally, older patients have a greater prevalence of hypertension, diabetes, 
and smoking, which exacerbate the age-dependent angiogenic insufficiencies [13, 14]. In this 
study, oral ketone supplementation significantly increased blood flow in young and aged rats 
supplemented with BD or BMS+MCT (Figure 5.3B).  In the raw Laser Doppler data, darker 
colors are indicative of low blood flow/ischemia and lighter colors demonstrate increased blood 
flow. The increased blood flow in the ketone-supplemented rats is clearly visible in the raw data 
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(Figure 5.3A). This wound-healing model was created to induce ischemia and thus delay 
wound healing [15, 16]. Further studies need to be conducted to measure oxygen concentrations 
during wound healing to establish that increased blood flow reverses flap ischemia leading to 
accelerated wound healing.  In a study by Hasselbalch and colleagues, exogenous ketone 
supplementation exhibited a 39% increase in cerebral blood flow [17]. Additionally, VEGF, a 
potent angiogenic factor, has shown to be elevated with exogenous ketone supplementation [18-
20]. As discussed in Chapter 3, ketone supplementation has been determined to increase the 
potent vasodilator, adenosine. These two mechanisms may explain how ketone supplementation 
increased blood flow in the ischemic wound model.  
 
4.2.4 Ketone supplementation accelerates wound closure in young and aged rats 
 As the population continues to age, there is a critical need to develop effective wound 
healing therapies. In this study, we have demonstrated that exogenous ketone supplementation 
enhanced wound closure by ten days (36% faster) in aged rats supplemented with BMS+MCT 
and three days (10% faster) in aged rats supplemented with BD compared to control aged rats 
(Figure 4.4). Additionally, young rats supplemented with BMS+MCT healed three days earlier 
(14% faster) compared to standard diet fed young rats (Figure 4.4). Future studies are designed 
to determine the wound healing effect of topical ketone administration alone and in combination 
with the oral exogenous ketone therapy. As is, this therapy could allow patients to benefit from 
nutritional ketosis without dietary restriction.  
Studies by Nevin and colleagues investigated the influence of a topical application of 
virgin coconut oil (VCO) on the healing of dermal wounds in young rats [21-23]. Their results 
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demonstrated a significant beneficial effect of VCO administration on intracellular and 
extracellular matrix components compared to controls including increased cross-linking 
collagen molecules indicating greater wound tensile strength and increased total DNA of the 
granulation tissue.  Additionally, VCO therapy induced greater antioxidant capacity (superoxide 
dismutase 2, glutathione reductase, glutathione peroxidase) during wound healing, which led to 
a decrease in lipid peroxides (MDA). They concluded that the wound healing property of VCO 
might be due to its minor biologically active components and antimicrobial fatty acids. Previous 
studies have demonstrated that food integrated coconut oil was able to eliminate bacterial 
infection and stimulate the immune response [24]. Coconut oil is a natural source of medium 
chain triglycerides (MCTs), which have been shown to modulate cellular proliferation, cell 
signaling, and growth factor activities as well as elicit ketogenesis as seen in this study and our 
previous study [4, 25-27].   
 The BMS contains potassium and other minerals to prevent sodium overload.  
Maintaining an optimal sodium-mineral ratio should help offset any potential adverse effects of 
sodium on blood pressure. For example, multiple studies have shown that potassium provides 
an antihypertensive effect and protects cardiovascular damage in salt-sensitive hypertension 
[28, 29]. It is speculated that this formulation will be especially beneficial for elderly patients 
most susceptible to sodium-induced hypertension [11]. The dose of the salt solution is easily 
adjusted to benefit the patients’ needs. In this study a 10% ketone salt solution is mixed in a 1:1 
ratio with MCT oil, which allows for reduced dosing of each component compared to 
administering the compounds individually. This reduces the potential for side effects (sodium-
induced hypertension, gastric side effects, etc.) and results in distinct synergistic blood ketone 
profile [30]. A noteworthy observation from our previous study revealed that in rats, MCT alone 
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was more effective than BMS+MCT or BMS alone at inducing ketosis.  However, preliminary 
human data suggests that the BMS+MCT mixture is most effective at inducing ketosis and 
MCT the least. This suggests that there is inter-species variability in the metabolic response to 
ketone supplements, which will need to be further characterized to fully understand effects in 
humans. In the rats, the BMS+MCT supplement elevated blood ketones similar to that of MCT 
alone; however, the gastric side effects were not observed suggesting a potential method for 
avoiding this unwanted adverse effect [31]. 
 
 4.2.5. Food- integrated ketone supplementation did not elicit weight loss in young and 
aged rats  
The KD is hypothesized to induce weight loss by reducing appetite through the satiety 
effect of ketone bodies, reducing lipogenesis and increasing lipolysis, and enhancing metabolic 
efficiency with fat and ketone metabolism [32]. Recently, preliminary studies have shown that 
exogenous ketone supplementation can also induce weight loss. The administrations of both 
βHB and BD have been shown to decrease food intake in rats and pigmy goats [33-37]. 
Similarly, it is suggested that MCTs increase satiety, resulting in reduced food intake and 
weight loss as a consequence of their rapid oxidation into ketone bodies [38-40]. MCTs may 
further counteract fat deposition in adipocytes by increasing thermogenesis [41]. Several studies 
in animals and humans have revealed increased energy expenditure and lipid oxidation with 
MCTs compared to LCTs [42-51].  Ketone esters have also been shown to affect weight in 
mice, rats, and humans [20, 52-55]. In Chapter 3, all five ketogenic supplements tested via 
intragastric oral gavage (BD, KE, MCT, BMS, BMS+MCT) inhibited weight gain compared to 
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control animals [4]. Similarly, a 15-week chronic feeding study in which KE, BMS, or 
BMS+MCT replaced approximately 20% of the diet by weight, fed ad libitum, led to reduced 
weight gain compared to control animals (data not shown, unpublished data).   
Even though weight loss has been noted in a variety of studies, significant weight loss 
was not observed in either young or aged rats of this study (Figure 4.6A).  To improve post-
anesthetic appetite, thereby limiting the initial weight loss that is standard with an invasive 
surgery, the rats were fasted for 18 hours before surgery. . Weight loss was noted during the 
first week after surgery, but did not reach significance in any group, and was similar across all 
groups demonstrating that it wasn’t a ketone-mediated effect.  Weight was maintained in all 
groups for the remainder of the study. This initial fasting may be a reason that the initial weight 
loss during the first week post-surgery did not reach significance. In the previously discussed 
studies, rats were Sprague Dawley and were either juvenile or still in a growth phase, whereas 
in this study the rats were mature or elderly Fischer 344s. Age and strain variability may 
account for the lack of weight loss in this study compared to previously discussed experiments.  
Particularly in elderly patients where malnutrition may already be present, it is critical to 
prevent the wound from parasitizing substrates from the rest of the body for energy production, 
resulting in what is called protein-energy malnutrition (PEM).  The body catabolizes the 
muscle, skin, and bone to support the synthesis of proteins, inflammatory cells, and collagen 
needed to fight infection and repair the wound, causing a loss of lean body mass (LBM). As an 
individual loses more LBM, wound healing is more likely to be delayed.  A loss of more than 
15% LBM impairs wound healing, a 30% LBM loss stops wound healing, and a loss of 40% 
LBM typically results in death [56-60]. A body in ketosis has been shown to be muscle sparing 
as it is adapted to using the readily available fat stores, attenuating the catabolic effects [7].  The 
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weight maintenance seen in this wound healing study may reflect this protein-sparing effect. 
Moreover, if ketosis enhances insulin sensitivity, glucose uptake by the insulin-sensitive 
skeletal muscle should be increased. Together, these effects would help support muscle tissue 
health and function, suggesting another possible mechanism of ketone supplementation in 
diminishing LBM and PEM.  
 
4.3 Closing Remarks 
It has been debated if chronological age alone affects wound healing. However, with the 
aged population showing decreased blood flow leading to the decline of nutrient exchange, 
decreased metabolic activity and ATP production at the wound bed, it is clear how these factors 
may result in an exacerbation of chronic wounds in older adults. The discouraging results from 
studies focusing on single molecular targets are not surprising since wound healing is the 
outcome of a complex set of interactions between numerous factors. This is likely one reason 
most wound therapies are minimally effective.  Our approach utilizes endogenous physiology to 
reach the wound bed systemically with one therapy, exogenous ketone supplementation, that 
has multiple downstream effects.. Even though there is much work still to be done, this 
approach shows promising results as a potential wound therapy.  
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Figure 4.1 Effects of ketone supplementation on blood ketone and blood glucose levels: (A, 
B) Blood βHB and blood glucose levels at times 0, 0.5, 1, 4, 8, 12, and 24 hours post (6.5 g/kg) 
intragastric gavage for ketone supplements tested. BMS+MCT and BD supplementation rapidly 
elevated and sustained significant βHB elevation (p< 0.05) (A) and significantly reduced 
glucose (p < 0.05) (B) compared to controls in both young (8M) and aged (20M) rats. Two-Way 
ANOVA with Tukey’s post-hoc test, results considered significant if p<0.05. Error bars represent 
mean (SD). 
Figure 4.2 Relationship between blood ketone and blood glucose levels attenuated with 
age: At four hours post intragastric gavage, BMS+MCT (6.5 g/kg) supplemented rats 
demonstrated a significant correlations between elevated blood ketone levels and decreased 
blood glucose levels in young (8M) rats (r2=0.4775, p=0.0393); however, correlation was not 
present in aged (20M) rats (r2=0.0088, p=0.8431).  Linear regression analysis, results 
considered significant if p<0.05. Error bars represent mean (SD).  
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Figure 4.3 Ketone Supplementation increases blood flow in both young and aged rats: 
Laser Doppler was used to measure blood flow weekly in the ischemic flap. Raw data from 
aged rats fed SD, BD and BMS ketone supplements at day 14 demonstrates the difference in 
blood flow seen by the laser doppler (A). Laser Doppler imaging of the ischemic peri-wound 
tissue every 7 days for 28 days demonstrated significantly increased blood flow in young rats 
(n=10 per group) with the BD at day 14 (p<0.0001) and 28 (p=0.0002) and the BMS+MCT at 
day 7 (p=0.0007), 14(p<0.0001), and 28 (p=0.0036) compared to control. There was an increase 
in blood flow in the aged rat flaps (n=10 per group) treated with the BD at day 14 (p=0.0039) 
and BMS+MCT at days 7 (p=0.0305) and 14 (p=0.0008) compared to control. Two-Way 
ANOVA with Tukey’s post-hoc test, results considered significant if p<0.05. Error bars represent 
mean (SD). 
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Figure 4.4 Ketone supplementation enhances wound closure time in young and aged rats: 
Visualized using Kaplan-Meier survival plot. Wound healing (closure) was determined to be 
significantly different in the young (n=10 per group) Fischer rats in BD at day 11 (p=0.0493) 
and in BMS+MCT at day 11 (p=0.0022) and 14 (p=0.0349). In the aged Fischer rats (n=10 per 
group), the BD was significantly different at day 11 (p=0.0230) and 14 (p=0.0233) and 
BMS+MCT was significantly different at day 11 (p=0.0115), 14 (p=0.0016) and 28 (p=00010). 
Two-Way ANOVA with Tukey’s post-hoc test, results considered significant if p<0.05.  
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Figure 4.5 Ketone supplementation elevates blood ketones levels but does not affect blood 
glucose levels: (A) Hyperketonemia was sustained for the duration of the wound healing 
progression in BD supplemented young and aged animals. (B) Ketone supplementation did not 
significantly reduce blood glucose levels at any point of the healing period. Two-Way ANOVA 
with Tukey’s post-hoc test, results considered significant if p<0.05. Error bars represent mean (SD). 
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Figure 4.6 Body and Spleen Weight: (A) Ketone supplementation did not result in significant 
weight loss through the study in young and aged animals. (B) Though aged animals’ spleen size 
trended towards splenomegaly, results did not reach significance. Two-Way ANOVA with 
Tukey’s post-hoc test, results considered significant if p<0.05. Error bars represent mean (SD). 
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CHAPTER 5: POTENTIAL MECHANISMS FOR EXOGENOUS KETONE 
SUPPLEMENTATION TO ENHANCE WOUND HEALING 
 
5.1. Chapter Synopsis 
In this chapter, we present data defining some potential mechanisms by which exogenous 
ketone supplementation augments ischemic wound healing. We focus on four main age 
dependent factors: inflammation, ROS production, angiogenesis, and metabolism. Since ketone 
supplementation enhanced wound healing, we hypothesized that there would be measurable 
physiological changes in wound healing as early three days post-wounding. Periwound tissue 
was harvested at day three and day seven post-wounding for mechanistic analysis. Additionally 
mechanistic studies were conducted using primary human dermal fibroblast (HDFs) to confirm 
ex vivo observations. From these studies we conclude that exogenous ketone supplementation 
decreases ROS production, increases migration and proliferation, and decreases lactate 
production. Ketone supplementation did not affect inflammatory markers or antioxidants SOD2 
and NQO1. Though there were similarities in effects of ketone supplements, BD and BMS+MCT 
elicited distinctive mechanistic profiles. We propose further studies at later time points of wound 
healing to determine if exogenous ketone supplementation will affect wound healing at a later 
phase than we originally hypothesized.  
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5.2. Potential Mechanisms of Action for Exogenous Ketone Enhancement of Ischemic 
Wound Healing in Young and Aged Fisher Rats  
In the previous chapter, we reported that oral ketone supplementation without dietary 
restriction enhanced wound closure and increased blood flow in young and aged Fisher 344 rats. 
We hypothesized that exogenous ketone supplementation promoted wound healing via 
enhancement of physiological factors such as increasing proliferation, advancing migration, 
reducing ROS production, and resolving inflammation. Experiments in vitro with young and 
aged primary human dermal fibroblasts supplemented with 5mM βHB for 72 hours ahead of an 
oxidative stimulus (100μM tert-butyl-hydrogen peroxide) resulted in significantly decreased 
cellular ROS production, enhanced cell migration, and augmented cellular proliferation (p<0.05). 
Comparing peri-wound tissue lysates isolated from rats fed 1,3 Butanediol (BD), βHB NA+/K+ 
salt mixed with MCT oil in a 1:1 ratio (BMS+MCT), or standard diet (SD) we show that ketone 
administration during wound healing induced changes in cytokines, including a significant 
elevation in epidermal growth factor (EGF) at day 7 of wound healing compared to control 
(p<0.05). BMS+MCT supplementation in aged rats significantly decreased tumor necrosis 
factor- alpha (TNF-α) levels on day 7 compared to control (p<0.05). Furthermore, ketone 
supplementation significantly reduced leptin levels in ischemic wound tissue lysates in both 
young and aged rats. Changes in pro-inflammatory (IRF-5 labeled, M1) to anti-inflammatory 
(CD206 labeled, M2) macrophage ratio and blood vessel density were demonstrated by 
immunohistochemistry.  We conclude that ketone supplementation in vivo and in vitro modifies 
systemic physiology to enhance wound closure. 
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5.2.1 Effects of ketone supplementation on inflammation 
Inflammation is a key regulatory step in the progression of wound healing. Chronic 
wounds are stuck in the inflammatory phase characterized by a proteolytic environment in which 
pro-inflammatory cells, cytokines, and chemokines inhibit the normal progression of wound 
healing [1]. Pro-inflammatory cytokines including IL-6, IL-1β, and TNF-α are upregulated 
during the inflammatory phase of wound healing [2]. IL-6 is produced by neutrophils and 
monocytes and has been shown to be important in initiating the healing response, has mitogenic 
and proliferative effects on keratinocytes, and is chemoattractive to neutrophils [3-8]. TNF-α 
alone has been shown to enhance wound healing in a concentration-dependent manner. Low 
levels of TNF-α can promote wound healing indirectly by stimulating inflammation and 
macrophage-produced growth factors. However, at higher levels, TNF-α has a detrimental effect 
on wound healing by suppressing ECM synthesis and TIMPs while increasing MMPs, inhibiting 
re-epithelialization. Additionally, levels of TNF-α and IL-1β are elevated in chronic wounds and 
have been shown to work synergistically and perpetuate each other’s expression to amplify the 
pro-inflammatory environment [9-11].  
Exogenous ketone supplementation did not affect pro-inflammatory markers IL-6 or IL-
1β in young or aged periwound tissue lysates on day three or day seven of wound healing 
(Figure 5.2). BMS+MCT supplementation significantly reduced TNF-α levels in periwound 
tissue lysates of aged rats after seven days of wound healing compared to aged controls. 
Significant changes were not observed in selected anti-inflammatory cytokines including IL-4, 
IL-10, or IL-13 (Figure 5.2). In an unpublished study from our laboratory, rats were fed one of 
three exogenous ketone supplements (1, 3-butanediol diacetoacetate ester (KE), Na+/Ca+2-β-
hydroxybutyrate mineral salt (ΒHB-S), or a 1:1 mixture of Na+/Ca+2-β-hydroxybutyrate mineral 
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salt: Medium Chain Triglyceride Oil (S/MCT) mixed into standard rodent chow at 5-20% by 
weight for 15 weeks. Inflammatory profiling was performed on serum collected from the rats at 
the end of the chronic feeding study and revealed decreases in several pro-inflammatory and 
anti-inflammatory cytokines including IL-1β, IL-6, IFN-γ, MCP-1, RANTES, IL-4, IL-10, IL-13. 
These findings suggest that ketone supplementation may suppress total inflammation and not 
affect pro-inflammatory or anti-inflammatory markers independently; however, further 
experiments need to be conducted to confirm this observation. Because ketone supplementation 
hastened wound healing, we hypothesized that we would see early resolution of inflammation. 
Further studies need to be conducted on subsequent days of wound healing to see if ketone 
supplementation affects inflammatory markers after day 7. Epidermal growth factor (EGF) is 
secreted by platelets, macrophages and fibroblasts to accelerate epithelialization and increase the 
tensile strength of wounds [12-15]. Topical EGF administration has shown promising results for 
venous ulcers and diabetic ulcers; however, the heterogeneity of wounds, modes of 
administration, patient management protocols, and varied clinical trial outcomes has limited 
clinical application to outside of the USA [16]. Exogenous ketone supplementation with BD 
elevated EGF levels in day seven periwound tissue lysates of young rats (Figure 5.3B).  
Leptin is a hormone that works in opposition of ghrelin to regulate energy homeostasis by 
inhibiting hunger and establishing satiety. The KD has been demonstrated to slow weight gain by 
altering leptin levels. Juvenile rats fed a KD for two weeks had slower weight gain, had higher 
leptin levels, and lower insulin levels compared to those fed an SD [17]. We demonstrated a 
similar slowing of weight gain in juvenile Sprague-Dawley rats in Chapter 3, consistent with this 
observation. In the same study, they demonstrated that calorie restriction did not elicit the same 
leptin elevation as the KD. However, Kolacynski and colleagues investigated the responses of 
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leptin following a short term fasting, demonstrating that leptin levels declined following a 12 
hours fast. Re-feeding prompted leptin levels to rise and return to normal values within 24 hours 
[18]. They demonstrated a reverse relationship between levels of βHB and leptin. Small amounts 
of glucose added to inhibit hepatic ketogenesis was enough to prevent the fall of leptin. 
However, exogenous ketone administration did not reduce leptin, causing the team to conclude 
that the relationship was due to a physiological response to ketogenesis and not ketone bodies 
themselves.  
An increasing number of studies have determined that leptin has a broad spectrum of 
physiological effects in the wound-healing environment. Leptin has been shown to directly cause 
T cells and monocytes to release pro-inflammatory cytokines, to produce angiogenesis in 
endothelial cells, and to induce neo-vascularization in corneal cells. Leptin production has been 
documented in a variety of non-adipose cells including placental trophoblasts, mammary 
epithelial cells, gastric fundic mucosa, and ovarian follicle cells [19-29]. In a study by Murad and 
colleagues, it was demonstrated that cells within an incisional dermal wound produced a burst of 
leptin shortly after surgery [30]. The study concluded that leptin might have a multifunctional 
role during wound healing and serves a critical functional role as an autocrine/paracrine regulator 
of normal wound healing.  
As discussed previously, leptin is produced locally in the wound bed. In our experiment 
leptin was only measured in the wound bed tissue lysates, not in circulating blood serum. BD and 
BMS+MCT significantly reduced leptin levels in ischemic wound tissue lysates in young 
animals compared to controls on day three post-wounding but this observation was no longer 
apparent after seven days of wound healing (Figure 5.3C). In aged animals, leptin levels were 
decreased in both ketone-supplemented groups on both day three and day seven post-wounding 
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(Figure 5.3C). This decrease in leptin levels in the ischemic wound bed may play a role to the 
enhanced wound healing via exogenous ketone supplementation. The circulating blood serum 
levels may give more insight to the data. If these measurements were in systemic blood serum, it 
may indicate that the rats were not eating the food-integrated ketone supplements, as leptin levels 
were elevated in the SD. Additionally, this would suggest that the elevations in blood ketone 
levels would be due to caloric restriction and not ingestion of the supplement. Further 
experiments monitoring food intake would be required to decipher this observation. Further 
experiments need to be conducted to determine the full impact of decreasing leptin levels with 
ketone supplementation.  
 As discussed in Chapter 1, macrophages in the wound bed can exhibit two distinct 
functional phenotypes: M1 (classically activated, pro-inflammatory) and M2 (alternatively 
activated, anti-inflammatory). During the early inflammatory phase, macrophages that are 
activated by lipopolysaccharide (LPS) or inflammatory cytokines like interferon gamma (IFN-γ) 
continue the job of neutrophils by phagocytizing bacteria and damaged tissue. Additionally, the 
M1 macrophages release pro-inflammatory cytokines such as TNF-α and IL-6 [31]. During the 
late inflammatory phase, initiated by the phagocytosis of apoptotic cells, M1 macrophages 
phenotypically convert to M2 macrophages [32]. M2 macrophages, activated by interleukin-4 
(IL-4) and interleukin-13 (IL-13), play a critical role in the resolution of inflammation. 
Additionally, they facilitate transition to the proliferative phase by promoting angiogenesis, 
tissue remodeling, and repair [31, 33-40]. In this study, we did not see an effect of exogenous 
ketone supplementation on IFN-γ, IL-4, or IL-13 as previously hypothesized (Figure 5.2). 
Additionally, exogenous ketone supplementation did not elicit a significant change in M1 to M2 
phenotype in day seven aged ischemic wounds (Figure 5.4). This observation supports the 
  150 
inflammatory array data and further supports that the aged ischemic wounds were still in a pro-
inflammatory environment seven days post-wounding. Heterogeneity seen in the wound healing 
in this model is consistent with patient heterogeneity seen in the clinical setting and accounts for 
the lack of statistical significance in the immunohistochemical analysis (Figure 5.1). In general, 
ketone supplemented wounds demonstrated more epithelial advancement, granulation tissue 
formation, and fewer labeled macrophages (Figure 5.1, Figure 5.4). Further studies need to be 
conducted to confirm these histological observations.  
 
5.2.2 Effects of ketone supplementation on ROS production  
As discussed in previous chapters ROS production is an important bactericidal 
component in acute wound healing. However, in a chronic wound environment, ROS production 
isn’t properly mitigated, leading to mitochondrial dysfunction, DNA damage, lipid peroxidation, 
and even cell death, which delays wound healing [41, 42]. Ketones have been shown to decrease 
ROS production through a variety of physiological effects [43-46]. Additionally, ketones have 
been shown to decrease oxidative stress by increasing the downstream antioxidant glutathione 
via the Nrf2-ARE pathway [47]. Nrf2 is the primary transcription factor that responds to 
oxidative stress. Under normal conditions, Nrf2 is targeted for proteasomal degradation by the 
E3 ubiquitin ligase, Keap1. Oxidants and electrophiles disrupt the Nrf2/Keap1 binding allowing 
Nrf2 to translocate to the nucleus, bind DNA at the antioxidant or electrophilic response element 
(ARE), and transcribe downstream antioxidants including SOD2, NAD (P) H: quinone 
oxidoreductase (NQO1) and enzymes for glutathione synthesis [48-50]. Additionally, Nrf2 has 
been shown to play a role in wound healing as disruption of Nrf2 has shown to impair the 
  151 
angiogenic capacity of endothelial cells [51]. It has been shown that Nrf2 and antioxidant 
capacity are decreased with age, leading to increased oxidative stress [52, 53]. Recently, Moor 
and colleagues demonstrated age-dependent deficiencies in the glutathione and SOD2 
antioxidant pathways. In an ischemic wound model, wounds from aged rats had lower SOD2 
protein expression and activity, decreased ratio of reduced/oxidized glutathione, and decreased 
glutathione peroxidase activity [54]. These age-exaggerated insufficiencies lead to excessive 
inflammation and impaired wound healing. New data indicate that nutrient intake, energy 
metabolism, and ROS are linked at the nuclear level via the Nrf2/ARE pathway [55]. The KD 
has been shown to increase glutathione synthesis via the Nrf2/ARE pathway [56-59]. 
Additionally, the age-dependent deficit in Nrf2 has been reversed with lipoic acid 
supplementation [60]. Lipoic acid is derived from the MCFA caprylic acid (a main component of 
MCT oil); thus we hypothesized that exogenous ketone supplementation would result in similar 
effects.  
In this study, we were unable to measure Nrf2 levels via Western blot due to inefficient 
antibodies; the downstream antioxidants SOD2 and NQO1, measured by Western blot analysis, 
were not significantly altered by exogenous ketone supplementation in either primary human 
dermal fibroblasts (HDFs) or ischemic wounds (Figure 5.6). Western blot sensitivity may not be 
able to detect the subtle changes in these antioxidants during the first few days of wound healing; 
thus, further experiments need to be conducted to determine antioxidant levels. However, DHE 
and Mitosox Red labeled ROS production in primary human dermal fibroblasts was significantly 
reduced with 5mM βHB supplementation (Figure 5.5). Metabolomic studies demonstrated that 
ketone supplementation increased antioxidants carnosine and anserine. Further studies are 
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needed to investigate other antioxidant pathways and determine how ketone supplementation is 
suppressing ROS production in a wound-healing environment.  
 
5.2.3. Effects of ketone supplementation on angiogenesis  
As a continuation of Chapter 4, we sought to delineate if the observed increase in blood 
flow occurred via enhanced angiogenesis or vasodilatation. Immunohistochemical analysis of 
CD31 blood vessel density demonstrated a trend of increased blood vessels in the ischemic 
wounds of aged rats supplemented with BD and BMS+MCT seven days post-wounding; 
however, this observation did not reach significance (Figure 5.7). As discussed, VEGF is a 
potent angiogenic factor. Periwound tissue lysates were analyzed for VEGF levels, revealing a 
trend of elevation of VEGF on day seven of wound compared to day three in both young and 
aged animals though this did not reach significance. Ketone supplementation did not affect levels 
of VEGF in this study, (Figure 5.2) but in the unpublished chronic feeding study, in which rats 
were ketone supplemented via food-integration for 15-weeks, low dose KE significantly 
increased serum (systemic) VEGF levels. As discussed in the metabolomics data in Chapter 3, 
exogenous ketone supplementation leads to an increase in the potent vasodilator adenosine. 
These observations suggest that the increased blood flow may be due to increased vasodilation 
and not angiogenesis. Further studies need to be conducted to determine the impact of 
vasodilation on ketone supplemented wound healing and to determine the exact mechanisms of 
the observed increase in blood flow.  
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5.2.4. Effects of ketone supplementation on metabolism 
 Proliferation and migration represent crucial processes by which epidermal and dermal 
layers restore anatomical integrity to the wound site. During the formation of granulation tissue 
in the dermis, platelets, monocytes, and other cellular blood constituents release various peptide 
growth factors, stimulating fibroblasts to migrate into the wound site where they proliferate to 
reconstitute the various connective tissue components [61]. We investigated if ketone 
supplementation enhanced proliferation and migration of primary human dermal fibroblasts; 
indeed, 5mM HB supplementation elicited a significant increase in migration and proliferation 
in both young and aged HDFs (Figure 5.8 and Figure 5.9). Further experiments need to be 
conducted using keratinocytes of the epidermal layer to examine if ketone supplementation also 
increases proliferation and migration in those cells. These further studies will help determine if 
ketone supplementation affects all layers of the wound healing process or the dermal layer 
independently. Additionally, the enhanced proliferation and migration may explain the enhanced 
granulation tissue detected in the histological analysis (Figure 5.1, Figure 5.4).  
Proliferating and migrating cells require more nutrients and energy production to perform 
their functions; thus, an increase in these physiological factors may be a reflection of a higher 
metabolic state. As discussed in Chapter 1, one of the fates of pyruvate is lactate production and 
is indicative of anaerobic respiration. The hypoxic wound environment shifts to higher anaerobic 
respiration and thus higher lactate production. Throughout the last decade, wound-healing 
studies have revealed that high lactate levels (10-15 mM) are characteristic in healing, stimulate 
collagen deposition, and enhance angiogenesis [62-66]. Subsequent studies demonstrated that 
lactate has several sources in wounds, remains elevated even in the presence of oxygen, and 
intense neutrophil respiratory bursts drive lactate and ROS accumulation through aerobic 
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glycolysis (Warburg effect) [64, 67-71]. These studies have concluded that lactate is produced in 
both aerobic and anaerobic environments during tissue repair and the presence of both lactate 
and oxygen is required for optimal wound healing. However, it is the quantity of lactate that is 
critically significant [72]. Systemic lactate concentration rarely exceeds 10 mM due to tight 
metabolic control; accumulation exceeding this level is associated with a poor wound-healing 
prognosis [73]. When lactate levels reach ~20 mM it becomes deleterious to the wound bed as 
high lactate levels reduce cell viability, diminish cell motility, and decrease polymerized 
cytoskeletal actin, which impedes angiogenesis, fibroplasia, and wound contraction [74]. Aging 
further complicates this environment as cells of older patients have shown decreased sensitivity 
to growth factor and cytokine stimulation, diminished antioxidant capacity, and reduced cell 
motility and proliferation, causing their tissues to be very susceptible to hypoxic and oxidant 
stress and worsening patient survival outcome [75-78]. In this study, we demonstrated the 5 mM 
βHB supplementation in young and aged HDFs significantly reduced lactate production (Figure 
5.10). Further research needs to be conducted to investigate lactate levels in the wound bed with 
exogenous ketone supplementation and explore lactate production in keratinocytes of the 
epidermal layer to determine the full impact of ketone supplementation on lactate production 
during wound healing.  
 
5.3. Closing Remarks 
In summary, we have just begun to elicit some of the mechanisms by which exogenous 
ketone supplementation impacts ischemic wound healing. As ketone supplementation represents 
a multifaceted tool, it is likely that multiple mechanisms are acting simultaneously to provide a 
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therapeutic effect and unlikely that a single, clearly delineated mechanism of action could be 
elucidated. However, understanding these mechanistic attributes will help to optimize exogenous 
ketone supplementation as a wound healing therapy.  
 
 
Figure 5.1 Heterogeneity of Aged Ischemic Wound Healing: Histological hematoxylin and 
eosin staining of aged ischemic wounds on day seven post-wounding demonstrated heterogeneity 
in healing within rats supplemented with SD, BD, and BMS+MCT.  
 
SD1	 SD2	
BD1	 BD2	
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Non-Wounded	
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Figure 5.2 Effects of ketone supplementation on pro-inflammatory and anti-inflammatory cytokines: Multiplex immunoassay 
on peri-wound tissue lysates isolated from SD, BD, and BMS+MCT fed rats on day three and day seven post-wounding. BMS+MCT 
supplementation in aged rats significantly decreased tumor necrosis factor- alpha (TNF-α) levels on day 7 of wound healing compared 
to controls (p<0.05) (A). No other pro-inflammatory (IL-1β, IL-6) or anti-inflammatory (IL-4, IL-10, IL-13) cytokines were 
significantly changed (A, B). Two-way ANOVA with Tukey’s post-hoc analysis, results were considered significant when p<0.05. 
Error Bars Represent mean (SD).  
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Figure 5.3 Effects of ketone supplementation on growth factors and the hormone leptin: 
Peri-wound tissue lysates isolated from SD, BD, and BMS+MCT fed rats on day three and day 
seven post-wounding. Eve Technologies analyzed samples with a 27-biomarker multiplex 
immunoassay. Neither ketone supplement affected vascular endothelial growth factor (VEGF) 
levels in young nor aged animals (A). BD ketone supplementation elicited a significant elevation 
in epidermal growth factor (EGF) at day 7 of wound healing in young rats compared to control 
(p<0.05)(B). Ketone supplementation with BMS+MCT and BD significantly reduced leptin 
levels in both young and aged rats (C). Two-way ANOVA with Tukey’s post-hoc analysis, 
results were considered significant when p<0.05. Error Bars Represent mean (SD). 
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Figure 5.4 Ketone supplementation does not affect M1 to M2 ratio of day 7 ischemic 
wounds in aged rats: Paraffin embedded wound tissues harvested from SD, BD, and 
BMS+MCT supplemented rats were stained with H&E for morphological analysis or labeled 
with IRF-5 (M1, pro-inflammatory macrophage, red) or CD206 (M2, anti-inflammatory 
macrophage, red) and CD68 (all macrophages, green) and DAPI (blue). Immunofluorescent 
scans demonstrated that there was not a significant transition from M1 to M2 macrophage 
phenotype with exogenous ketone supplementation, suggesting a pro-inflammatory environment 
at day seven of wound healing.  
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Figure 5.5 Ketone supplementation deceases ROS production: Primary human dermal 
fibroblasts from young and aged donors (24 and 88 years) were incubated in the presence or 
absence of 5mM βHB for 72 hours. The cells were stressed with 100uM tert-butyl-hydrogen 
peroxide for 3 hrs. ROS production was measured via dihydroethidium (DHE) and Mitosox Red 
fluorescence (A, B). DHE fluorescence: Aged HDFs produced 25% more ROS compared to their 
young counterparts (p<0.05). βHB treatment decreased ROS production in young HDFs by 40% 
and aged HDFs by 41% (p<0.05) (A). Mitosox Red fluorescence: Aged HDFs produced 27% 
more ROS than young HDFs (p<0.05). βHB treatment decreased ROS production in young 
HDFs by 29% and by 51% in aged HDFs compared to control (p<0.05) (B). One-way ANOVA 
with Tukey’s post-hoc analysis, results were considered significant when p<0.05. Error Bars 
Represent mean (SD). 
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Figure 5.6 Ketone supplementation does not affect antioxidants SOD2 and NQO1 in vitro and ex vivo: Primary human dermal 
fibroblasts from young and aged donors (24 and 88 years) were incubated in the presence or absence of 5mM βHB for 72 hours. The 
cells were stressed with 100uM tert-butyl-hydrogen peroxide for 3 hrs. Western blot protein expression analysis of antioxidants SOD2 
and NQO1 demonstrated no change fibroblast expression of these antioxidants with ketone supplementation (A). Periwound tissue 
lysates were isolated on day three and day seven post wounding. Western blot protein analysis showed no change in SOD2 or NQO1 
expression with BD or BMS+MCT supplementation (B). Two-way ANOVA with Tukey’s post-hoc analysis, results were considered 
significant when p<0.05. Error Bars Represent mean (SD). 
  
 
 
161 
 
Figure 5.7 Ketone supplementation does not significantly increase blood vessel density in 
day 7 aged ischemic wounds: Quantification of histological staining with CD31 demonstrated 
that exogenous ketone supplementation did not significantly increase blood vessel density at this 
time point. One-way ANOVA, Tukey’s post-hoc analysis, results were considered significant 
when p<0.05. Error Bars Represent mean (SD). 
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Figure 5.8 Ketone supplementation increases migration in young and aged HDFs: Young 
and aged HDFs were grown to confluence in 0.2% FBS 5mM glucose DMEM media, cells were 
treated with or without the presence of 5mM βHB for 72 Hrs, cells were scratched with 200uL 
yellow pipette tip. After 18 hours, migrated cells were counted using Dapi staining. Migration 
was increased in both young and aged HDFs compared to the controls (p=0.0260 and p=0.0004) 
(A, B). One-way ANOVA, Tukey’s post-hoc analysis, results were considered significant when 
p<0.05. Error Bars Represent mean (SD).  
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Figure 5.9 Ketone supplementation increases proliferation in young and aged HDFs: Young 
and aged HDFs were seeded with 75,000 cells in 10% FBS, 5mM Glucose DMEM media with or 
without the presence of 5mM βHB. Total cell number was counted at 24, 48, 72, 96, and 120 
hours post seeding. Young and aged HDFs treated with 5mM βHB had significantly more cells 
at 72 and 96 hours (p<0.05). Two-way ANOVA with Tukey’s post-hoc analysis, results were 
considered significant when p<0.05. Error Bars Represent mean (SD).  
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Figure 5.10 Ketone supplementation decreases lactate production in young and aged HDFs: 
Young and aged primary human dermal fibroblasts were seeded with 250,000 cells in 10% FBS, 
5mM glucose DMEM media with or without the presence of 5mM βHB. Extracellular lactate 
was measured in cellular media at 24, 48 and 72 hours using Nova Biomedical Lactate Plus 
blood lactate measuring meter. Young and aged HDFs treated with 5mM βHB produced 
significantly less extracellular lactate at 72 hours p<0.05). Two-way ANOVA with Tukey’s post 
hoc analysis, results were considered significant when p<0.05. Error Bars Represent mean (SD). 
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CHAPTER 6: IMPLICATIONS FOR WOUND HEALING 
 
6.1. Chapter Synopsis 
In this chapter, we describe the major findings of this work based on the detailed 
discussion of the data in previous chapters. This chapter will discuss the major implications for 
wound healing as well as future directions for the project.  
 
6.2. Implications for Wound Healing 
The major goals of this dissertation work were to establish a method of sustaining 
nutritional ketosis via exogenous ketone administration, determine the healing capabilities of 
exogenous ketone supplementation in an aged rat population, and to acquire data of potential 
mechanisms of action. As mentioned earlier, there is a dire need for a therapy that can accelerate 
wound healing and efficiently restore normal tissue functionality.  Chronic wounds, as discussed 
in Chapter 1, impact several million people annually and is a billion dollar growing market. The 
therapy presented within this dissertation exhibits great potential to accelerate cutaneous wound 
healing closure and to be used as a multifaceted tool to stimulate wound repair and regeneration 
in poor healing tissues especially chronic wounds in the aged population.  
The KD has proven effective for the metabolic management of seizures and potentially 
numerous other disorders, but is limited clinically [1-26]. Exogenous ketone supplements are 
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primarily being developed as an alternative or adjuvant method of inducing therapeutic ketosis to 
free patients from the restrictiveness of the KD. In Chapter 3, we were able to clearly 
demonstrate that nutritional ketosis can be established with exogenous ketone supplementation 
without negatively affecting blood triglyceride and lipoprotein profiles. Importantly, exogenous 
ketone supplementation provides a tool for achieving ketosis in patients that are unable, 
unwilling, or uninterested in consuming a low carbohydrate or ketogenic diet. It may also help 
circumvent some of the difficulties associated with KD therapy initiation and maintenance, as it 
allows for rapid induction of ketosis in a dose-dependent fashion, eases the transition to 
nutritional ketosis, enhances the speed of keto-adaptation, and easily sustains ketosis with 
prolonged consumption. Simultaneously, it could provide patients with the opportunity to reap 
the benefits of ketosis without the practical and social difficulties of a highly restrictive diet. 
Additionally, we demonstrated the ability of several ketone supplements to elevate blood ketone 
levels, providing multiple options to induce therapeutic ketosis based on patient need. Many 
patients that previously were unable to benefit from the KD may now have an alternative method 
of achieving therapeutic ketosis. Ketone supplementation may also represent a means to further 
augment ketonemia in those that respond to the ketogenic diet, especially in those individuals 
where maintaining low glucose and insulin through carbohydrate restriction is important. 
In Chapter 3, we demonstrated the exogenous ketone supplementation produced a 
hypoglycemic effect, which in Chapter 4, was no longer apparent in the aged rats. Further 
experiments need to be performed to determine what role age has explicitly on the observed 
hypoglycemic effect. Additionally, further experiments need to be conducted to determine the 
role that insulin sensitivity has in the age-dependent diminished hypoglycemic effect. As Chapter 
3’s hypoglycemic effect was the result of an intragastric bolus and Chapter 4 transitioned to 
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food-integrated administration, future studies need to be conducted to determine the effects of 
administration on the observed hypoglycemic effect.	
 It should be noted that in these studies, rats were administered high doses due to their 
higher basal metabolic rate (5.6x faster than humans). Future studies are needed to optimize 
doses for humans. Preliminary data from the D’Agostino laboratory demonstrates that a 100 kg 
male can obtain elevated ketone levels at a 0.4 g/kg dose compared to the 5 g/kg and 10 g/kg 
doses that were administered to the rats. Follow up studies are currently being conducted to 
determine the safety and toxicity profile of the ketone supplements KE and BMS as BD is 
already FDA approved and MCT is a naturally occurring food source. Clarke and colleagues 
have already demonstrated the safety of a similar ketone ester administration in humans; thus, we 
don’t anticipate difficulty with the feasibility of using ketone supplements in humans [27]. 
However, one obstacle to overcome in the synthetic ketone supplements tested in this project is 
their palatability. Both BD and KE are not pleasing to taste and will need to be optimized for 
flavor without sacrificing their functionality. Additionally, future studies are needed to determine 
the best route of administration for ketone supplements in patients, it may be more suitable to 
have the supplements available in a variety of applications including parenteral nutrition, 
integrated into food that the patients could ingest, meal replacement drinks, and oral pills.  
As described in Chapter 2, exogenous ketone supplementation has the potential to 
simultaneously target several underlying etiologies associated with age-impaired wound healing, 
including unrelieved inflammation, unquenched ROS production, insufficient blood flow, and 
dysfunctional metabolism. This is very different from most current wound therapies being 
studied, which target a specific molecular or cellular mechanism. Because of the complexity of 
wound healing, and the fact that there are often multiple mitigating factors that prevent normal 
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wound closure, most wound therapies are minimally effective. We hypothesize that using 
exogenous ketone supplementation, as a component of standard care would target the 
multifaceted etiologies underling most chronic wounds in the aged population. In Chapter 4, we 
demonstrated that both BD and BMS+MCT ketone supplement therapies were effective in 
enhancing wound healing in aged animals and the BMS+MCT also enhanced wound healing in 
young animals. Further studies are needed to confirm the optimal dosing protocol to maximize 
wound-healing efficacy. 
Additionally, we elucidated some potential mechanisms of actions by which this novel 
proposed therapy was able to significantly enhance wound healing. We demonstrated that 
exogenous ketone supplementation altered the serum and hippocampal metabolome including 
increasing Kreb’s cycle intermediates, antioxidants carnosine and anserine, and the potent 
vasodilator adenosine. Further metabolomic studies need to be conducted to determine the 
effects of age on ketone supplementation changes to the metabolome. Furthermore, young and 
aged metabolomic studies of the wound healing environment with and without ketone 
supplementation would offer great insights to the wound healing process. Mechanistically, we 
demonstrated that ketone supplementation increases fibroblast proliferation and migration, 
reduces ROS production, reduces lactate production, and increases blood flow. However, we did 
not demonstrate a signifcant effect of ketone supplementation on antioxidants SOD2 or NQO1, 
further studies need to be conducted to determine if the administration of ketone supplements 
elicit the same physiological changes in other antioxidants. Further investigation into exploring 
potential mechanisms of action are needed to fully understand the impact exogenous ketone 
supplementation has on wound healing, specifically in an aged population. However, the 
complexity of wound healing and the multifaceted targets of ketone bodies may constrain 
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elucidating a single, clearly delineated mechanism of action.   
Moreover, futures studies will explore a topical application of ketone bodies. Even 
though there was a significant increase in blood flow, this may not efficient for some patients; 
thus, a direct application of the ketones or a combination of both therapies may be more 
beneficial. Base on the results included in this dissertation we propose that exogenous ketone 
supplementation could offer a novel therapeutic option for chronic wounds, especially in the 
aging population. 
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APPENDIX A: MATERIALS AND METHODS 
 
A.1 Ethics Statement 
 All animal studies were approved by and performed within strict adherence to the 
University of South Florida and James A. Haley Veterans Hospital’s Institutional Animal Care 
and Use Committee (IACUC) protocols R00006 and V4251.  
 
A.2 Materials and Methods for Experiments included in Chapter 3: Establishing 
Therapeutic Ketosis (Metabolic Therapy with Exogenous Ketone Supplementation) 
 
A.2.1 Synthesis and Formulation of Ketone Supplements 
 KE was synthesized as previously described [1]. BMS is a novel agent 
(sodium/potassium- βHB mineral salt) supplied as a 50% solution containing approximately 
375mg/g of pure βHB and 125 mg/g of sodium/potassium.  Both KE and BMS were developed 
and synthesized in collaboration with Savind Inc. Pharmaceutical grade MCT oil (~65% caprylic 
triglyceride; 45% capric triglyceride) was purchased from Now Foods (Bloomingdale, IL). BMS 
was formulated in a 1:1 ratio with MCT at the University of South Florida (USF), yielding a final 
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mixture of 25% water, 25% pure βHB mineral salt and 50% MCT. BD was purchased from 
Sigma-Aldrich (Prod # B84785, Milwaukee, WI).  
 
A.2.2. Daily Gavage to Induce Dietary Ketosis 
 Animal procedures were performed in accordance with the University of South Florida 
Institutional Animal Care and Use Committee (IACUC) guidelines (Protocol #0006R). Juvenile 
male Sprague-Dawley rats (275-325 g, Harlan Laboratories) were randomly assigned to one of 
six study groups: control (water, n=11), BD (n=11), KE (n=11), MCT (n=10), BMS (n=11), or 
BMS+MCT (n=12). Caloric density of standard rodent chow and dose of ketone supplements are 
listed in Table 1. On days 1-14, rats received a 5 g/kg body weight dose of their respective 
treatments via intragastric gavage.  Dosage was increased to 10 g/kg body weight for the second 
half of the study (days 15-28) for all groups except BD and KE to prevent excessive 
hyperketonemia (ketoacidosis). Each daily dose of BMS would equal ~1000-1500 mg of βHB, 
depending on the weight of the animal. Intragastric gavage was performed at the same time 
daily, and animals had ad libitum access to standard rodent chow 2018 (Harlan Teklad) for the 
duration of the study. The macronutrient ratio the standard rodent chow was 62.2%, 23.8% and 
14% of carbohydrates, protein and fat respectively. 
 
 
 
	 181	
Table A.1. Caloric density of standard rodent chow and dose of ketone supplements  
 
A.2.3. Measurement and analysis of blood glucose, ketones, and lipids 
 Every 7 days, animals were briefly fasted (4 hrs, water available) prior to intragastric 
gavage to standardize levels of blood metabolites prior to glucose and βHB measurements at 
baseline. Baseline (time 0) was immediately prior to gavage.  Whole blood samples (10 µL) were 
taken from the saphenous vein for analysis of glucose and βHB levels with the commercially 
available glucose and ketone monitoring system Precision Xtra™ (Abbott Laboratories, Abbott 
Park, IL). Blood glucose and βHB were measured at 0, 0.5, 1, 4, 8, and 12 hrs after test 
substance administration, or until βHB returned to baseline levels. Food was returned to animals 
after blood analysis at time 0 and gavage. At baseline and week 4, whole blood samples (10 µL) 
were taken from the saphenous vein immediately prior to gavage (time 0) for analysis of total 
cholesterol, high-density lipoprotein (HDL), and triglycerides with the commercially available 
CardioChek™ blood lipid analyzer (Polymer Technology Systems, Inc., Indianapolis, IN). Low-
density lipoprotein (LDL) cholesterol was calculated from the three measured lipid levels using 
the Friedewald equation: (LDL Cholesterol = Total Cholesterol - HDL - (Triglycerides / 5))[2, 
Macronutrient 
Information 
Standard 
Diet Water BMS+MCT BMS MCT KE BD 
% Cal from Fat 18.0 0.0 N/A 50.0 100.0 N/A N/A 
% Cal from Protein 24.0 0.0 N/A N/A 0.0 N/A N/A 
% Cal from 
Carbohydrates 58.0 0.0 N/A N/A 0.0 N/A N/A 
Total Caloric Density 
(Kcal/g) 3.1 0.0 5.1 1.9 8.3 5.6 6.0 
Dose 0-14 Days (g/kg) ad libitum N/A 5.0 5.0 5.0 5.0 5.0 
Dose 15-28 Days (g/kg) ad libitum N/A 10.0 10.0 10.0 5.0 5.0 
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3]. Animals were weighed once per week to track changes in body weight associated with 
hyperketonemia.  
 
A.2.4. Organ Weight and Collection 
 On day 29, rats were sacrificed 4-8 hrs after intragastric gavage which correlated to the 
time range where the most significantly elevated blood βHB levels were observed. Brain, lungs, 
liver, kidneys, spleen and heart were harvested, weighed (AWS-1000 1kg portable digital scale 
(AWS, Charleston, SC)), and flash-frozen in liquid nitrogen or preserved in 4% 
paraformaldehyde for future analysis.  
 
A.2.5. Statistics 
 All data are presented as the mean ± standard deviation (SD). Data analysis was 
performed using GraphPad PRISM™ version 6.0a and IBM SPSS Statistics 22.0. Results were 
considered significant when p<0.05.  Triglyceride and lipoprotein profile data were analyzed 
using One-Way ANOVA.  Blood ketone and blood glucose were compared to control at the 
applicable time points using a Two-Way ANOVA.  Correlation between blood βHB and glucose 
levels in ketone supplemented rats was compared to controls using ANCOVA analysis. Organ 
and body weights were analyzed using One-Way ANOVA. Basal blood ketone and blood 
glucose levels were analyzed using Two-Way ANOVA. All mean comparisons were carried out 
using Tukey’s multiple comparisons post-hoc test.  
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A.2.6. Metabolomics Profiling of KE and BMS+MCT Treated Rats 
 On day 29, approximately 500 uL of whole blood was collected from the saphenous vein 
of control, KE, and BMS+MCT-treated animals 4 hours post-intragastric gavage. Serum was 
separated by centrifugation using Microtainer© Tubes with Serum Separator (Becton 
Dickinson). Serum was transferred to screw-to cryovials and flash frozen in liquid nitrogen. 
Frozen serum samples were shipped to Metabolon, Inc. for global metabolomics profiling using 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) and gas chromatography-mass 
spectrometry (GC-MS). The concentration of 388 named biochemicals of known identity was 
analyzed in the serum samples. Welch’s two-sample t-test was used to determine which 
metabolites differed significantly in concentration between ketone supplemented animals and 
controls. Results were considered significant when p<0.05.  
 
A.3. Materials and Methods for Experiments included in Chapter 4: Enhancing Wound 
Healing With Metabolic Therapy 
 
A.3.1. Synthesis and Formulation of Ketone Precursors 
 BMS is a novel agent (sodium/potassium- βHB mineral salt) supplied as a 50% solution 
containing approximately 375mg/g of pure βHB and 125 mg/g of sodium/potassium.  Both KE 
and BMS were developed and synthesized in collaboration with Savind Inc. Pharmaceutical 
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grade MCT oil (~65% caprylic triglyceride) was purchased from Now Foods (Bloomingdale, 
IL). BMS was mixed in a 1:1 ratio with MCT at the University of South Florida (USF), yielding 
25% water, 25% pure βHB mineral salt and 50% MCT. BD was purchased from Sigma-Aldrich 
(Prod # B84785, Milwaukee, WI).  
 
A.3.2 Animal Gavage to Induce Dietary Ketosis 
 Animal procedures were performed in accordance with the University of South Florida 
Institutional Animal Care and Use Committee (IACUC) guidelines (Protocol #V4251) and 
abided by all requirements of the Animal Welfare Act and the Guide for Care and Use of 
Laboratory Animals. Healthy 8 month (young) and 20 month (aged) male Fisher 344 rats (Harlan 
Laboratories and NIA) were randomly assigned to one of three groups: Control (water, n≥6), BD 
(n≥6), or BMS+MCT (n≥6). Rats received one 6.5 g/kg dose of their respective treatments via 
intragastric gavage. Animals had ad libitum access to standard rodent chow 2018 (Harlan 
Teklad) for duration of the study. Whole blood samples (10 µL) were taken from the saphenous 
vein for analysis of glucose and βHB levels with the commercially available glucose and ketone 
monitoring system Precision Xtra™ (Abbott Laboratories, Abbott Park, IL).  The Precision 
Xtra™ ketone monitoring system only measures βHB blood levels; therefore, total blood ketone 
levels would be higher than measured. Blood glucose and βHB were measured at 0, 0.5, 1, 4, 8, 
12, and 24 hrs after test substance administration. 
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A.3.3. Surgical Procedure 
 Healthy 8 month (young) and 20 month (aged) Fisher 344 rats (National Institutes of 
Aging, Bethesda, MD) were utilized to create and ischemic wound model adapted from our 
previous work [4-6]. In all Fisher 344 rats, a dorsal bi-pedicle 10.5x3 cm flap was surgically 
created on day 0 (time of wounding), in which a silicone sheet was placed under the panniculus 
carnosus fascia and above the paraspinous muscles, limiting revascularization and causing the 
flap to become ischemic. Two 6mm punch biopsies created full thickness wounds extending just 
above the fascia within the flap (ischemic wounds) and two 6mm punches were created laterally 
to ischemic flap giving the control (non-ischemic) wounds in the same animal. 
 
A.3.4. Diet Administration 
 The day before flap creation, animals are fasted overnight (~18hrs) to enable initiation of 
the diet immediately upon waking from surgery. On the day of ischemic flap creation (day 0), 
young and aged rats were randomly assigned to one of three study groups: Control standard diet 
(SD), BD or BMS+MCT.  Control rats were fed a combination of standard rodent chow (2018 
Teklad Global 18% Protein Rodent Diet, Harlan Laboratories), water, and peanut butter mixed 
into a pudding and fed ad libitum. Rats in BD group received a pudding diet of standard rodent 
chow, peanut butter, water, 1% saccharine, and 20% 1,3-Butanediol by weight ad libitum. Rats 
in the BMS+MCT group received a pudding diet of standard rodent chow, peanut butter, water, 
1% saccharine, and 10% MCT oil by weight and 10% βHB mineral salt solution (10% βHB) by 
weight ad libitum. Diets were continuously replaced to maintain freshness and to allow rat to 
feed ad libitum. 
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A.3.5. βHB, Glucose, and Weight Measurements 
Every 7 days, whole blood samples (10 µL) were taken from the saphenous vein for 
analysis of glucose and βHB levels with the commercially available glucose and ketone 
monitoring system Precision Xtra™ (Abbott Laboratories, Abbott Park, IL) to confirm that the 
dietary ingestion of BD and BMS+MCT induced continuous ketosis in the blood.  Rats were 
weighed 2x weekly with scales (Mittler Toledo SB16001) available in the Morsani College of 
Medicine vivarium. Blood and weight measurements were taken at the same time of day each 
week to limit variation based on normal metabolism fluctuations.  
 
A.3.6. Analysis of Blood Flow and Wound Size 
Every 7 days, while under anesthesia, Laser Doppler scanning was used to measure blood 
flow over the course of the study. On days 3, 7, 10, 14, 21, 25, and 28 animals were anesthetized, 
both ischemic and non-ischemic wounds were digitally photographed, and wound sizes were 
determined (Bamboo Create v5, Wacom Co, Ltd, and Image J 64 Version 10.2).  
 
A.3.7. Extraction of Tissue  
On day 28 of the study, the rats were euthanized by carbon dioxide (CO2) asphyxiation 
where periwound tissue (tissue surrounding the wound) including the wound, spleen and liver 
were surgically harvested. Portions of the spleen, liver and wounds were flash frozen by liquid 
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nitrogen, formalin-fixed, or preserved in optimal cutting temperature (OCT) freezing media for 
future analysis. 
 
A.3.8. Statistics 
All data are presented as the mean ± standard deviation (SD). Data analysis was performed using 
GraphPad PRISM™ version 6.0a. Results were considered significant when p<0.05. Blood 
ketone and blood glucose were compared to controls at the applicable time points using a Two-
Way ANOVA.  Correlation between blood βHB and glucose levels was determined by linear 
regression analysis. Blood flow and wound healing progression were analyzed compared to 
controls at the applicable time points using Two-Way ANOVA. Organ and body weights were 
analyzed using One-Way ANOVA. All mean comparisons were carried out using Tukey’s 
multiple comparisons post-hoc test. 
 
A.4. Materials and Methods for Experiments included in Chapter 5: Potential Mechanisms 
for Exogenous Ketone Supplementation to Enhance Wound Healing 
 
A.4.1. Cytokine Array 
 After 3 days and 7 days post-wounding, young and aged Fischer rats were humanely 
euthanized and per-wound tissue was harvested and preserved in liquid nitrogen. 500 mg of 
periwound tissue was measured and razor blade minced on a petri dish in 400 µL of RIPA Lysis 
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Buffer (Sigma Chemical Co, St. Louis, MO) with 10 µL / mL of Halt protease and phosphatase 
inhibitor cocktail (Pierce, Rockford, IL). Minced tissue with liquid was placed into lysing 
matrix-A tubes (MP Biomedical, Santa Ana, CA). An additional 400 µL of RIPA Lysis Buffer 
was used to wash petri dish and added to the tube. Tissues were homogenized for 20 seconds 
using FastPrep®-24 Instrument (MP Biomedical, Santa Ana, CA). Tubes were centrifuged at 
16,000xg for 10 minutes, supernatants were transferred to a clean 1.5 mL conical tube, and 
lysates were sonicated at low power setting and centrifuged at 16,000xg for 10 minutes. The 
supernatant of the lysates was frozen at -80° for future use. Protein concentration of the lysate 
supernatant was determined using Pierce BCA protein Assay Kit (Rockford, IL) reading 
absorbance at 540 nanometers. 50µg of samples were sent to Eve Technologies Inc. (Calgary, 
Alberta, Canada), where they were analyzed on Bio-Plex 200 Systems (Bio-Rad Laboratories, 
Inc., Hercules, CA) via Rat Cytokine Array/ Chemokine Array 27-Plex/ Discovery Assay, a 
multiplex assay that measures twenty-seven inflammatory biomarkers in a single microwell 
(Millipore MILLIPLEX®, Billerica, MA).  
 
A.4.2. Macrophage Profile Analysis with Immunofluorescence of CD68, IRF-5, CD206 
After 3 days and 7 seven days post-wounding, young and aged Fischer 344 rats were 
humanely euthanized and peri-wound tissue, livers, and spleen were harvested and preserved in 
10% neutral, paraformaldehyde or phosphate buffered formalin. The peri-wound tissue was 
paraffin-embedded, cut into 5-micron sections, and mounted onto microscope slides at the USF 
Morsani College of Medicine Histology Core. One set of slides was stained with hematoxylin 
and eosin and mounted with cover slips for morphological analysis. Another set of slides was co-
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probed with either interferon regularity factor-5 (IRF-5) to label M1 pro-inflammatory 
macrophages or CD206 to label M2 anti-inflammatory macrophages and CD68 to label all 
macrophages. These slides were rehydrated through a series of xylene and ethanol washes, and 
antigen was retrieved via standard heat-mediated citrate buffer method. Slides were incubated in 
0.3% H2O2 in dH2O to inhibit endogenous peroxide activity. Immunofluorescent analysis of the 
slides was performed using the VECTASTAIN Elite ABC Kit (Vector Laboratories Inc., 
Burlingame, CA). Slides were blocked for 60 minutes in normal anti-rabbit blocking serum, and 
then incubated in anti-IRF-5 antibody (1:100, ab175317, Abcam) or anit-CD206 antibody 
(1:100, ab64693, Abcam) over night at 4 degrees in a humidified container. Slides were then 
incubated in ALEXA Fluor 568 donkey anti-rabbit secondary antibody (Life Technologies, 
Eugene, OR) in normal blocking serum for 30 mints at room temperature in the dark, followed 
by VECTASTAIN ABC reagent containing avidin and biotinylated horseradish peroxidase 
solution for 30 minutes at room temperature in the dark. Slides were blocked for 60 minutes in 
normal anti-mouse blocking serum in the dark, and then incubated in anti-CD68 antibody (1:25, 
ab955, Abcam) over night at 4 degrees in a dark humidified container. Slides were then 
incubated in ALEXA Fluor 488 donkey anti-mouse secondary antibody (Life Technologies, 
Eugene, OR) in normal anti-mouse blocking serum for 30 mints at room temperature in the dark, 
followed by VECTASTAIN ABC reagent containing avidin and biotinylated horseradish 
peroxidase solution for 30 minutes at room temperature. Slides were wet mounted with 
VECTASHIELD mounting media with DAPI (Vector Laboratories Inc., Burlingame, CA) and 
sealed with clear nail polish.   
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A.4.3. Cellular ROS production 
DHE 
Cells were grown on 6-well poly-d lysine coated plates in DMEM +Glutamax 4.5g/L 
glucose media with 10% FBS and 1% penicillin and streptomycin until 50-60% confluent, 
appropriate wells were grown with or without the addition of 5 mM βHB to the media for 72 
hours. After 72 hours, they were then serum starved for 18 hrs with DMEM phenol red free 4.5 
g/L glucose + L-Glutamine media with 0.2% FBS and 1% penicillin and streptomycin. At the 
end of the 18 hours, cells were subjected to either 100uM tBOOH (Sigma Chemical Co, St. 
Louis, MO) in serum starve media for three hours or media only. At the end of three hours, the 
media was taken off and the cells were treated with 5 µM Dihydroethidium (DHE) in DMSO 
(Life Technologies, Eugene, OR) dissolved in serum starve media for 30min. The cells were put 
into Hank’s BSS and fluorescence was read on the plate reader at [528, 617] excitation and 
emission. 3 wells in each grouping did not receive the DHE and the average RFUs of these wells 
were used as a blank to normalize the readings. The control values have an N=3 (total N=9) and 
the 100 µM has an N=6 (total N=18). Graph and statistics were created using GraphPad 
PRISM™ for Mac OSX version 6.0a, statistical significance was determined using a one-way 
ANOVA with Tukey’s post-hoc analysis.  
 
Mitosox Red 
Cells were grown on 6-well poly-d lysine coated plates in DMEM +Glutamax 4.5g/L 
glucose media with 10% FBS and 1% penicillin and streptomycin until 50-60% confluent, 
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appropriate wells were grown with or without the addition of 5 mM βHB to the media for 72 
hours. After 72 hours, they were then serum starved for 18 hrs with DMEM phenol red free 4.5 
g/L glucose + L-Glutamine media with 0.2% FBS and 1% penicillin and streptomycin. Cells 
were subjected to 100uM tBOOH (Sigma Chemical Co, St. Louis, MO) in serum starve media 
for three hours or media only. At the end of three hours, the media was taken off and the cells 
were treated with 1 µM Mitosox Red (Life Technologies, Eugene, OR) in Hank’s Balanced Salt 
Solution (with magnesium and calcium) for 10 min. The cells were put into fresh Hank’s BSS 
and fluorescence was read on the plate reader at [510, 580] excitation and emission. 3 wells in 
each grouping did not receive the Mitosox Red and the average RFUs of these wells were used 
as a blank to normalize the readings. The control values have an N=3 (total N=12) and the 100 
uM has an N=6 (total N=24). Graph and statistics were created using GraphPad PRISM™ for 
Mac OSX version 6.0a, statistical significance was determined using a one-way ANOVA with 
Tukey’s post-hoc analysis. 
 
 A.4.4. Western Blot Analysis for in vitro and ex vivo SOD2 and NQO1 
In Vitro 
Cells were grown on 100 mm poly-d lysine coated petri dishes in DMEM +Glutamax 4.5 
g/L glucose media with 10% FBS and 1% penicillin and streptomycin until cells were around 50-
60% confluent. Cells were changed to DMEM phenol red free 5mM glucose + L-Glutamine 
media with 10% FBS and 1% penicillin and streptomycin and appropriate cells were treated with 
5mM βHB for 72 hours. Media was replaced every 24 hours. After 72 hours, appropriate cells 
were subjected to 100uM tBOOH (Sigma Chemical Co, St. Louis, MO) or media only. At the 
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end of three hours, the media was taken off, cells were washed with 1mL 1x cold PBS, then 
incubated with 300 uL per well of Triton X-100 Lysis Buffer [containing 50mM Tris-HCl pH 
7.4,150 mM NaCl, 5mM EDTA and 1% Triton-X 100], with 10 uL/ mL of Halt protease and 
phosphatase inhibitor cocktail (Pierce, Rockford, IL) for 30 minutes at 4° Celsius. The cells were 
scrape-harvested, and three wells were pooled for each sample. The lysates were sonicated at low 
power setting and centrifuged at 16,000xg for 10 minutes. The supernatant of the lysates was 
frozen at -80° for future use. Protein concentration of the lysate supernatant was determined 
using Pierce BCA protein Assay Kit (Rockford, IL) reading absorbance at 540 nanometers. 20 
µg of samples were separated on a 4-20% SDS gel and transferred to nitrocellulose membrane. 
Membrane was blocked with 5% Milk in TBS-T (50 mM Tris HCl, 150 mM NaCl and 0.1% 
Tween 20, pH 7.5) and then probed with anti-SOD2 antibody (1:2500, ab13533, Abcam), anti-
NQO1 antibody (1:500, ab34173, Abcam) followed by anti Pan-Actin antibody (1:3000, Cell 
Signaling, Boston, MA) as a loading control and Anti-Rabbit IgG, HRP-linked (1:3000, Cell 
Signaling, Boston, MA) as secondary antibody.  Membrane was developed using Pierce ECL 
Western Blotting Substrate (Rockford, IL). Quantitative densitometry was determined using 
Image J software version 1.45s and graph and statistics were determined using GraphPad 
PRISM™ for Mac OSX version 6.0a. Data in graph is represented as an N=3 for each group.   
 
Ex vivo 
After 3 days and 7 days post-wounding, young and aged Fischer rats were humanely 
euthanized and per-wound tissue was harvested and preserved in liquid nitrogen. 500 mg of 
periwound tissue was measured and razor blade minced on a petri dish in 400 µL of RIPA Lysis 
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Buffer (Sigma Chemical Co, St. Louis, MO) with 10 µL / mL of Halt protease and phosphatase 
inhibitor cocktail (Pierce, Rockford, IL). Minced tissue with liquid was placed into lysing 
matrix-A tubes (MP Biomedical, Santa Ana, CA). An additional 400 µL of RIPA Lysis Buffer 
was used to wash petri dish and added to the tube. Tissues were homogenized for 20 seconds 
using FastPrep®-24 Instrument (MP Biomedical, Santa Ana, CA). Tubes were centrifuged at 
16,000xg for 10 minutes, supernatants were transferred to a clean 1.5 mL conical tube, and 
lysates were sonicated at low power setting and centrifuged at 16,000xg for 10 minutes. The 
supernatant of the lysates was frozen at -80° for future use. Protein concentration of the lysate 
supernatant was determined using Pierce BCA protein Assay Kit (Rockford, IL) reading 
absorbance at 540 nanometers. 20 µg of samples were separated on a 4-20% SDS gel and 
transferred to nitrocellulose membrane. Membrane was blocked with 5% Milk in TBS-T (50 mM 
Tris HCl, 150 mM NaCl and 0.1% Tween 20, pH 7.5) and then probed with anti-SOD2 antibody 
(1:2500, ab13533, Abcam), anti-NQO1 antibody (1:500, ab34173, Abcam) followed by anti Pan-
Actin antibody (1:3000, Cell Signaling, Boston, MA) as a loading control and Anti-Rabbit IgG, 
HRP-linked (1:3000, Cell Signaling, Boston, MA) as secondary antibody.  Membrane was 
developed using Pierce ECL Western Blotting Substrate (Rockford, IL). Quantitative 
densitometry was determined using Image J software version 1.45s and graph and statistics were 
determined using GraphPad PRISM™ for Mac OSX version 6.0a. Data in graph is represented 
as an N=6 for each group.   
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A.4.5 Immunohistochemistry Analysis of Periwound Tissue Vascularization 
After 3 days and 7 seven days post-wounding, young and aged Fischer 344 rats were 
humanely euthanized and peri-wound tissue, livers, and spleen were harvested and preserved in 
10% neutral, phosphate buffered formalin. The peri-wound tissue was paraffin-embedded, cut 
into 5-micron sections, and mounted onto microscope slides at the USF Morsani College of 
Medicine Histology Core. One set of slides was stained with hematoxylin and eosin and mounted 
with cover slips for morphological analysis. Another set of slides was probed for the endothelial 
cell marker CD31 to visualize blood vessels. These slides were rehydrated through a series of 
xylene and ethanol washes, and antigen was retrieved via standard heat-mediated citrate buffer 
method. Slides were incubated in 0.3% H2O2 in dH2O to inhibit endogenous peroxide activity. 
Immunohistochemical analysis of the slides was performed using the VECTASTAIN Elite ABC 
Kit (Vector Laboratories Inc., Burlingame, CA). Slides were blocked for 60 minutes in normal 
blocking serum, and then incubated in anti-CD31 antibody (1:25, ab28364, Abcam) over night at 
4 degrees Celsius in a humidified container. Slides were then incubated in biotinylated anti-
rabbit secondary antibody in normal blocking serum for 30 mints at room temperature, followed 
by VECTASTAIN ABC reagent containing avidin and biotinylated horseradish peroxidase 
solution for 30 minutes at room temperature. Slides were developed using the VECTOR 
NovaRED Peroxidase (HRP) Substrate Kit (Vector Laboratories Inc., Burlingame, CA). Slides 
were counterstained with hematoxylin, washed, mounted with coverslips, sealed with clear nail 
polish, and visualized and scanned with light microscope via Moffitt Core Facilities. The entire 
periwound tissue was analyzed for blood vessels. The number of CD31+ blood vessels in the 
peri wound tissue were counted between control and treated groups as a measure of wound 
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vascularization. Statistical analysis was performed via one-way ANOVA with Tukey’s post-hoc 
analysis. Results were considered significant when p<0.05.   
 
A.4.6 Migration Analysis of young and aged HDFs  
 Cells were grown on 6-well poly-d lysine coated plates in DMEM +Glutamax 4.5g/L 
glucose media with 10% FBS and 1% penicillin and streptomycin until 75-80% confluent. Cells 
were changed to DMEM phenol red free 5mM glucose + L-Glutamine media with 10% FBS and 
1% penicillin and streptomycin and appropriate cells were treated with 5mM βHB for 72 hours. 
Media was replaced every 24 hours. After 72 hours, cells were then serum starved for 18 hrs 
with DMEM phenol red free 4.5 g/L glucose + L-Glutamine media with 0.2% FBS and 1% 
penicillin and streptomycin. There was not a need to use mytomycin to stop proliferation since 
used the serum free media. After 18 hours, two scratches were created per well using a 200 µL 
pipette tip. Wells were rinsed with 1mL RT Hank’s BBS to remove floating and loose cells. 
Wells were visualized using phase contrast microscopy and a picture was taken for baseline 
comparison. After 18 hours, cells were fixed with 4% paraformaldehyde for 15 minutes, rinsed 
with RT 1x PBS, and a cover slip was placed in the well using VECTASHIELD mounting media 
with DAPI (Vector Laboratories Inc., Burlingame, CA) and sealed with clear nail polish. Wells 
were visualized using phase contrast and fluorescent microscopy, and number of cells that 
migrated into scratch area was counted. Statistical analysis was performed via one-way ANOVA 
with Tukey’s post-hoc analysis. Results were considered significant when p<0.05.   
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A.4.7. Proliferation Analysis of young and aged HDFs 
 75,000 young and aged HDF cells were seeded on 6-well poly-d lysine coated plates in 
DMEM phenol red free 5mM glucose + L-Glutamine media with 10% FBS and 1% penicillin 
and streptomycin with or without the presence of 5 mM βHB. Media was replaced every 24 
hours. Total cell number was counted at 24, 48, 72, 96, and 120 hours post seeding. At given 
time point, media was removed and cells were washed with 1 mL sterile RT 1x PBS, cells were 
suspended using 250 µL (0.25% Trypsin in Hank’s Phenol Red BBS) and 750 µL of appropriate 
media (with or with out βHB).  Total cell density was measured using hemocytometry. Two-way 
ANOVA with Tukey’s post-hoc analysis, results were considered significant when p<0.05. Error 
Bars Represent mean (SD). 
 
A.4.8. Lactate Quantification of young and aged HDFs 
Young and aged primary HDFs were seeded with 250,000 cells on 6-well poly-d lysine 
coated plates in DMEM phenol red free 5mM glucose + L-Glutamine media with 10% FBS and 
1% penicillin and streptomycin with or without the presence of 5 mM βHB. Extracellular lactate 
was measured in 10 µL of cellular media at 24, 48 and 72 hours post-seeding using Nova 
Biomedical© Lactate Plus (Nova Biomedical, Waltham, MA) blood lactate measuring meter. 
Two-way ANOVA with Tukey’s post-hoc analysis, results were considered significant when 
p<0.05. Error Bars Represent mean (SD). 
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Effects of exogenous ketone
supplementation on blood ketone, glucose,
triglyceride, and lipoprotein levels in
Sprague–Dawley rats
Shannon L. Kesl1*, Angela M. Poff1, Nathan P. Ward1, Tina N. Fiorelli1, Csilla Ari1, Ashley J. Van Putten1,
Jacob W. Sherwood1, Patrick Arnold2 and Dominic P. D’Agostino1
Abstract
Background: Nutritional ketosis induced by the ketogenic diet (KD) has therapeutic applications for many disease
states. We hypothesized that oral administration of exogenous ketone supplements could produce sustained
nutritional ketosis (>0.5 mM) without carbohydrate restriction.
Methods: We tested the effects of 28-day administration of five ketone supplements on blood glucose, ketones,
and lipids in male Sprague–Dawley rats. The supplements included: 1,3-butanediol (BD), a sodium/potassium β-
hydroxybutyrate (βHB) mineral salt (BMS), medium chain triglyceride oil (MCT), BMS + MCT 1:1 mixture, and 1,3
butanediol acetoacetate diester (KE). Rats received a daily 5–10 g/kg dose of their respective ketone supplement via
intragastric gavage during treatment. Weekly whole blood samples were taken for analysis of glucose and βHB at
baseline and, 0.5, 1, 4, 8, and 12 h post-gavage, or until βHB returned to baseline. At 28 days, triglycerides, total
cholesterol and high-density lipoprotein (HDL) were measured.
Results: Exogenous ketone supplementation caused a rapid and sustained elevation of βHB, reduction of glucose,
and little change to lipid biomarkers compared to control animals.
Conclusions: This study demonstrates the efficacy and tolerability of oral exogenous ketone supplementation in
inducing nutritional ketosis independent of dietary restriction.
Keywords: Ketogenic diet, Ketone ester, Ketone supplement, Appetite, β-hydroxybutyrate, Hyperketonemia,
Triglycerides
Background
Emerging evidence supports the therapeutic potential of
the ketogenic diet (KD) for a variety of disease states,
leading investigators to research methods of harnessing
the benefits of nutritional ketosis without the dietary
restrictions. The KD has been used as an effective non-
pharmacological therapy for pediatric intractable sei-
zures since the 1920s [1–3]. In addition to epilepsy, the
ketogenic diet has elicited significant therapeutic effects
for weight loss and type-2 diabetes (T2D) [4]. Several
studies have shown significant weight loss on a high fat,
low carbohydrate diet without significant elevations of
serum cholesterol [5–12]. Another study demonstrated
the safety and benefits of long-term application of the
KD in T2D patients. Patients exhibited significant weight
loss, reduction of blood glucose, and improvement of
lipid markers after eating a well-formulated KD for
56 weeks [13]. Recently, researchers have begun to
investigate the use of the KD as a treatment for acne,
polycystic ovary syndrome (PCOS), cancer, amyotrophic
lateral sclerosis (ALS), traumatic brain injury (TBI) and
Alzheimer’s disease (AD) with promising preliminary
results [14–26].
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The classical KD consists of a 4:1 ratio of fat to pro-
tein and carbohydrate, with 80–90 % of total calories de-
rived from fat [27]. The macronutrient ratio of the KD
induces a metabolic shift towards fatty acid oxidation
and hepatic ketogenesis, elevating the ketone bodies
acetoacetate (AcAc) and β-hydroxybutyrate (βHB) in the
blood. Acetone, generated by decarboxylation of AcAc, has
been shown to have anticonvulsant properties [28–32].
Ketone bodies are naturally elevated to serve as alternative
metabolic substrates for extra-hepatic tissues during the
prolonged reduction of glucose availability, suppression of
insulin, and depletion of liver glycogen, such as occurs
during starvation, fasting, vigorous exercise, calorie
restriction, or the KD. Although the KD has clear
therapeutic potential, several factors limit the efficacy
and utility of this metabolic therapy for widespread
clinical use. Patient compliance to the KD can be low
due to the severe dietary restriction - the diet being
generally perceived as unpalatable - and intolerance to
high-fat ingestion. Maintaining ketosis can be difficult
as consumption of even a small quantity of carbohydrates
or excess protein can rapidly inhibit ketogenesis [33, 34].
Furthermore, enhanced ketone body production and tissue
utilization by the tissues can take several weeks (keto-adap-
tation), and patients may experience mild hypoglycemic
symptoms during this transitional period [35].
Recent studies suggest that many of the benefits of the
KD are due to the effects of ketone body metabolism.
Interestingly, in studies on T2D patients, improved gly-
cemic control, improved lipid markers, and retraction of
insulin and other medications occurred before weight
loss became significant. Both βHB and AcAc have been
shown to decrease mitochondrial reactive oxygen species
(ROS) production [36–39]. Veech et al. have summarized
the potential therapeutic uses for ketone bodies [28, 40].
They have demonstrated that exogenous ketones favorably
alter mitochondrial bioenergetics to reduce the mitochon-
drial NAD couple, oxidize the co-enzyme Q, and increase
the ΔG’ (free enthalpy) of ATP hydrolysis [41]. Ketone
bodies have been shown to increase the hydraulic effi-
ciency of the heart by 28 %, simultaneously decreasing
oxygen consumption while increasing ATP production
[42]. Thus, elevated ketone bodies increase metabolic effi-
ciency and as a consequence, reduce superoxide production
and increase reduced glutathione [28]. Sullivan et al. demon-
strated that mice fed a KD for 10–12 days showed increased
hippocampal uncoupling proteins, indicative of decreased
mitochondrial-produced ROS [43]. Bough et al. showed an
increase of mitochondrial biogenesis in rats maintained on a
KD for 4–6 weeks [44, 45]. Recently, Shimazu et al. reported
that βHB is an exogenous and specific inhibitor of class I
histone deacetylases (HDACs), which confers protection
against oxidative stress [38]. Ketone bodies have also been
shown to suppress inflammation by decreasing the
inflammatory markers TNF-a, IL-6, IL-8, MCP-1, E-selectin,
I-CAM, and PAI-1 [8, 46, 47]. Therefore, it is thought that
ketone bodies themselves confer many of the benefits asso-
ciated with the KD.
Considering both the broad therapeutic potential and
limitations of the KD, an oral exogenous ketone supple-
ment capable of inducing sustained therapeutic ketosis
without the need for dietary restriction would serve as a
practical alternative. Several natural and synthetic ketone
supplements capable of inducing nutritional ketosis have
been identified. Desrochers et al. elevated ketone bodies
in the blood of pigs (>0.5 mM) using exogenous ketone
supplements: (R, S)-1,3 butanediol and (R, S)-1,3
butanediol-acetoacetate monoesters and diester [48]. In
2012, Clarke et al. demonstrated the safety and efficacy
of chronic oral administration of a ketone monoester of
R-βHB in rats and humans [49, 50]. Subjects maintained
elevated blood ketones without dietary restriction and
experienced little to no adverse side effects, demonstrating
the potential to circumvent the restrictive diet typically
needed to achieve therapeutic ketosis. We hypothesized that
exogenous ketone supplements could produce sustained
hyperketonemia (>0.5 mM) without dietary restriction and
without negatively influencing metabolic biomarkers, such
as blood glucose, total cholesterol, HDL, LDL, and triglycer-
ides. Thus, we measured these biomarkers during a 28-day
administration of the following ketone supplements in rats:
naturally-derived ketogenic supplements included medium
chain triglyceride oil (MCT), sodium/potassium -βHB
mineral salt (BMS), and sodium/potassium -βHB mineral
salt +medium chain triglyceride oil 1:1 mixture (BMS +
MCT) and synthetically produced ketogenic supplements
included 1, 3-butanediol (BD), 1, 3-butanediol acetoace-
tate diester/ ketone ester (KE).
Methods
Synthesis and formulation of ketone supplements
KE was synthesized as previously described [29]. BMS is
a novel agent (sodium/potassium- βHB mineral salt)
supplied as a 50 % solution containing approximately
375 mg/g of pure βHB and 125 mg/g of sodium/potas-
sium. Both KE and BMS were developed and synthesized
in collaboration with Savind Inc. Pharmaceutical grade
MCT oil (~65 % caprylic triglyceride; 45 % capric trigly-
ceride) was purchased from Now Foods (Bloomingdale,
IL). BMS was formulated in a 1:1 ratio with MCT at the
University of South Florida (USF), yielding a final mix-
ture of 25 % water, 25 % pure βHB mineral salt and
50 % MCT. BD was purchased from Sigma-Aldrich
(Prod # B84785, Milwaukee, WI).
Daily gavage to induce dietary ketosis
Animal procedures were performed in accordance with
the University of South Florida Institutional Animal
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Care and Use Committee (IACUC) guidelines (Protocol
#0006R). Juvenile male Sprague–Dawley rats (275–325 g,
Harlan Laboratories) were randomly assigned to one of
six study groups: control (water, n = 11), BD (n = 11), KE
(n = 11), MCT (n = 10), BMS (n = 11), or BMS +MCT
(n = 12). Caloric density of standard rodent chow and
dose of ketone supplements are listed in Table 1. On
days 1–14, rats received a 5 g/kg body weight dose of
their respective treatments via intragastric gavage.
Dosage was increased to 10 g/kg body weight for the
second half of the study (days 15–28) for all groups
except BD and KE to prevent excessive hyperketone-
mia (ketoacidosis). Each daily dose of BMS would equal
~1000–1500 mg of βHB, depending on the weight of the
animal. Intragastric gavage was performed at the same time
daily, and animals had ad libitum access to standard
rodent chow 2018 (Harlan Teklad) for the duration of
the study. The macronutrient ratio the standard rodent
chow was 62.2, 23.8 and 14 % of carbohydrates, protein
and fat respectively.
Measurement and analysis of blood glucose, ketones,
and lipids
Every 7 days, animals were briefly fasted (4 h, water
available) prior to intragastric gavage to standardize
levels of blood metabolites prior to glucose and βHB
measurements at baseline. Baseline (time 0) was imme-
diately prior to gavage. Whole blood samples (10 μL)
were taken from the saphenous vein for analysis of
glucose and βHB levels with the commercially avail-
able glucose and ketone monitoring system Precision
Xtra™ (Abbott Laboratories, Abbott Park, IL). Blood
glucose and βHB were measured at 0, 0.5, 1, 4, 8,
and 12 h after test substance administration, or until
βHB returned to baseline levels. Food was returned to
animals after blood analysis at time 0 and gavage. At
baseline and week 4, whole blood samples (10 μL)
were taken from the saphenous vein immediately
prior to gavage (time 0) for analysis of total choles-
terol, high-density lipoprotein (HDL), and triglycerides
with the commercially available CardioChek™ blood
lipid analyzer (Polymer Technology Systems, Inc., In-
dianapolis, IN). Low-density lipoprotein (LDL)
cholesterol was calculated from the three measured
lipid levels using the Friedewald equation: (LDL Choles-
terol = Total Cholesterol - HDL - (Triglycerides/5)) [51,
52]. Animals were weighed once per week to track
changes in body weight associated with hyperketonemia.
Organ weight and collection
On day 29, rats were sacrificed via deep isoflurane
anesthesia, exsanguination by cardiac puncture, and de-
capitation 4–8 h after intragastric gavage, which correlated
to the time range where the most significantly elevated
blood βHB levels were observed. Brain, lungs, liver,
kidneys, spleen and heart were harvested, weighed (AWS-
1000 1 kg portable digital scale (AWS, Charleston, SC)),
and flash-frozen in liquid nitrogen or preserved in 4 %
paraformaldehyde for future analysis.
Statistics
All data are presented as the mean ± standard deviation
(SD). Data analysis was performed using GraphPad
PRISM™ version 6.0a and IBM SPSS Statistics 22.0. Re-
sults were considered significant when p < 0.05. Trigly-
ceride and lipoprotein profile data were analyzed using
One-Way ANOVA. Blood ketone and blood glucose
were compared to control at the applicable time points
using a Two-Way ANOVA. Correlation between blood
βHB and glucose levels in ketone supplemented rats was
compared to controls using ANCOVA analysis. Organ
and body weights were analyzed using One-Way
ANOVA. Basal blood ketone and blood glucose levels
were analyzed using Two-Way ANOVA. All mean com-
parisons were carried out using Tukey’s multiple com-
parisons post-hoc test.
Results
Effect of ketone supplementation on triglycerides and
lipoproteins
Baseline measurements showed no significant changes
in triglycerides or the lipoproteins (data not shown).
Data represent triglyceride and lipoprotein concentra-
tions measured after 4 weeks of daily exogenous ketone
supplementation. No significant change in total choles-
terol was observed at 4 weeks for any of the ketone
treatment groups compared to control. (Fig. 1a). No
Table 1 Caloric density and dose of ketone supplements
Macronutrient Information Standard Diet Water BMS + MCT BMS MCT KE BD
% Cal from Fat 18.0 0.0 50.0 N/A 100.0 N/A N/A
% Cal from Protein 24.0 0.0 N/A N/A 0.0 N/A N/A
% Cal from Carbohydrates 58.0 0.0 N/A N/A 0.0 N/A N/A
Total Caloric Density (Kcal/g) 3.1 0.0 5.1 1.9 8.3 5.6 6.0
Dose 0–14 Days (g/kg) ad libitum N/A 5.0 5.0 5.0 5.0 5.0
Dose 15–28 Days (g/kg) ad libitum N/A 10.0 10.0 10.0 5.0 5.0
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significant difference was detected in triglycerides for
any ketone supplement compared to control (Fig. 1b).
MCT supplemented animals had a significant reduction
in HDL blood levels compared to control (p < 0.001)
(Fig. 1c). LDL levels in ketone-supplemented animals did
not significantly differ from controls (Fig. 1d).
Ketone supplementation causes rapid and sustained
elevation of βHB
Over the 28-day experiment, ketone supplements ad-
ministered daily significantly elevated blood ketone
levels without dietary restriction (Fig. 2a, b). Naturally
derived ketogenic supplements including MCT (5 g/kg)
elicited a significant rapid elevation in blood βHB within
30–60 min that was sustained for 8 h. BMS +MCT (5 g/
kg) elicited a significant elevation in blood βHB at 4 h,
which was no longer significant at 8 h. BMS (5 g/kg) did
not elicit a significant elevation in blood βHB at any
time point. For days 14–28, BMS +MCT (10 g/kg) and
MCT (10 g/kg) elevated blood βHB levels within 30 min
and remained significantly elevated for up to 12 h. We
observed a delay in the peak elevation of blood βHB:
BMS +MCT peaked at 8 h instead of at 4 h and MCT at
4 h instead of at 1 h. Blood βHB levels in the BMS group
did not show significant elevation at any time point,
even after dose escalation (Fig. 2a). Synthetically derived
ketogenic supplements including KE and BD supple-
mentation rapidly elevated blood βHB within 30 min
and was sustained for 8 h. For the rats receiving ketone
supplementation in the form of BD or the KE, dosage
was kept at 5 g/kg to prevent adverse effects associated
with hyperketonemia. The Precision Xtra™ ketone moni-
toring system measures βHB only; therefore, total blood
ketone levels (βHB +AcAc) would be higher than mea-
sured. For each of these groups, the blood βHB profile
remained consistent following daily ketone supplementa-
tion administration over the 4-week duration. (Fig. 2b).
Ketone supplementation causes a significant decrease of
blood glucose
Administration of ketone supplementation significantly
reduced blood glucose over the course of the study
(Fig. 3a, b). MCT (5 g/kg) decreased blood glucose com-
pared to control within 30 min which was sustained for
Fig. 1 Effects of ketone supplementation on triglycerides and lipoproteins: Ketone supplementation causes little change in triglycerides and
lipoproteins over a 4-week study. Graphs show concentrations at 4-weeks of total cholesterol (a), Triglycerides (b), LDL (c), and HDL (d).
MCT supplemented rats had signfiicantly reduced concentration of HDL blood levels compared to control (p < 0.001) (b). One-Way ANOVA
with Tukey’s post hoc test, results considered significant if p < 0.05. Error bars represent mean (SD)
Kesl et al. Nutrition & Metabolism  (2016) 13:9 Page 4 of 15
	 214	
 
Fig. 2 Effects of ketone supplementation on blood βHB. a, b Blood βHB levels at times 0, 0.5, 1, 4, 8, and 12 h post intragastric gavage for ketone
supplements tested. a BMS +MCT and MCT supplementation rapidly elevated and sustained significant βHB elevation compared to controls for
the duration of the 4-week dose escalation study. BMS did not significantly elevate βHB at any time point tested compared to controls. b BD and
KE supplements, maintained at 5 g/kg, significantly elevated βHB levels for the duration of the 4-week study. Two-Way ANOVA with Tukey’s post
hoc test, results considered significant if p < 0.05. Error bars represent mean (SD)
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Fig. 3 Effects of ketone supplementation on blood glucose. a, b Blood glucose levels at times 0, 0.5, 1, 4, 8, and 12 h (for 10 dose) post intragastric
gavage for ketone supplements tested. a Ketone supplements BMS +MCT and MCT significantly reduced blood glucose levels compared to controls
for the duration of the 4-week study. BMS significantly lowered blood glucose only at 8 h/week 1 and 12 h/week 3 (b) KE, maintained at
5 g/kg, significantly reduced blood glucose compared to controls from week 1–4. BD did not significantly affect blood glucose levels at
any time point during the 4-week study. Two-Way ANOVA with Tukey’s post hoc test, results considered significant if p < 0.05. Error bars
represent mean (SD)
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8 h at baseline and at week 1. MCT (10 g/kg) likewise
decreased blood glucose within 30 min and lasted
through the 12 h time point during weeks 2, 3, and 4.
BMS +MCT (5 g/kg) lowered blood glucose compared
to control from hours 1–8 only at week 1. BMS +MCT
(10 g/kg) lowered blood glucose compared to control
within 30 min and remained low through the 12 h time
point at weeks 2, 3, and 4. Rats supplemented with BMS
had lower blood glucose compared to control at 12 h in
week 4 (10) (Fig. 3a). Administration of BD did not sig-
nificantly change blood glucose levels at any time point
during the 4-week study. KE (5 g/kg) significantly low-
ered blood glucose levels at 30 min for week 1, 2, 3, and
4 and was sustained through 1 h at weeks 2–4 and sus-
tained to 4 h at week 3. (Fig. 3b).
Hyperketonemia suppresses blood glucose levels
At baseline, 4 h after intragastric gavage, the elevation of
blood ketones was inversely related to the reduction of blood
glucose compared to controls following the administration
of MCT (5 g/kg) (p = 0.008) and BMS+MCT (5 g/kg) (p =
0.039) . There was no significant correlation between blood
ketone levels and blood glucose levels compared to controls
for any other ketone supplemented group at baseline
(Fig. 4a). At week 4, 4 h after intragastric gavage, there was a
significant correlation between blood ketone levels and
Fig. 4 Relationship between blood ketone and glucose levels: a BMS +MCT (5 g/kg) supplemented rats demonstrated a significant inverse relationship
between elevated blood ketone levels and decreased blood ketone levels (r2 = 0.4314, p = 0.0203). b At week 4, BMS +MCT (10 g/kg) and MCT (10 g/kg)
showed a significant correlation between blood ketone levels and blood glucose levels (r2 = 0.8619, p < 0.0001; r2 = 0.6365, p = 0.0057). Linear regression
analysis, results considered significant if p < 0.05
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blood glucose levels compared to controls in MCT (10 g/kg)
and BMS+MCT (10 g/kg) (p < 0.0001, p < 0.0001) (Fig. 4b).
Ketone supplementation changes organ weight and
decreases body weight
At day 29 of the study, animals were euthanized and
brain, lungs, liver, kidneys, spleen and heart were har-
vested and weighed. Organ weights were normalized to
body weight. Ketone supplementation did not signifi-
cantly change brain, lung, kidney, or heart weights
compared to controls (Fig. 5a, b, d, f ). MCT supple-
mented animals had significantly larger livers compared
to their body weight (p < 0.05) (Fig. 5c). Ketone supple-
ments BMS +MCT, MCT and BD caused a significant
reduction in spleen size (BMS +MCT p < 0.05, MCT p
< 0.001, BD p < 0.05) (Fig. 5e). Rats administered KE
gained significantly less weight over the entire study
compared to controls. BMS +MCT, BMS, and BD sup-
plemented rats gained significantly less weight than con-
trols during weeks 2 – 4, and MCT animals gained less
Fig. 5 Effects of ketone supplementation on organ weight: Data is represented as a percentage of organ weight to body weight. a, b, d, f
Ketone supplements did not significantly affect the weight of the brain, lungs, kidneys or heart. c Liver weight was significantly increased as
compared to body weight in response to administered MCT ketone supplement compared to control at the end of the study (day 29) (p < 0.001).
e Rats supplemented with BMS +MCT, MCT, and BD had significantly smaller spleen percentage as compared to controls (p < 0.05, p < 0.001, p < 0.05).
Two-Way ANOVA with Tukey’s post-hoc test; results considered significant if p < 0.05. Error bars represent mean (SD)
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weight than controls at weeks 3 – 4 (Fig. 6). Increased
gastric motility (increased bowel evacuation and changes
to fecal consistency) was visually observed in rats sup-
plemented with 10 g/kg MCT, most notably at the 8 and
12-h time points. All animals remained in healthy weight
range for their age even though the rate of weight gain
changed with ketone supplementation [53–54]. Food in-
take was not measured in this study. However, there was
not a significant change in basal blood glucose or basal
blood ketone levels over the 4 week study in any of the
rats supplemented with ketones (Fig. 7).
Discussion
Nutritional ketosis induced with the KD has proven
effective for the metabolic management of seizures and
potentially other disorders [1–26]. Here we present
evidence that chronic administration of ketone supple-
ments can induce a state of nutritional ketosis without
the need for dietary carbohydrate restriction and with
little or no effect on lipid biomarkers. The notion that
we can produce the therapeutic effects of the KD with
exogenous ketone supplementation is supported by our
previous study which demonstrated that acutely admin-
istered KE supplementation delays central nervous
system (CNS) oxygen toxicity seizures without the
need for dietary restriction [29]. We propose that
exogenous ketone supplementation could provide an
alternative method of attaining the therapeutic
benefits of nutritional ketosis, and as a means to
further augment the therapeutic potential of the KD.
Ketone supplementation causes little to no change in
triglycerides and lipoproteins
One common concern regarding the KD is its purported
potential to increase the risk of atherosclerosis by elevat-
ing blood cholesterol and triglyceride levels [55, 56]. This
topic remains controversial as some, but not all, studies
have demonstrated that the KD elevates blood levels of
cholesterol and triglycerides [57–62]. Kwitervich and col-
leagues demonstrated an increase in low-density lipopro-
tein (LDL) and a decrease in high-density lipoprotein
(HDL) in epileptic children fed the classical KD for
two years [27]. In this study, total cholesterol in-
creased by ~130 %, and stabilized at the elevated level
over the 2-year period. A similar study demonstrated that
the lipid profile returned to baseline in children who
remained on the KD for six years [63]. Children typically
remain on the diet for approximately two years then re-
turn to a diet of common fat and carbohydrate ingestion
[64]. The implications of these findings are unclear, since
the influence of cholesterol on cardiovascular health is
controversial and macronutrient sources of the diet vary
per study. In contrast to these studies, the majority of re-
cent studies have suggested that the KD can actually lead
to significant benefits in biomarkers of metabolic health,
including blood lipid profiles [65–72]. In these studies, the
Fig. 6 Effects of ketone supplementation on body weight: Rats administered ketone supplements gained less weight over the 4-week period;
however, did not lose weight and maintained healthy range for age. KE supplemented rats gained significantly less weight during the entire
4-week study compared to controls. BMS +MCT, BMS, and BD supplemented rats gained significantly less weight than controls over weeks 2–4.MCT
supplemented rats gained significantly less weight than controls over weeks 3–4, Two-Way ANOVA with Tukey’s post hoc test, results considered
significant if p < 0.05. Error bars represent mean (SD)
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KD positively altered blood lipids, decreasing total triglyc-
erides and cholesterol while increasing the ratio of HDL
to LDL [68–77]. Although, the KD is well-established in
children, it has only recently been utilized as a strategy to
control seizures in adults. In 2014, Schoeler and col-
leagues reported on the feasibility of the KD for adults,
concluding that 39 % of individuals achieved > 50 % reduc-
tion in seizure frequency, similar to the results reported in
pediatric studies. Patients experienced similar gastrointes-
tinal adverse advents that have been previously described
in pediatric patients, but they did not lead to discontinu-
ation of the diet in any patient [78].
With oral ketone supplementation, we observed a sig-
nificant elevation in blood βHB without dietary restric-
tion and with little change in lipid biomarkers (Fig. 1).
Over the 4 week study, MCT-supplemented rats demon-
strated decreased HDL compared to controls. No signifi-
cant changes were observed in any of the triglycerides or
lipoproteins (HDL, LDL) with any of the remaining ex-
ogenously applied ketone supplements. It should be
noted that the rats used for this study had not yet
reached full adult body size [79]. Their normal growth
rate and maturation was likely responsible for the
changes in triglyceride and lipoprotein levels observed in
the control animals over the 4 week study (baseline data
not shown, no significant differences) [80, 81]. Future
studies are needed to investigate the effect of ketone
supplementation on fully mature and aged animals.
Overall, our study suggests that oral ketone supplemen-
tation has little effect on the triglyceride or lipoprotein
profile after 4 weeks. However, it is currently unknown if
ketone supplementation would affect lipid biomarkers
after a longer duration of consumption. Further studies
are needed to determine the effects of ketone supplements
on blood triglyceride and lipoproteins after chronic
administration and as a means to further enhance the
hyperketonemia and improve the lipid profile of the clinic-
ally implemented (4:1) KD.
LDL is the lipoprotein particle that is most often associ-
ated with atherosclerosis. LDL particles exist in different
sizes: large molecules (Pattern A) or small molecules
(Pattern B). Recent studies have investigated the im-
portance of LDL-particle type and size rather than
total concentration as being the source for cardiovascular
risk [56]. Patients whose LDL particles are predominantly
small and dense (Pattern B) have a greater risk of
Fig. 7 Effects of ketone supplementation on basal blood ketone and basal blood glucose levels: Rats administered ketone supplements did not
have a significant change in basal blood ketone levels (a) or basal blood glucose levels (b) for the four week study. Two-Way ANOVA with Tukey’s
post-hoc test, results considered significant if p < 0.05. Error bars represent mean (SD)
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cardiovascular disease (CVD). It is thought that small,
dense LDL particles are more able to penetrate the endo-
thelium and cause in damage and inflammation [82–85].
Volek et al. reported that the KD increased the pattern
and volume of LDL particles, which is considered to re-
duce cardiovascular risk [73]. Though we did not show a
significant effect on LDL levels for ketone supplements,
future chronic feeding studies will investigate the effects
of ketone supplementation on lipidomic profile and LDL
particle type and size.
Therapeutic levels of hyperketonemia suppress blood
glucose levels
We demonstrated that therapeutic ketosis could be
induced without dietary (calorie or carbohydrate) restric-
tion and that this acute elevation in blood ketones was
significantly correlated with a reduction in blood glucose
(Figs. 2, 3 and 4). The BMS ketone supplement did not
significantly induce blood hyperketonemia or reduced
glucose in the rats. The KE supplemented rats trended
towards reduced glucose levels; however, the lower dose
of this agent did not lower glucose significantly, as re-
ported previously in acute response of mice [59]. MCTs
have previously been shown to elicit a slight hypoglycemic
effect by enhancing glucose utilization in both diabetic
and non-diabetic patients [86–88]. Kashiwaya et al. dem-
onstrated that both blood glucose and blood insulin
decreased by approximately 50 % in rats fed a diet where
30 % of calories from starch were replaced with ketone es-
ters for 14 days, suggesting that ketone supplementation
increases insulin sensitivity or reduced hepatic glucose
output [89]. This ketone-induced hypoglycemic effect has
been previously reported in humans with IV infusions of
ketone bodies [90, 91]. Recently, Mikkelsen et al. showed
that a small increase in βHB concentration decreases glu-
cose production by 14 % in post-absorptive health males
[92]. However, this has not been previously reported with
any of the oral exogenous ketone supplements we studied.
Ketones are an efficient and sufficient energy substrate for
the brain, and will therefore prevent side effects of
hypoglycemia when blood levels are elevated and the pa-
tient is keto-adapted. This was most famously demon-
strated by Owen et al. in 1967 wherein keto-adapted
patients (starvation induced therapeutic ketosis) were
given 20 IU of insulin. The blood glucose of fasted pa-
tients dropped to 1–2 mM, but they exhibited no
hypoglycemic symptoms due to brain utilization of ke-
tones for energy [93]. Therefore, ketones maintain brain
metabolism and are neuroprotective during severe
hypoglycemia. The rats in the MCT group had a correl-
ation of blood ketone and glucose levels at week 4,
whereas the combination of BMS +MCT produced a sig-
nificant hypoglycemic correlation both at baseline and at
week 4. No hypoglycemic symptoms were observed in the
rats during this study. Insulin levels were not measured in
this study; however, future ketone supplementation stud-
ies should measure the effects of exogenous ketones on
insulin sensitivity with a glucose tolerance test. An
increase in insulin sensitivity in combination with our
observed hypoglycemic effect has potential therapy impli-
cations for glycemic control in T2D [40]. Furthermore, it
should be noted that the KE metabolizes to both AcAc
and βHB in 1:1 ratio [29]. The ketone monitor used in this
study only measures βHB as levels of AcAc are more diffi-
cult to measure due to spontaneous decarboxylation to
acetone; therefore, the total ketone levels (βHB+AcAc)
measured were likely higher, specifically for the KE [14].
Interestingly, the 10 g/kg dose produced a delayed blood
βHB peak for ketone supplements MCT and BMS +MCT.
The higher dose of the ketogenic supplements elevated
blood levels more substantially, and thus reached their
maximum blood concentration later due to prolonged
metabolic clearance. It must be noted that the dosage used
in this study does not translate to human patients, since
the metabolic physiology of rats is considerably higher.
Future studies will be needed to determine optimal dosing
for human patients.
Effects of ketone supplementation on organ weight and
body weight percentage
Ketone supplementation did not affect the size of the
brain, lungs, kidneys or heart of rats. As previously men-
tioned, the rats were still growing during the experimen-
tal time frame; therefore, organ weights were normalized
to body weight to determine if organ weight changed in-
dependently to growth. There could be several reasons
why ketones influenced liver and spleen weight. The ra-
tio of liver to body weight was significantly higher in the
MCT supplemented animals (Fig. 5). MCTs are readily
absorbed in the intestinal lumen and transported directly
to the liver via hepatic portal circulation. When given a
large bolus, such as in this study, the amount of MCTs
in the liver will likely exceed the β-oxidation rate, caus-
ing the MCTs to be deposited in the liver as fat droplets
[94]. The accumulated MCT droplets in the liver could
explain the higher liver weight to body weight percentage
observed with MCT supplemented rats. Future toxicology
and histological studies will be needed to determine the
cause of the observed hepatomegaly. It should be empha-
sized that the dose in this study is not optimized in
humans. We speculate that an optimized human dose
would be lower and may not cause hepatomegaly or po-
tential fat accumulation. Nutritional ketosis achieved with
the KD has been shown to decrease inflammatory markers
such as TNF-α, IL-6, IL-8, MCP-1, E-selectin, I-CAM, and
PAI-1 [8, 46], which may account for the observed
decrease in spleen weight. As previously mentioned,
Veech and colleagues demonstrated that exogenous
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supplementation of 5 mM βHB resulted in a 28 % increase
in hydraulic work in the working perfused rat heart and a
significant decrease in oxygen consumption [28, 41, 42].
Ketone bodies have been shown to increase cerebral blood
flow and perfusion [95]. Also, ketone bodies have been
shown to increase ATP synthesis and enhance the effi-
ciency of ATP production [14, 28, 40]. It is possible that
sustained ketosis results in enhanced cardiac efficiency
and O2 consumption. Even though the size of the
heart did not change for any of the ketone supple-
ments, further analysis of tissues harvested from the
ketone-supplemented rats will be needed to determine
any morphological changes and to understand changes in
organ size. It should be noted that the Harlan standard
rodent chow 2018 is nutritionally complete and formu-
lated with high-quality ingredients to optimize gestation,
lactation, growth, and overall health of the animals. The
same cannot be said for the standard American diet
(SAD). Therefore, we plan to investigate the effects of
ketone supplements administered with the SAD to deter-
mine if similar effects will be seen when the micronutrient
deficiencies and macronutrient profile mimics what most
Americans consume.
MCT oil has recently been used to induce nutritional
ketosis although it produces dose-dependent gastrointes-
tinal (GI) side effects in humans that limit the potential
for its use to significantly elevate ketones (>0.5 mM).
Despite these limitations, Azzam and colleagues pub-
lished a case report in which a 43-year-old-man had a
significant decrease in seizure frequency after supple-
menting his diet with 4 tablespoons of MCT oil twice
daily [96]. An attempt to increase his dosage to 5 table-
spoons twice daily was halted by severe GI intolerance.
Henderson et al. observed that 20 % of patients re-
ported GI side effects with a 20 g dose of ketogenic
agent AC-1202 in a double blind trial in mild to moderate
Alzheimer’s patients [24]. We visually observed similar
gastrointestinal side effects (loose stools) in the rats
treated with MCT oil in our study. Rats were closely mon-
itored to avoid dehydration, and gastric motility returned
to normal between 12–24 h. Interestingly, the BMS +
MCT supplement elevated βHB similarly to MCT oil
alone, without causing the adverse gastrointestinal effects
seen in MCT-supplemented rats. However, this could be
due to the fact in a 10 g/kg dose of BMS +MCT, only 5 g/
kg is MCT alone, which is less than the 10 g/kg dose that
elicits the GI side effects. This suggests that this novel
combination may provide a more useful therapeutic
option than MCT oil alone, which is limited in its ability
to elevate ketones in humans.
Exogenously delivered ketone supplements signifi-
cantly altered rat weight gain for the duration of the
study (Fig. 6). However, rats did not lose weight and
maintained a healthy range for their age. Rats have been
shown to effectively balance their caloric intake to prevent
weight loss/gain [97–99]. Due to the caloric density of the
exogenous ketone supplements (Table 1) it is possible for
the rats to eat less of the standard rodent chow and there-
fore less carbohydrates while maintaining their caloric
intake. Food intake was not measured for this study.
However, if there was a significant carbohydrate restric-
tion there would be a signifcant change in basal blood ke-
tone and blood glucose levels. As the hallmark to the KD,
carbohydrate restriction increases blood ketone levels and
reduces blood glucose levels. Neither an increase in basal
blood ketone levels nor a decrease in basal blood glucose
levels was observed in this study (Fig. 7). Additionally, if
there were an overall blood glucose decrease due to a
change in food intake, this would not explain the
rapid reduction (within 30 min) in blood glucose cor-
related with an elevation of blood ketone levels after
an intragastric bolus of ketone supplement (Figs. 2, 3
and 4).
Conclusions
Several studies have investigated the safety and efficacy
of ketone supplements for disease states such as AD and
Parkinson’s disease, and well as for parenteral nutrition
[40, 48–50, 100–103]. Our research demonstrates that
several forms of dietary ketone supplementation can ef-
fectively elevate blood ketone levels and achieve deleted:
therapeutic nutritional ketosis without the need for diet-
ary carbohydrate restriction. We also demonstrated that
ketosis achieved with exogenous ketone supplementation
can reduce blood glucose, and this is inversely associated
with the blood ketone levels. Although preliminary results
are encouraging, further studies are needed to determine
if oral ketone supplementation can produce the same
therapeutic benefits as the classic KD in the broad-
spectrum of KD-responsive disease states . Additionally,
further experiments need to be conducted to see if the ex-
ogenous ketone supplementation affects the same physio-
logical features as the KD (i.e. ROS, inflammation, ATP
production). Ketone supplementation could be used as an
alternative method for inducing ketosis in patients
uninterested in attempting the KD or those who have pre-
viously had difficulty implementing the KD because of
palatability issues, gall bladder removal, liver abnormal-
ities, or intolerance to fat. Additional experiments should
be conducted to see if ketone supplementation could be
used in conjunction with the KD to assist and ease the
transition to nutrition ketosis and enhance the speed of
keto-adaptation. In this study we have demonstrated the
ability of several ketone supplements to elevate blood
ketone levels, providing multiple options to induce thera-
peutic ketosis based on patient need. Though additional
studies are needed to determine the therapeutic potential
of ketone supplementation, many patients that previously
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were unable to benefit from the KD may now have an
alternate method of achieving therapeutic ketosis. Ketone
supplementation may also represent a means to further
augment ketonemia in those responsive to therapeutic
ketosis, especially in those individuals where maintaining
low glucose is important.
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